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The regulation of food intake is one of the most intricate internal balances in 
mammalian behaviour. Dysregulation of the central mechanisms underlying appetite 
control and metabolism result in both disorders of under- and over-eating. Disorders 
of appetite result in significant morbidity and mortality, and represent a major unmet 
clinical need. The endogenous hormone ghrelin and its receptor, the growth hormone 
secretagogue receptor (GHSR-1a), have long been known as pharmacological targets 
for appetite-related and metabolic disorders. Nutraceutical and bioactive peptides offer 
the opportunity to prevent onset and escalation of lifestyle-associated diseases of 
appetite and metabolism. However, there is a dearth of clinical evidence to justify the 
development of many bioactives as nutraceuticals. The potential applicability of dairy-
derived bioactives in appetite-related disorders is now becoming increasingly 
apparent. We investigate whether a dairy-derived hydrolysate can increase GHSR-1a 
signalling in vitro, and whether this can be translated to evidence of effect in vivo in a 
pre-clinical model (Chapter 2). Subsequently, by leveraging advanced pharmaceutical 
technology, we develop a gastro-protective and sustained delivery system with a high 
payload capacity (Chapter 3). Furthermore, ligand-dependent biased signalling, and 
ligand biodistribution may have important roles to play in increasing efficacy of 
ghrelin ligands in vivo. Therefore, we investigate whether two synthetic ghrelin 
ligands, anamorelin and HM01, exert differential effects on the GHSR-1a in vitro 
(Chapter 4). The divergent effects of these two ligands on appetite and reward-
motivated behaviours, as well as effects on central neuronal activation and reward 
system dopamine (DA) levels will also be investigated with a view to informing 
strategies to optimize future ghrelin therapies (Chapter 4 and 5). 
Chapter 2 and 3 provide an effective platform for gastro-protected delivery of 
bioactive peptides to enable further proof-of-concept studies across the appetite 
modulation field. Evidence of an orexigenic effect of the bioactive is seen in vivo in a 
rodent model. The oral delivery system developed served as a clinical formulation 
platform for proof-of-concept studies in humans to be conducted within the wider 
Food for Health Ireland research consortium. Chapters 4 and 5 show the importance 
of biased signalling and biodistribution of ghrelin ligands. Greater maximal food 
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intake is reported by the brain penetrant HM01 vs. the peripherally limited anamorelin. 
Divergent neuronal activation of the two ligands is also shown in reward processing 
areas using c-fos immunostaining. Targeting specific downstream signalling pathways 
will enable the provision of more efficacious appetite modulation therapies, while 
centrally penetrant ligands will provide further therapeutic avenues through greater 
reward system activation. 
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Evolutional perspectives on energy balance 
A fundamental requirement for survival of an organism is the appropriate 
maintenance of energy balance. Times of food deprivation require adequate storage of 
fat to utilize as an energy substrate, while times of food surplus often require 
overconsumption to replenish energy stores. The basic need for this energy 
conservation and replacement, as well as energy-expensive demands such as foraging 
for food, flight from predators, reproduction etc., require an effective metabolic 
machinery to maintain homeostasis. In the short term, this machinery must be capable 
of dealing with the circadian oscillations in energy intake e.g. fasting during sleep, to 
a longer-term cycle of famine that was synonymous with the lifestyle of our ancestral 
hunter-gatherers, and many other eras throughout history (Berbesque, Marlowe et al. 
2014). A malfunctioning internal milieu for energy balance confers a distinct 
disadvantage to our forebears who endured famine – indeed, those of us alive today 
are likely to have descended from evolution’s selection of those who are genetically 
geared to efficiently store energy during times of famine (Waterson and Horvath 
2015).   
However, the evolutionary drive to overconsume calories to compensate for 
periods of famine has become a redundant trait in the last century. The brain has 
evolved over millennia to promote the motivation to obtain food in order to enhance 
survival – nowadays, however, it is wired inappropriately to deal with the surplus of 
readily available energy in the Western world (Neel 1962). This results in the 
overconsumption of food and surplus in calories compared to metabolic requirements, 
and subsequent fat accumulation (Zheng, Lenard et al. 2009). In this respect, it is no 
surprise that the abundance of food, particularly high-calorie convenience food 
available to us in the Western world has resulted in an obesity crises of epidemic 
proportions (Wyatt, Winters et al. 2006).  
On the converse, dysregulation of these fundamental mechanisms for energy 
balance are seen in conditions of undereating and illness-associated weight loss, where 
appetite and motivation to seek out food is very low (Morley, Thomas et al. 2006). A 
natural decline in appetite and food intake occurs in elderly populations – this can lead 
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to malnutrition with a reduction in immunity, energy levels, independent living and 
overall health (Chapman 2004, Hickson 2006, Thomas 2007, Malafarina, Uriz-Otano 
et al. 2013). The reasons behind decreases in appetite result from a combination of 
physiological changes, which lead to earlier satiation and a decreased ability of the 
body to regulate energy balance (Chapman 2004, Hickson 2006). Furthermore, 
changes to sensory system, cognitive and emotional processes lead to a reduced 
incentive valuation placed on food (Jacobson, Green et al. 2017). Complicating this,  
ageing population demographics lead to an increased prevalence of chronic illnesses, 
which compound a weakening metabolism (Organization 2015). Subsequently, this 
can result in the wasting syndrome known as cachexia, which is a complex metabolic 
syndrome accompanied by illness resulting in intractable loss of weight and a poorer 
prognosis for the accompanying illness (Morley, Thomas et al. 2006, Evans, Morley 
et al. 2008).  
The neural circuits controlling energy metabolism are critical junctures for the 
successful treatment of conditions of both over-eating and under-eating (Gautron, 
Elmquist et al. 2015, Waterson and Horvath 2015). The mechanisms underlying food 
intake have been under scrutiny for decades, with particular advances being made 
since the late 1990’s and the discovery of ghrelin. However, a lot remains to be 
uncovered in the neural control of appetite, while the search for successful appetite 
modulation strategies to harness these evolved mechanisms is ongoing. 
1.1 Neural basis of energy homeostasis 
Research has revealed that food intake is one of the most deceptively variable 
and complex of mammalian behaviours. Daily food intake varies both between and 
within individuals – basal energy requirements are dictated by calories consumed and 
expended, while more subjective factors such as social conformity, stress levels, cost, 
convenience, perceived palatability etc. all ultimately feed into the decision to eat in 
any given situation (Waterson and Horvath 2015). One of the most recognized 
explanations of appetite control is the energy balance theory, although recent years 
have led to some criticism of this. While there may be limitations, this “set-point” 
theory is probably the most influential and argued theory of body weight control to 
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date. This theory is based on the premise that a delicate homeostatic “set-point” for 
body weight is maintained, from which body weight can fluctuate slightly with eating 
behaviours. However, the reality is that the plethora of factors which impact on our 
ultimate appetite levels is highly complex and variable. The mechanisms underpinning 
our drive to consume food have become increasingly known since the turn of the 
century. In more recent years, the “set-point” theory has been largely overshadowed 
by the neural basis of appetite regulation, which has become widely known (Harris 
1990, Waterson and Horvath 2015). Specific neuronal populations have been 
identified which are responsible for enhancing hunger and satiety. Furthermore, there 
are neuronal highways which connect these areas to the pleasure centres of the brain 
which can affect our perception of food, or the motivation to obtain it.  
 
 
Figure 1.1. Neural basis of appetite and food reward. Schematic representation of 
two overlapping areas of appetite and food intake; homeostatic food intake is 
regulated through the hypothalamus, while non-homeostatic largely feeds into the 
reward circuitry. Abbreviations: Arc; arcuate nucleus, PVN; paraventricular nucleus, 
LH; lateral hypothalamus, V/DMN; ventral/dorsomedial nucleus, VTA; ventral 
tegmental area; NAcc; nucleus accumbens, NPY; neuropeptide Y, AgRP; agouti-




The neural basis of appetite and food intake can for simplicity be subdivided 
into two distinct yet overlapping areas of homeostatic and non-homeostatic 
(pleasurable or hedonic) feeding (Figure 1.1). The primary fulcrum for homeostatic 
neuronal control of appetite is the hypothalamus. The mammalian hypothalamus is a 
forebrain structure which can be divided into 40 different sub nuclei, and is associated 
with various behaviours, including drinking, sexual behaviour, aggression, as well as 
body temperature regulation and immunity (Berthoud 2002). Critically, it is the key 
structure responsible for the regulation of food intake, energy balance and fat storage. 
The strategic location of the hypothalamus within the mammalian neuroendocrine 
machinery means that it receives a wealth of neurohumoral input, thereby allowing it 
to gain information on the central and peripheral state of affairs with regard to energy 
state (presence of satiating or hunger factors in the blood), and the availability of food 
(olfactory, visual, gustatory etc.), as well as many other inputs such as stress, fight or 
flight response etc. Three key hypothalamic substructures relating to food intake are 
the arcuate nucleus, the lateral hypothalamus and the paraventricular hypothalamus. 
 The arcuate nucleus (Arc) is in an ideal location to receive a wealth of 
information regarding energy balance. Leptin, produced from adipose tissue, provides 
humoral information about long-term energy stores (Klok, Jakobsdottir et al. 2007), 
while more short-term information is obtained from plasma levels of hormones related 
to meal-intake (e.g. insulin, ghrelin) and from glucose-sensing neurons (Grossman 
1986). Furthermore, signals are conveyed from the gut to the hypothalamus by way of 
the vagus nerve, an information highway between the gut and the brain (Sawchenko 
1983). Top-down information from neurons in various cortical areas, amygdala, and 
bed nucleus of the stria terminalis convey immediate visual, gustatory and olfactory 
information, as well as reward expectancies, learned behaviours and emotional aspects 
of particular foods (Berthoud 2002). In turn, the Arc neurons have reciprocal 
connections to all of these areas, many of these via the lateral hypothalamus (LH) 
(Berthoud 2002).  
The LH is another key hypothalamic substructure, which although lacking a 
strong direct endocrine output due to its spatial separation from the median eminence 
(ME), has an impressive array of output connections to the telencephalon, hindbrain 
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and spinal cord, enabling it to engage both the skeletal (behavioural) and autonomic 
output systems. Of these outputs, melanocortin hormone (MCH) and orexin neurons 
play significant roles in feeding and energy balance. In turn, the LH receives direct 
and indirect sensory signals from various hypothalamic, cortical and limbic structures 
ranging from olfactory, gustatory and visual input, to mechanical information from the 
gut (Simerley 1995, Rempel-Clower and Barbas 1998) (Berthoud 2002). 
Overall, these areas of the hypothalamus along with many others (not 
described here for brevity) play pivotal roles in the regulation of energy balance. The 
neural mechanisms of energy balance involve an intricate balance of communication 
and feedback between the various hypothalamic nuclei and an information highway 
with hormonal, metabolite and neural traffic. This dynamic internal picture is then 
relayed to endocrine and autonomic effectors to complete a complex, fluid feedback 
loop.   
However, the hypothalamus-regulated homeostatic regulation of appetite and 
food intake is only one part of the appetitive framework. Non-homeostatic neural 
mechanisms are also an important consideration in the overall control of food intake 
(Berthoud 2006, Wise 2006, Egecioglu, Skibicka et al. 2011, Waterson and Horvath 
2015). The term “non-homeostatic” encompasses both motivation and incentive 
salience applied to food rewards, but also the inherent palatability or “hedonic” aspect 
of eating in itself. These rewarding properties of eating, beyond metabolic demand are 
largely controlled by the mesolimbic reward system (Wise 2006). The reward system 
circuitry is comprised of the ventral tegmental area (VTA) and its main projection site, 
the nucleus accumbens (NAcc), a hotspot for dopamine (DA) release (Swanson 1982, 
Bassareo and Di Chiara 1999, Spanagel and Weiss 1999). This pathway is critical to 
the motivation to seek-out and obtain a rewarding stimulus, and is associated with 
promoting incentive valuation of drugs of abuse, as well as natural rewards, including 
food (Kenny 2011, Volkow, Wang et al. 2012). 
Although spatially and functionally separated from the hypothalamus, there is 
a lot of overlap between the mesolimbic reward circuitry and the neural pathways 
involved in homeostatic food intake (Berthoud 2006, Volkow, Wang et al. 2011, 
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Howick, Griffin et al. 2017). Indeed, almost any food tastes better when hungry 
compared to a state of satiation (Perello and Dickson 2015). Orexin and glutamatergic 
neurons from the LH activate dopaminergic neurons in the VTA, the main projection 
site to the NAcc. Indeed, VTA activation by peripheral ghrelin is dependent on 
functional orexin neurons in the LH (Perello, Sakata et al. 2010). By contrast, the 
hypothalamic effect on food intake is dependent on the reward circuitry to effect the 
intended modification to food intake. Therefore, it seems that the so-called 
homeostatic and non-homeostatic feeding behaviours are intertwined (Volkow, Wang 
et al. 2011). 
In summary, the presence or perception of hunger in a given situation is a net 
result of a dynamic balance of ascending neurohumoral feedback on energy status, as 
well as sensory information from higher brain areas associated with reward and 
motivation. The top-down regulation of food intake and the underlying neural 
mechanisms are extremely complex, and although a lot is now known, a lot is yet to 
be discovered in this area. The vast array of communicating neuropeptides and the 
volume of neuronal communication between the various sub-regions of the 
hypothalamus, telencephalon and brainstem is a testament to this very complicated 
picture (Berthoud 2002). One of the most investigated hormones orchestrating many 
changes to these areas is the peptide hormone and neuropeptide, ghrelin. 
Ghrelin and the GHSR-1a in appetite and food intake 
regulation 
The ghrelin hormone is the only known peripherally produced orexigen. The 
28aa peptide was discovered by Kojima and colleagues in 1999, is synthesized by 
gastric endocrine cells (Kojima et al., 1999). Initially, ghrelin was discovered to be the 
endogenous ligand for the GHSR-1a, responsible for eliciting growth hormone (GH) 
release from the anterior pituitary gland. Matthias Tschöp and colleagues reported 
soon after that ghrelin was responsible for regulating food intake, body weight, 
adiposity and glucose metabolism (Tschop, Smiley et al. 2000). Due to its proximal 
relationship with mealtimes, spiking pre-prandially and returning to baseline in the 
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post-ingestive phase, ghrelin was originally known as a “meal initiation” or “hunger” 
hormone (Cummings, Purnell et al. 2001). It was postulated to act as a gastrointestinal 
signal for fuel status to the brain, adjusting food intake and energy expenditure (Inui 
2001, Asakawa, Inui et al. 2005). Consistent with this notion, the oxyntic cells of the 
stomach release ghrelin into the bloodstream (Inui 2001) when hunger is perceived 
(Cummings, Purnell et al. 2001). Subsequent hypothalamic GHSR-1a-mediated 
activation of arcuate nucleus neuropeptide Y/agouti-related peptide neurons serves to 
stimulate orexigenic activity through Y1 receptors, while concomitantly inhibiting 
satiating pro-opiomelanocortin neurons (Nakazato, Murakami et al. 2001, Cowley, 
Smith et al. 2003). Furthermore, ghrelin contributes to the regulation of body weight 
by potently stimulating GH secretion from the pituitary, increasing adiposity and 
reducing energy expenditure (Takaya, Ariyasu et al. 2000, Wren, Small et al. 2000). 
Recently, however, this traditional and narrowly defined view of ghrelin as a “hunger 
hormone” has been challenged (McFarlane, Brown et al. 2014).  
Increasing evidence supports a more complex role for ghrelin in the regulation 
of hunger and metabolism. Goldstein and Brown showed that ghrelin-stimulated GH 
secretion is critical to protecting the body from starvation-induced hypoglycaemia 
(Goldstein, Zhao et al. 2011). Ghrelin is also implicated as a contributor in reward 
processing, memory consolidation, response to stress, gastrointestinal motility, 
glucose homeostasis and many other functions (Masuda, Tanaka et al. 2000, Carlini, 
Monzon et al. 2002, Abizaid, Liu et al. 2006, Chuang, Perello et al. 2011). 
1.2 Ghrelin - Production, Cleavage and Octanoylation 
Ghrelin is encoded by the ghrelin gene (ghrl) in humans, located on 
chromosome 3p25-26 from which alternative splicing and post translational 
modification can yield a variety of bioactive molecules such as obestatin and des-acyl 
ghrelin (Figure 1.2) (Zhang, Ren et al. 2005). Ghrelin is derived from enzymatic 
cleavage of preproghrelin with ghrelin-o-acetyl transferase (GOAT) (Gualillo, Lago 
et al. 2008), an enzyme which activates the peptide via n-octanoylation on the serine 
3 residue, yielding acyl-ghrelin (Kojima, Hosoda et al. 1999). Acylated and des-
acylated found in the circulation, however only the acylated form acts as a modulator 
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of the GHSR-1a (Bednarek, Feighner et al. 2000). Des-acylated ghrelin is the most 
abundant from found in the circulation and is suggested to be the active ligand for an 
additional, unidentified, subtype of the GHSR. There is also increasing evidence 
pointing to the importance of des-acyl ghrelin as a distinct, pharmacologically active 
moiety, rather than an inactive, neutral entity (Inhoff, Monnikes et al. 2008, Delporte 
2013). Indeed, recent evidence has begun to unravel various effects of desacyl-ghrelin 
on food intake and gastric motility. The reader is directed to the latter part of this 
introduction (Section 1.7.1) for more information here.  
 
Figure 1.2. Production and Cleavage of Acyl-ghrelin: Ghrelin is encoded by 
the ghrelin gene (ghrl) in humans, located on chromosome 3p25-26, and enzymatic 
cleavage of preproghrelin with ghrelin-o-acetyl transferase (GOAT) activates the 
peptide via n-octanoylation on the serine 3 residue, yielding acyl-ghrelin. Figure 
reproduced from Schellekens et. al (Schellekens, Dinan et al. 2013)  
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1.3 Role of ghrelin in homeostatic and non-homeostatic feeding 
Like appetite and food intake, ghrelin’s role can be subdivided into the two 
mutually dependent categories of homeostatic and non-homeostatic feeding (Berthoud 
2006, Jerlhag, Egecioglu et al. 2006, Dickson, Egecioglu et al. 2011, Egecioglu, 
Skibicka et al. 2011, Schellekens, Dinan et al. 2013). The term “non-homeostatic” 
encompasses both motivation and incentive salience applied to food rewards, but also 
the inherent palatability or “hedonic” aspect of eating in itself. The ghrelin system not 
only acts as a barometer for energy balance (Tschop, Smiley et al. 2000, Nakazato, 
Murakami et al. 2001), but also contributes to the drive for eating beyond metabolic 
demand and the consumption of palatable foods (Dickson, Egecioglu et al. 2011, 
Egecioglu, Skibicka et al. 2011). Therefore, ghrelin and the GHSR-1a, have been 
extensively investigated as potential therapeutic targets to tackle metabolic, eating- 
and appetite-related disorders by virtue of the unique position which the ghrelinergic 
system occupies at the interface of homeostatic and hedonic feeding (Lutter and 
Nestler 2009, Schellekens, Finger et al. 2012, Schellekens, Dinan et al. 2013, Perello 
and Dickson 2015). 
The ghrelinergic system has received considerable focus as a target in 
maladaptive changes to homeostatic energy balance (Tschop, Smiley et al. 2000, 
Cummings 2006, Argilés, López-Soriano et al. 2008). This is achieved through 
manipulating a number of physiological mechanisms resulting in a net anabolic effect 
in the body (Cowley, Smith et al. 2003, De Vriese, Perret et al. 2010). The normal 
ageing process yields a number of physiological changes, which lead to a reduction in 
appetite and appropriate nutritional intake (Chapman 2004, Malafarina, Uriz-Otano et 
al. 2013). Declining ghrelin levels contribute to this reduction in food intake and lean 
body mass (Malafarina, Uriz-Otano et al. 2013). Furthermore, ageing population 
demographics translate to a greater incidence of chronic conditions such as 
cardiovascular disease, respiratory disease and cancer (Organization 2015). Chronic 
diseases compound a weakening ghrelin axis by increasing systemic inflammation and 
cytokine output (DeBoer 2008). Cytokine-mediated activation of anorexigenic neuron 
populations in the hypothalamus causes a cascade of metabolic changes resulting in 
loss of lean and fat mass, and the development of cachexia (Chapman 2004, DeBoer 
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2011, Malafarina, Uriz-Otano et al. 2013). Thus, a metabolic backdrop is created 
which antagonises ghrelin’s somatotrophic effect (DeBoer 2008, DeBoer 2011, Nass, 
Gaylinn et al. 2011). Age-related malnutrition and under-eating following chronic 
diseases results in prolonged hospital stays, decreased independence and poorer 
response to treatment, leading to a greater burden on global health infrastructures and 
poorer clinical outcomes (Chapman 2004, Hickson 2006, Malafarina, Uriz-Otano et 
al. 2013). 
Further to its role as a key mediator of the energy balance “set point”, ghrelin 
is also implicated in incentive salience and motivation to eat, and consequently has 
become a therapeutic target for development of therapies for overeating and obesity 
(Wren, Small et al. 2001, Horvath, Castaneda et al. 2003). The need for anti-obesity 
therapeutics is highlighted by the global increase in incidence of obesity in recent 
years. In 2014, more than 1.9 billion adults (39% globally) were overweight (WHO 
2016) and obesity continues to rise to epidemic proportions. In Western society 
particularly, consumption of readily available high-fat and high-sugar meals, together 
with increasingly sedentary lifestyles has led to a rise in the “metabolic syndrome”. 
This is a condition associated with weight gain, hyperglycaemia, insulin resistance, 
hypercholesterolaemia and a general inflammatory phenotype (Isomaa, Almgren et al. 
2001, Martin, Mani et al. 2015). In addition to homeostasis, neuronal pathways also 
exist which promote the consumption of palatable, calorie-dense foods beyond the 
metabolic demands of the organism (Kenny 2011). This is thought to be an evolutional 
mechanism that promotes over-eating of calorie-dense foods in preparation for times 
of food deprivation. This is redundant in the Western world where there is an 
abundance of food. The mesolimbic dopaminergic pathway in the brain is known to 
be a key mediator in this primitive drive (Spanagel and Weiss 1999, Pierce and 
Kumaresan 2006, Volkow, Wang et al. 2012). Overconsumption of palatable foods is 
thought to be triggered by hyperactivity of the reward system (Stoeckel, Weller et al. 
2008, Stice, Yokum et al. 2010). Furthermore, the late Bart Hoebel and colleagues in 
Princeton proved that sugar in itself can share many of the properties of addictive 
substances (Konturek, Konturek et al. 2004, Avena, Rada et al. 2008). In fact, palatable 
foods are now known to share the same reward pathways as non-psychostimulant 
drugs of abuse (Tanda and Di Chiara 1998). It should be noted that although the 
31 
 
concept of food addiction has gained significant ground, it has many heuristic 
limitations (Volkow, Wang et al. 2013, Hebebrand, Albayrak et al. 2014). 
Increases in circulating levels of endogenous ghrelin, following periods of food 
restriction, signal an increase in appetite and hunger and are correlated with a general 
increase in both “liking” and “wanting” of food (Druce, Wren et al. 2005, Perello and 
Dickson 2015). Interestingly, the elevated endogenous ghrelin levels have been 
associated with an increased DA output in the brain (Kawahara, Kaneko et al. 2013), 
while functional magnetic resonance imaging in human subjects has shown that 
ghrelin administration enhances the activation of the central reward circuitry in 
response to images of pleasurable foods (Malik, McGlone et al. 2008, Goldstone, 
Prechtl et al. 2014). Subsequently, ghrelin’s role in increasing the incentive valuation 
of food at the level of the mesolimbic circuitry has come to the fore in recent reviews 
(Andrews 2011, Perello and Dickson 2015).  
1.4 GHSR-1a – Biodistribution and Signalling 
The target for ghrelin and ghrelin ligands is the GHSR-1a, a 7 transmembrane 
G-protein coupled receptor (GPCR). The GHSR-1a is expressed both in the central 
nervous system (CNS) and peripherally in the body, and binding of acyl-ghrelin leads 
to receptor activation (Kojima, Hosoda et al. 1999). The distribution of the GHSR-1a 
is of paramount importance as it is the executor of ghrelin’s function. Indeed, it is the 
peripheral (exclusive to non-CNS tissue) and central (exclusive to the CNS) 
distribution of the GHSR-1a which is responsible for the plethora of physiological 
effects which ghrelin exerts (Figure 1.3)(Howick, Griffin et al. 2017). The GHSR-1a 
is densely expressed in the hypothalamic nuclei which sends neuronal projections to 
other appetite regulating centres (Gnanapavan, Kola et al. 2002, Andrews 2011). 
Peripherally, GHSR-1a is located on vagal afferents, pancreatic cells, spleen, cardiac 
muscle, bone, adipose, thyroid, adrenal glands and on immune cells (Gnanapavan, 
Kola et al. 2002, Stengel, Goebel et al. 2010). Therefore, given the ubiquitous 
expression of the receptor, any instance of exogenous ghrelin or ghrelin ligand 
administration leads to a combination of downstream effects. Neither exogenous 
ghrelin nor ghrelinergic compounds can effectively target centrally-controlled food 
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intake, without affecting a multitude of other central and peripheral outputs (Horvath, 
Castaneda et al. 2003, Müller, Nogueiras et al. 2015). The non-specific tissue effects 
of peripheral ghrelin administration may be further complicating an intricate metabolic 
balance and need to be considered. 
 
Figure 1.3. Central and Peripheral functions of ghrelin. This combines the 
documented methods of ghrelin’s action after its release from the stomach, or 
exogenous administration. Ghrelin travels via the circulation to activate the growth 
hormone secretagogue receptor (GHSR-1a) in the arcuate nucleus (Arc) and the 
nucleus tractus solitarius (NTS) after circumventing the blood-brain barrier (BBB), 
denoted by the red arrow. Peripheral signals are conveyed to the central nervous 
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system (CNS) via vagal afferents also. Activation of the GHSR-1a leads to a multitude 
of centrally and/or peripherally mediated effects 
1.4.1 Central Ghrelinergic Signalling 
Food intake, adiposity and energy homeostasis are centrally controlled functions 
of ghrelin and the GHSR-1a which have been extensively described in the literature 
(Tschop, Smiley et al. 2000, Nakazato, Murakami et al. 2001, Cowley, Smith et al. 
2003). Chronic central administration of ghrelin induces adiposity in rodents by 
reducing the utilization of fat as an energy substrate (Tschop, Smiley et al. 2000). 
Further work confirmed this central action, with expression of mRNA for fat-sparing 
enzymes fatty-acid synthase, acetyl-CoA carboxylase α, stearoyl-CoA desaturase-1, 
and lipoprotein lipase all being increased with chronic intracerebroventricular infusion 
of ghrelin. In addition, mRNA expression for carnitine palmitoyltransferase-1α, 
involved in fat utilisation is decreased while lipid mobilization is reduced following 
ghrelin treatment, as shown by an increase in respiratory exchange ratio in vivo 
(Theander-Carrillo, Wiedmer et al. 2006, Davies, Kotokorpi et al. 2009). Furthermore, 
ghrelin stimulates lipid deposition in human visceral adipose tissue in a dose-
dependent manner (Rodriguez, Gomez-Ambrosi et al. 2009). Acute ghrelin 
administration consistently stimulates food intake across species (Wren, Small et al. 
2000, Cummings, Purnell et al. 2001, Nagaya, Uematsu et al. 2001, Wren, Small et al. 
2001, Mericq, Cassorla et al. 2003, Chen, Trumbauer et al. 2004, Druce, Wren et al. 
2005, Schmid, Held et al. 2005, Wynne, Giannitsopoulou et al. 2005). In recent years 
however, research has proven that ghrelin may not be the critical regulator of food 
intake it was once heralded to be. 
Studies in knockout mice have confirmed the ghrelin peptide is not a key 
mediator of food intake or growth (Sun, Ahmed et al. 2003). In contrast with 
predictions, ghrelin knockout mice are neither undersized nor hypophagic; their 
behavioural phenotype for food intake and physical attributes are indistinguishable 
from wild-type littermates (Sun, Ahmed et al. 2003, McFarlane, Brown et al. 2014). 
Ghrelin-null rodents also display normal responses to starvation and diet-induced 
obesity (Sun, Ahmed et al. 2003). Furthermore, ablation of ghrelin in adulthood failed 
to elicit effects on food intake, body weight, or resistance to diet-induced obesity 
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(McFarlane, Brown et al. 2014). Interestingly, both germline ghrelin-deficient and 
ghrelin cell-ablated mice display a profound hypoglycaemia following prolonged 
calorie restriction. Overall however, the phenotype in ghrelin-knockouts is suggestive 
of a non-critical role for ghrelin in food intake and growth. 
Despite the apparent compensatory mechanisms that exist in the absence of 
ghrelin, exogenous ghrelin or ghrelin ligands have the potential to significantly 
modulate appetite, most likely via central GHSR-1a signalling. Recently it was shown 
through neuronal-specific ablation of the GHSR-1a that receptor signalling within the 
CNS is a crucial regulator of energy metabolism. This is important to consider in the 
context of the high constitutive activity of the GHSR-1a, which does not require 
ghrelin in order to become activated (Holst and Schwartz 2004, Petersen, Woldbye et 
al. 2009). Zigman and colleagues, amongst others, have demonstrated that GHSR-1a-
null mice are resistant to diet-induced obesity (Zigman, Nakano et al. 2005, Ma, Lin 
et al. 2011, Lin, Lee et al. 2014). Neuronal GHSR-1a is also essential for ghrelin-
induced meal initiation and maintenance of body weight in conditions of caloric deficit 
(Lee, Lin et al. 2016). Central GHSR-1a signalling therefore seems to be critical for 
not only acute initiation of food intake, but also is a key mediator of body weight. 
Supporting this, a genetic mutation in GHSR-1a that allows ghrelin binding but 
prevents activation of the receptor, leads to the condition of familial short stature 
(Pantel, Legendre et al. 2006). 
Consistent with the notion of a multifunctional role for ghrelin, the GHS-R1a 
is also expressed in several non-hypothalamic brain areas. In-situ binding studies have 
demonstrated the existence of the GHSR-1a in the midbrain DA system, particularly 
the main mesolimbic reward circuitry structures; the ventral tegmental area (VTA) and 
its primary projection site, the NAcc (Abizaid, Liu et al. 2006, Zigman, Jones et al. 
2006, Landgren, Simms et al. 2011). The VTA projects GHSR-1a-expressing 
dopaminergic neurons which terminate in the NAcc, a hotspot for DA release which 
is critically associated with promoting incentive value of drugs of abuse and natural 
rewards, including food (Liu and Borgland 2015). Further projections from the VTA 
to the medial prefrontal cortex, an important part of the reward system which also 
encodes the genes for the GHSR-1a, are described as part of this pathway (Swanson 
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1982, Tzschentke 2000, Landgren, Engel et al. 2011). Consequently, the GHSR-1a 
located in the midbrain dopaminergic pathway may be a driver for the decision to eat 
palatable, calorie-dense foods, irrespective of metabolic need. 
GHSR-1a is also expressed in areas associated with memory, emotional arousal 
and cue-potentiated feeding (Diano, Farr et al. 2006, Kern, Mavrikaki et al. 2015, 
Müller, Nogueiras et al.). For example, GHSR-1a in the hippocampus is known to play 
a role in synaptic plasticity, increasing hippocampal spine density and enhancing long-
term potentiation, an important phenomenon in learning and memory consolidation 
(Diano, Farr et al. 2006). Activation of hippocampal GHSR-1a in vivo increased 
performance and retention of memory-dependent tasks (Carlini, Monzon et al. 2002, 
Diano, Farr et al. 2006). Furthermore, the GHSR-1a is densely expressed in several 
sub-nuclei of the amygdala and is associated with amelioration of anxiety-like 
behaviours in food scarcity (Alvarez-Crespo, Skibicka et al. 2012). Altogether, the 
above is supportive of a broader, non-homeostatic function for GHSR-1a signalling in 
higher brain functions dependent on metabolic status, for example, heightened 
salience and increased memory consolidation in times of hunger to remember where 
food can be obtained (Diano, Farr et al. 2006). Critically, although ghrelin peptide 
mRNA is not found in the brain, it’s expression is noted peripherally, suggesting 
multiple potential autocrine or paracrine roles of the hormone (Gnanapavan, Kola et 
al. 2002, Sakata, Nakano et al. 2009, Furness, Hunne et al. 2011). Indeed, direct 
actions of ghrelin in the periphery have been reported in several organ systems. 
1.4.2 Peripheral Ghrelinergic Signalling 
The GHSR-1a is responsible for several peripheral mechanisms modulated by 
ghrelin including, but not limited to, cardiac contractility, bone formation and 
reproductive function. Firstly, GHSR-1a is expressed on rodent and human immune 
cells, including monocytes and T cells (Gnanapavan, Kola et al. 2002, Dixit, Schaffer 
et al. 2004). Ghrelin and ghrelin agonists have shown a protective effect under acute 
endotoxaemia, enhancing the effectiveness of immune response through tissue 
infiltration in vivo (Chen, Liu et al. 2008, Li, Li et al. 2010), leading to decreased 
mortality. Ghrelin is also known to directly reduce the expression of inflammatory 
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cytokines (Dixit, Schaffer et al. 2004). Secondly, protective effects have also been 
attributed to ghrelin in rodent cardiomyocytes (Baldanzi, Filigheddu et al. 2002, Lear, 
Iglesias et al. 2010). The cardioprotective mechanisms underlying this have been 
described in detail elsewhere (Pang, Xu et al. 2004). The ghrelin agonist, hexarelin, 
was shown to increase cardiac output in rodents and humans (Bisi, Podio et al. 1999, 
Nagaya, Uematsu et al. 2001). Thirdly, ghrelin and the GHSR-1a are expressed in rat 
and human testis (Barreiro, Gaytan et al. 2002, Gnanapavan, Kola et al. 2002, Gaytan, 
Barreiro et al. 2004) and in females both have been documented to be expressed in 
ovary, hilus cells (leydig cells) and corpora lutea, all of which are hormone secreting 
cells which play roles in the female reproductive cycle (Muccioli, Lorenzi et al. 2011). 
Ghrelin plays a crucial role in the regulation of the hypothalamic-pituitary-gonadal 
axis mainly through reducing secretion of hypothalamic gonadotropin-releasing 
hormone and stimulating local luteinizing hormone and follicle stimulating hormone 
secretion. 
1.4.3 Complementary Ghrelinergic Signalling: 
Gastrointestinal Motility, Glucose Homeostasis and 
Visceral Pain 
All of the above have discussed distinct centrally-mediated and non-central 
autocrine or paracrine functions of GHSR-1a. In certain instances, central and 
peripheral ghrelinergic signalling appear to be complementary, as is the case for 
regulation of gastrointestinal motility, glucose homeostasis and visceral pain. The role 
of ghrelin and the GHSR-1a in the regulation of gastrointestinal tract motility has 
already been reviewed (De Smet, Mitselos et al. 2009). The GHSR-1a is located in the 
mucosa and myenteric plexus of rodent and human gastrointestinal tract, reinforcing 
the local neural role for ghrelin in gut motility (Date, Murakami et al. 2002, Dass, 
Munonyara et al. 2003, Takeshita, Matsuura et al. 2006). In vitro, this notion was 
supported by contractility studies showing that ghrelin directly activates both 
cholinergic (Dass, Munonyara et al. 2003, Fukuda, Mizuta et al. 2004, Depoortere, De 
Winter et al. 2005) and tachykinergic excitatory neurons in fundus and antrum. In vivo, 
peripheral administration of ghrelin accelerates gastric emptying in a dose-dependent 
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manner (Trudel, Tomasetto et al. 2002, Depoortere, De Winter et al. 2005, Dornonville 
de la Cour, Lindqvist et al. 2005, Kitazawa, De Smet et al. 2005). In humans, ghrelin 
infusion stimulates gastric emptying in healthy participants and ameliorates symptoms 
of gastroparesis (Levin, Edholm et al. 2006). However, central administration also 
displays a pronounced effect on gastrointestinal tract motility (Asakawa, Inui et al. 
2001, Fujino, Inui et al. 2003). Vagotomy or chemical deactivation of the vagus were 
shown to abolish the observed effects of peripherally administered ghrelin (Masuda, 
Tanaka et al. 2000, Fukuda, Mizuta et al. 2004). Ghrelin’s effects in respect of 
gastrointestinal motility thus seem to be vago-vagal in origin—meaning that it results 
from reciprocal vagal communication between the gut and the dorsal vagal complex 
of the brain. Similar to food intake and adiposity above, gastric emptying is unaffected 
in ghrelin knockout rodents, suggesting the existence of compensatory mechanisms 
(De Smet, Mitselos et al. 2009). Critically, it has been suggested that local mechanisms 
become operational under abnormal conditions such as vagal denervation or 
pharmacological stimulation (Fujino, Inui et al. 2003). Supporting this, it was shown 
that downregulation of GHSR-1a in the small intestine delays transit in vagotomised 
mice (Yang, Qiu et al. 2011). Overall, evidence suggests that ghrelin acts from the 
periphery in a remote fashion to modulate gastrointestinal function from the CNS via 
the vagus nerve, however the gastrointestinal distribution of the GHSR-1a paves the 
way for local activity which may be heightened by pharmacological stimulation 
(Fujino, Inui et al. 2003). The motilin receptor has also been characterized in the 
human gastrointestinal tract (Feighner, Tan et al. 1999) and displays close structural 
homology and a functional compensatory role with the GHSR-1a in gastrointestinal 
motility (Nunoi, Matsuura et al. 2012). 
Interacting central and peripheral GHSR-1a signalling is evident in the 
physiology of glucose homeostasis. Many peripheral hormones act in a central manner 
to regulate energy metabolism and glucose balance, including glucagon, glucagon-like 
peptide 1 and insulin (Obici, Zhang et al. 2002, Sandoval, Bagnol et al. 2008, Morton 
and Schwartz 2011, Mighiu, Yue et al. 2013). However, the GHSR-1a is expressed in 
pancreatic α and β cells (Date, Murakami et al. 2002, Date, Nakazato et al. 2002, 
Dezaki, Hosoda et al. 2004, Kageyama, Funahashi et al. 2005), and peripheral ghrelin 
acts directly on the receptor in pancreatic islets to modulate the release of insulin 
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(Reimer, Pacini et al. 2003, Dezaki, Hosoda et al. 2004, Tong, Prigeon et al. 2010). In 
humans, Broglio and colleagues found that acute administration of acyl-ghrelin in the 
fasted state significantly reduced plasma insulin while promoting hyperglycaemia, 
however, a continuous infusion stimulated insulin secretion secondary to elevated 
glucose levels (Broglio, Arvat et al. 2001, Broglio, Prodam et al. 2008). Supporting 
this, several studies have consistently shown that ghrelin administration promotes 
hyperglycaemia (Garin, Burns et al. 2013). Central administration of ghrelin also 
regulates plasma insulin in rodents (Kim, Namkoong et al. 2004, Nesic, Stevanovic et 
al. 2008, Heppner, Piechowski et al. 2014, Stark, Reichenbach et al. 2015). Somewhat 
confusingly, it seems that central GHSR-1a signalling exerts an insulinotropic effect, 
versus the inhibition of glucose-stimulated insulin secretion by peripheral GHSR-1a 
activation (Tong, Prigeon et al. 2010, Heppner, Piechowski et al. 2014), meaning that 
the receptor may play distinct roles in glucose homeostasis depending on the site of 
action. Furthermore, administration of acyl-ghrelin into the portal, but not the femoral 
vein inhibited glucose-stimulated insulin secretion. Hepatic vagotomy attenuated this 
inhibition suggesting indirect central control over insulin secretion via neural 
signalling (Cui, Ohnuma et al. 2008, Meyer 2010). Critically, fasting decreases insulin 
levels in both wild type and ghrelin knockouts, as well as producing comparable 
responses to both hypo-caloric and hyper-caloric situations. Hence, compensatory 
pathways seem to exist for glucose homeostasis, however GHSR-1a knockout leads to 
reduced glucose levels under calorie- deprivation (Sun, Ahmed et al. 2003, Sun, Butte 
et al. 2008). Later work from the same group used GHSR-1a-null mice to show 
reduced adiposity and insulin resistance (Lin, Saha et al. 2011). Thus, a body of 
evidence exists to support the indirect central control of GHSR-1a signalling over 
glucose homeostasis. Furthermore, it seems that metabolic status is a key determinant 
of the regulatory action of central ghrelin on peripheral glucose homeostasis (Stark, 
Reichenbach et al. 2015). A recent review summarized the complex interrelationship 
that exists between ghrelin, insulin and glucose (Chabot, Caron et al. 2014). The ability 
of insulin and glucose levels to appreciably impact on appetite (Woods, Lutz et al. 
2006) means that indiscriminate targeting of the GHSR-1a without due consideration 
of the effects on peripheral glucose and insulin metabolism may ultimately decrease 
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efficacy of appetite modulation therapy (Lavin, Wittert et al. 1996, Flint, Gregersen et 
al. 2007). 
Ghrelin and the GHSR-1a have also been the subject of investigation in the 
modulation of pain transmission (Ferrini, Salio et al. 2009). Originally, ghrelin’s role 
in pain sensitivity was thought to be through a combination of central and peripheral 
GHSR-1a signalling (Guneli, Kazikdas et al. 2007, Vergnano, Ferrini et al. 2008). 
Chronic peripheral ghrelin administration has been shown to attenuate neuropathic 
pain in rats (Guneli, Onal et al. 2010). Ghrelin treatment resulted in elevated levels of 
anti-inflammatory cytokines in vivo in a rodent model of inflammatory pain 
(Azizzadeh, Mahmoodi et al. 2016). It has also been shown that central and peripheral 
ghrelin administration prevents the pain response caused by intraplantar insults 
(Sibilia, Lattuada et al. 2006). Furthermore, mRNA for GHSR-1a is found in pain-
processing centres including the sensory motor cortex and the dorsal horn of the spinal 
cord (Guan, Yu et al. 1997, Hou, Miao et al. 2006, Vergnano, Ferrini et al. 2008, Zhou, 
Li et al. 2014). Current opinion seems to agree that ghrelin’s analgesic effect is 
conveyed mainly through central mechanisms via the opioid system (Sibilia, Lattuada 
et al. 2006, Ferrini, Salio et al. 2009, Sibilia, Pagani et al. 2012, Wei, Zhi et al. 2013). 
Therefore, ghrelin and the GHSR-1a may have communicating peripheral and central 
pathways in the modulation of pain sensitivity, which may have interesting potential 




The challenge of changing food intake, from in vitro to in 
vivo 
1.5 GHSR1a as a promiscuous target 
Further to the distribution of GHSR-1a and the consideration of central and 
peripheral effects, the receptor is known to display heterogenous signalling cascades, 
downregulation/internalization and heterodimerization—all of which are akin to other 
GPCR’s and constitute important considerations for appetite modulation therapy 
(Luttrell 2008) (Figure 1.4). Downstream effects of the GHSR-1a via coupling to 
different G-proteins have been reviewed in detail elsewhere (Schellekens, Dinan et al. 
2013). Importantly, it is worth emphasising that the GHSR-1a displays heterogenous 
functions dependant on the location of the receptor expression in the body. For 
example, in neurons of the arcuate nucleus, ghrelin acting on the GHSR-1a induces 
orexigenic neuropeptide Y release through N-type voltage-gated Ca2β channels via 
cyclic adenosine monophosphate (cAMP) increases in the cell (Kohno, Gao et al. 
2003). In pituitary cells responsible for effecting somatotrophin release, GHSR-1a 
mainly acts via Gαq coupled G-protein to trigger calcium release from intracellular 
stores (Malagon, Luque et al. 2003). These signalling pathways are both excitatory- 
interestingly, in the periphery, ghrelin binding to GHSR-1a in pancreatic β cells leads 





Figure 1.4. Ubiquitous distribution and pleiotropic pharmacodynamics of GHSR-
1a: The GHSR-1 displays heterogenous tissue distribution as well as signalling 
cascades. The tissue distribution of GHSR-1a spans various areas of the brain 
involved in appetite, reward, memory, fear amongst others. Peripheral GHSR-1a is 
also widely distributed. Furthermore, GHSR-1a displays pleiotropic downstream 
signalling cascades as well as ability to heterodimerize and cross-talk with other 
GPCR systems. The widespread tissue distribution as well as the wide-ranging nature 
of GHSR-1a signalling leads to various downstream pharmacodynamic effects and 




The GHSR-1a not only exhibits site- and ligand-dependant signalling; it 
demonstrates an ability to “cross-talk” with other neuroendocrine GPCRs 
(Schellekens, van Oeffelen et al. 2013) (Figure 1.4). The receptor has been shown to 
pair or dimerize with other receptors, leading to either attenuation or augmentation of 
signalling. GHSR-1a: melanocortin-3 receptor protomers have been described; 
melanocortin-3 receptor is an important downstream signalling receptor in the 
homeostatic control of food intake (Irani, Xiang et al. 2011). Rediger and colleagues 
showed that the signalling modalities of one GPCR was dependent on the 
conformational activity of the other. In essence, ghrelin-induced GHSR-1a activation 
is attenuated by interaction with the melanocortin-3 receptor (Rediger, Piechowski et 
al. 2011). We previously demonstrated the existence of GHSR-1a: Serotonin 2C 
dimers in vitro, hypothesizing novel pharmacological targets for drug treatment based 
on the involvement of serotonin 2C receptor in satiety signalling (Miller 2005, Dutton 
and Barnes 2006, Garfield and Heisler 2009, Schellekens, van Oeffelen et al. 2013). 
Furthermore, GHSR-1a: Dopamine D2 receptor co-expressed on neurons leads to 
attenuated dopaminergic response upon administration of a GHSR-1a antagonist in 
vivo (Kern, Albarran-Zeckler et al. 2012). Critically, it is the allosteric interaction of 
the GPCR protomer which results in the observed cross-talk, rather than the net effect 
of independent neuroendocrine signalling (Kern, Albarran-Zeckler et al. 2012). More 
recently, it was shown that hippocampal-dependent synaptic plasticity is modulated 
by GHSR-1a: Dopamine D1 heterodimerization (Kern, Mavrikaki et al. 2015). 
Moreover, an inactive isoform of GHSR-1a, the GHS-R1b, is worthy of mention here 
though it is not a major focus of this work. GHSR-1b is a truncated, 5-transmembrane 
receptor (Chow, Sun et al. 2012). The GHSR-1b receptor exhibits widespread tissue 
distribution and exhibits an ability to co-localize with the GHSR-1a causing a 
subsequent attenuation of activity through an increased internalization of the active 
receptor. This is potentially significant in the backdrop of ghrelin signalling as the 
GHSR-1a exhibits high constitutive signalling in the absence of its native ligand (Holst 
and Schwartz 2004, Petersen, Woldbye et al. 2009, Mear, Enjalbert et al. 2013). 
As well as heterogenous signalling and neuroendocrine cross-talk, the 
expression of the GHSR-1a on the cell membrane is critical to it being a successful 
therapeutic target. However, GPCRs are known to downregulate via receptor 
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internalization or endocytosis causing a subsequent attenuation of effect (Tsao and von 
Zastrow 2000). Unsurprisingly, the GHSR-1a has been shown to downregulate in 
response to various stimuli, including ghrelin- and ghrelin-ligand mediated activation 
(Kaji, Kishimoto et al. 2001, Orkin, New et al. 2003, Camina, Carreira et al. 2004). 
After binding of ghrelin to GHSR-1a, the complex is internalised into clathrin-coated 
pits, from which the receptor needs to be recycled back to the surface of the cell (Orkin, 
New et al. 2003). In vitro GH release is rapidly desensitized after exposure to a ghrelin 
agonist, MK-0677, and in vivo response in beagles was reduced to 25% after 4 days 
of daily administration (Guyda 2002). In line with this, GH release declines rapidly 
upon repeated ghrelin administration in humans (Gardiner and Bloom 2008). There is 
a dearth of information in the literature to suggest an ability of ghrelin to sustain 
elevated food intake in animals or humans upon long-term administration, and it is 
feasible that downregulation would contribute to a decline in orexigenic effects over 
time. One study showed no overall effect on food intake in rats after chronic 
administration of acyl-ghrelin (Davies, Kotokorpi et al. 2009). A limited number of 
clinical studies have failed to show an appreciable difference in food intake with 
chronic administration of ghrelin (Lundholm, Gunnebo et al. 2010) or the synthetic 
agonist growth hormone releasing peptide-2 (Mericq, Cassorla et al. 2003). However, 
in acute situations consistently pronounced orexigenic effects are reported in both 
animals and humans (Wren, Seal et al. 2001, Druce, Wren et al. 2005, Schmid, Held 
et al. 2005, Neary, Druce et al. 2006). Conversely, GHSR-1a has been shown to 
upregulate, in the hypothalamus at least, during fasting (Petersen, Woldbye et al. 
2009). Hence, GHSR-1a expression levels, and subsequent effect of receptor 
modulation, are heavily dependent on the metabolic state. To further confirm this, it 
has been noted that leptin-deficient Zucker rats, characterized by profound 
hyperphagia, display a heightened expression of the GHSR-1a and a corresponding 
increased sensitivity to ghrelin and ghrelin agonists (Hewson, Tung et al. 2002). 
In summary, the above described heterogeneity of the GHSR-1a in terms of 
distribution, downstream signalling, tachyphylaxis and neuroendocrine 
communication paints a complex picture. This complexity has hindered development 
of an effective GHSR-1a targeting therapy for appetite modulation. It seems that the 
effect of GHSR-1a modulation hinges on the metabolic backdrop in which the therapy 
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is delivered, hence the indiscriminate targeting of the GHSR-1a with non-specific 
systemic delivery of varying ligands may be one of the reasons for a lack of efficacy 
to date. The widespread nature of the receptor in the body leads to GHSR-1a activation 
in off-target sites, potentially leading to local effects which can ultimately inhibit the 
intended benefit.  
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1.6 Ghrelin and Ghrelin Ligands: Pharmacokinetic Perspectives 
On the whole, central action seems to be critical for GHSR-1a-mediated 
appetite modulation and energy balance. Understanding the pathway by which 
peripheral ghrelin acts centrally, after either endogenous release or exogenous 
administration, is critical to achieving therapeutic exploitation. As mentioned earlier, 
the question of whether ghrelin peptide is expressed in the brain is controversial and 
the subject of debate. Ghrelin immuno-reactive cells have been reported in the 
hypothalamus in some studies (Lu, Guan et al. 2002, Cowley, Smith et al. 2003), while 
the existence of ghrelin-producing cells was reported in the Arc of the hypothalamus 
(Kageyama, Kitamura et al. 2008). Recent evidence seems to refute these claims and 
now it is thought ghrelin is only present in these areas due to access of circulating 
ghrelin from the periphery (Furness, Hunne et al. 2011, Cabral, De Francesco et al. 
2015, Perello and Dickson 2015). The main pathways by which ghrelin is thought to 
exert its orexigenic effect after it is released from the stomach have been extensively 
reviewed (Horvath, Castaneda et al. 2003). 
1.6.1 Blood Brain Barrier Penetration 
The orexigenic effects of ghrelin have immediate onset, with food intake 
increasing 10 min after systemic administration (Cummings, Purnell et al. 2001, 
Cabral, De Francesco et al. 2015). It follows therefore that ghrelin must have ready 
access into the brain. In fact, ghrelin can directly cross the blood brain barrier (BBB) 
at areas which are not highly protected, and subsequently convey its effect via neural 
projections from the site of entry to various feeding centres (Inui 2001, Andrews 
2011). This is supported by the suggested “leaky” nature of the BBB surrounding the 
circumventricular organs of the brain (Banks 2002, Wang, Saint-Pierre et al. 2002, 
Takayama, Johno et al. 2007). The fenestrated endothelia surrounding the 
hypothalamus are supplied by capillaries which confer a rich blood supply, allowing 
the hypothalamus to sample the contents of the systemic circulation (Ciofi, Garret et 
al. 2009). This affords many central nervous system (CNS) active peptides, including 
ghrelin, access to the CNS while still retaining effective and selective barrier function 
for the brain (Zigman, Jones et al. 2006, Cabral, Valdivia et al. 2014). Furthermore, 
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the blood—cerebrospinal fluid (CSF) barrier which exists at the choroid plexus also 
has been shown to allow ghrelin access to the Arc. This is composed of a differentiated 
layer of cells that surround a core of capillaries in some brain ventricles and produce 
CSF, and/or the hypothalamic tanycytes, a specialized layer of bipolar ependymal cells 
that line the floor of the third ventricle and bridge the CSF and the capillaries of the 
median eminence (Redzic, Preston et al. 2005, Bolborea and Dale 2013). Other 
circumventricular organs such as the area postrema, a part of the dorsal vagal complex, 
affords ghrelin diffusive access to the abundance of GHSR-1a’s in the nucleus tractus 
solitarius and dorsovagal nucleus. The nucleus tractus solitarius (NTS) is a relay hub 
for appetite regulation with a complex network of efferent and afferent connections. 
The NTS converts humoral responses into neuronal communication (Grill and Hayes 
2012). 
1.6.2 Vagus Nerve Signalling 
The NTS is also important to the other described route by which peripheral 
ghrelin accesses central GHSR-1a; remote modulation from the gut signalling through 
the vagus nerve and the brainstem (Date, Murakami et al. 2002, Horvath, Castaneda 
et al. 2003). Indeed, several gastrointestinal hormones such as cholecystokinin (CCK), 
peptide YY, and glucagon-like peptide 1 (GLP-1), transmit orexigenic and satiating 
signals to the brain, at least in part, via vagal afferents (Smith, Jerome et al. 1981, 
Koda, Date et al. 2005, Abbott, Small et al. 2006). Feeding-related information can 
travel directly to the dorsal vagal complex and NTS, where signals are converted from 
humoral to neural format and further relayed to higher brain levels. Indeed, it is known 
that gut derived peptides such as the satiating CCK exert their central action via vagal 
afferents from the gastrointestinal tract (Rogers and Hermann 2008). Early studies 
using c-Fos expression as a marker of neuronal activation showed that peripheral 
administration of a ghrelin mimetic increased Fos protein in the NTS (Bailey, Smith 
et al. 1998). The NTS provides a direct noradrenergic projection to the hypothalamus 
which is believed to be important for neural regulation of energy balance and food 
intake (Smith, Sun et al. 2007). Date and colleagues demonstrate that peripheral 
ghrelin signalling reaches the NTS by either blood or neural mechanisms and relays 
noradrenergic stimuli to the hypothalamus to increase feeding (Date, Murakami et al. 
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2002, Date, Shimbara et al. 2006, Date 2012). Transections above the level of the NTS, 
or specific ablation of dopamine β-hydroxylase (the noradrenaline synthesizing 
enzyme), abolished peripheral ghrelin-induced feeding (Date, Shimbara et al. 2006). 
Moreover, it has been reported that the orexigenic action of ghrelin is attenuated in 
humans who underwent gastric surgery involving complete or partial vagotomies (le 
Roux, Neary et al. 2005). Vagotomy also abolishes the orexigenic activity of ghrelin 
in rats (Date, Murakami et al. 2002). Another preclinical study however, reports that 
ghrelin’s orexigenic effect remains intact after a sub diaphragmatic vagal 
deafferentiation. The authors argue that a bilateral vagotomy, as described in Date’s 
work, would indiscriminately remove both afferent and efferent vagal innervation, 
thereby severing a multitude of other physiological processes, including satiating 
signals (Arnold, Mura et al. 2006). It is thus stated that sub diaphragmatic vagal 
deafferentiation is a more representative model for ablating the vagal afferent 
connection as it is less invasive to other vagally-mediated physiological parameters 
such as heart rate and respiration. However, the dose of ghrelin used in this study was 
substantially higher than that used in the original work by Date therefore results cannot 
be directly compared. Critically, it points to the fact that vagal signalling is not 
essential to relay ascending orexigenic messages, likely due to the fact that the area 
postrema can facilitate diffusive access of ghrelin from the bloodstream to the NTS, 
enabling ascending signalling even without vagal innervation of the NTS. This is 
supported by the fact that intravenous ghrelin administration stimulates GH secretion 
in vagotomised patients (Takeno, Okimura et al. 2004). Taken together, all of the 
above information strongly suggests an interlinked role between blood and neural 
pathways for conveying ghrelin’s signal from the periphery to the CNS.  
1.7 Ghrelin administration in Human Studies 
Normal serum ghrelin levels vary in man and reach 0.2–0.4 pmol/mL in hunger 
states (Akamizu, Takaya et al. 2004, Druce, Wren et al. 2005), with active ghrelin 
levels peaking at of 0.01–0.035 pmol/mL (Akamizu, Iwakura et al. 2008, Paulo, 
Brundage et al. 2008, Veldhuis, Reynolds et al. 2008, Ashby, Ford et al. 2009). 
Intravenous infusions of 1–40 pmol/kg/min active ghrelin have been used clinically to 
increase appetite acutely in cachectic states (Wren, Seal et al. 2001, Rigamonti, 
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Pincelli et al. 2002, Druce, Wren et al. 2005, Levin, Edholm et al. 2006, Strasser, Lutz 
et al. 2008). From a pharmacological perspective, doses in this range are 
supraphysiological and have resulted in several hundred-fold changes in both active 
and total plasma ghrelin (Table 1.1). Lippl and colleagues administered doses of 
ghrelin more representative of the levels experienced endogenously, resulting in active 
ghrelin increasing to 0.057 pmol/mL (2.4-fold increase from baseline) (Lippl, 
Erdmann et al. 2012). This elevation failed to show an orexigenic effect in participants 
(Lippl, Erdmann et al. 2012). Critically, endogenous active ghrelin reaches similar 
levels after overnight fasting (0.1–0.35 pmol/mL) (Akamizu, Takaya et al. 2004, 
Druce, Wren et al. 2005, Tong, Dave et al. 2013), predictably stimulating food intake 
and increasing incentive salience of food (Cowley, Smith et al. 2003, Druce, Wren et 
al. 2005). However, higher levels of plasma active ghrelin (>1.6 pmol/mL) have been 
required to produce an appetite-stimulating effect in clinical studies (Druce, Wren et 
al. 2005). This may be indicative of the fact that many studies administer ghrelin in 
fasted states, therefore necessitating a higher dose in order to overcome elevated basal 
ghrelin levels. Indeed, Lippl and colleagues was the only study which administered 
ghrelin in the fed state to patients, and therefore had low basal levels of ghrelin (Table 
1.1). It also may be a reflection that many studies fail to account for des-acyl ghrelin. 
This was originally thought to be a pharmacologically inactive breakdown product of 
active ghrelin but recent evidence has shown this is not the case (Delhanty, Neggers 




Table 1.1 Summary of clinical dosing studies involving ghrelin: The acylation status, dose, food intake status and form of ghrelin assayed are 
summarised in the below table for the various clinical studies involving ghrelin.  
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Hansen et al. 
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Acylated 
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1.7.1 Acyl and Desacyl- Ghrelin—Implications for Therapeutic 
Approaches 
Both acylated and des-acylated forms of the hormone ghrelin are detected in the 
peripheral circulation (Delhanty, Neggers et al. 2012). Despite this, many studies assessing 
endogenous ghrelin levels in blood fail to specify the acylation status of the hormone (Stark, 
Santos et al. 2016). In fact, only some preclinical studies have distinguished between the effects 
of acyl- and desacyl-ghrelin (Andrews, Erion et al. 2009, Bayliss and Andrews 2013, Bayliss, 
Lemus et al. 2016). Furthermore, it is critical for accurate measurement of acyl- ghrelin that 
blood samples are appropriately stabilized in order to prevent des-acylation (Liu, Prudom et al. 
2008, Delhanty, Neggers et al. 2014). The binding of acyl-ghrelin and subsequent activation of 
GHSR-1a is well established (Kojima, Hosoda et al. 1999, Bednarek, Feighner et al. 2000). 
Similarly, the lack of desacyl- ghrelin binding to GHSR-1a is described (Kojima, Hosoda et al. 
1999). Desacyl-ghrelin does not compete with acyl-ghrelin for GHSR-1a binding at 
physiological concentrations (Veldhuis and Bowers 2010), however, it has been shown to 
activate the receptor at supraphysiological concentrations (Gauna, Van de Zande et al. 2007, 
Heppner, Piechowski et al. 2014). Desacyl-ghrelin is the most abundant form in the circulation 
and is purported to be the active ligand for additional, as yet unknown, GHSR subtypes 
(Broglio, Gottero et al. 2004, Schellekens, Dinan et al. 2013, Delhanty, Neggers et al. 2014). 
Peripheral acyl-ghrelin administration markedly increases circulating GH, prolactin, 
adrenocorticotrophic hormone, and cortisol levels (Broglio, Gottero et al. 2004). This is 
accompanied by a decrease in insulin and a concomitant increase in plasma glucose. 
Interestingly, although desacyl-ghrelin administration had no such effects in isolation, when 
administered in combination with acyl-ghrelin it was able to negate the observed effects on 
plasma insulin and glucose (Broglio, Gottero et al. 2004). Indeed, it has been suggested that 
desacyl-ghrelin should be considered as a hormone distinct from acyl-ghrelin given its ability 
to elicit effects on certain peripheral actions such as cardiovasculature, cell proliferation and 
certain aspects of adiposity (Broglio, Gottero et al. 2004). Overnight intravenous desacyl-
ghrelin infusion was found to improve glucose metabolism and, conversely to acyl-ghrelin, 
display a glucose-lowering effect (Benso, St-Pierre et al. 2012). Moreover, combined 
administration of acyl- and desacyl-ghrelin strongly improved insulin sensitivity compared to 




be metabolically active in an opposing manner to acyl-ghrelin to improve glycemic control. 
Furthermore, in vivo work has shown that desacyl-ghrelin alone does not alter food intake, but 
in keeping with the observed metabolic effects, attenuates acyl-ghrelin -induced food intake 
and arcuate nucleus neuronal activation (Neary, Druce et al. 2006, Inhoff, Monnikes et al. 2008, 
Kumar, Salehi et al. 2010). It has also been suggested that desacyl-ghrelin acts independently 
of acyl-ghrelin via the hypothalamus to decrease food intake and gastric motility (Asakawa, 
Inui et al. 2005), and central desacyl-ghrelin administration was reported to increase food 
intake via activation of orexin neurons in the LH (Toshinai, Yamaguchi et al. 2006). It has been 
further demonstrated that intracerebroventricular and intravenous injections of desacyl-ghrelin 
disrupted fasted motor activity in the stomach (Chen, Inui et al. 2005). For further information 
the reader is directed towards a comprehensive review by Soares and colleagues which 
summarise effects of both isoforms on the various systems and organs (Soares and Leite-
Moreira 2008). 
The pharmacokinetic parameters of infused acyl-ghrelin, desacyl-ghrelin, or a 
combination thereof in healthy subjects have been reported. The plasma half-life of acyl-
ghrelin was 9–11 min after an intravenous infusion, whereas the half-life of total ghrelin (acyl-
ghrelin + desacyl-ghrelin) was 35 min, indicating that desacyl-ghrelin has a slower clearance 
than acyl-ghrelin (Tong, Dave et al. 2013). Similar estimates of half-lives have been reported 
elsewhere (Akamizu, Takaya et al. 2004, Paulo, Brundage et al. 2008). It is estimated that the 
ratio of des-acylated: acylated form of ghrelin in the plasma exceeds 9:1 (Hosoda, Kojima et 
al. 2003, Bang, Soule et al. 2007, Takagi, Legrand et al. 2013). However, during an infusion 
of acyl-ghrelin, the ratio of desacylated: acylated is 2:1. Interestingly, it was also shown that 
acyl-ghrelin infusion is responsible for an absolute increase in circulating plasma levels of 
desacyl-ghrelin (Tong, Dave et al. 2013). This indicates that upon entry to the circulation, acyl-
ghrelin is de-acylated, hence leading to an increase in desacyl-ghrelin, which potentially 
counters the effects of acyl-ghrelin. Interestingly, in Prader-Willi syndrome, patients with an 
elevated ratio of acyl- to desacyl-ghrelin show pronounced hyperphagia and weight gain 
compared to those patients who display a normal acyl:desacyl ratio (Kuppens, Diene et al. 
2015). Therefore, acyl-ghrelin and desacyl-ghrelin not only exhibit different clearance rates 
from the circulation, but acyl-ghrelin is de-acylated in plasma. It is estimated that acyl-ghrelin 
accounts for only half of the increase in total ghrelin levels after dosing of acyl-ghrelin 




identified in the circulation (Satou, Nishi et al. 2010). The ratio of desacyl- ghrelin: acyl-ghrelin 
can also change pending the metabolic state i.e. hunger can increase circulating acyl-ghrelin 
(Liu, Prudom et al. 2008, Kirchner, Gutierrez et al. 2009). Given the proposed opposing effects 
of acyl- and desacyl- ghrelin, and the variable information in the literature vis-à-vis 
pharmacokinetic disposition, due consideration is warranted in the interpretation of trials to 
date. 
1.7.2 Synthetic Ghrelin Ligands 
The short half-life of acyl-ghrelin, the ubiquitous expression of GHSR-1a and the often- 
overlooked presence of a functional antagonist in desacyl- ghrelin, leads to an unpredictable 
relationship between the pharmacokinetics and pharmacodynamics of ghrelin. Numerous 
synthetic ghrelin ligands have been developed over the years, all of which are more stable and 
exhibit a longer duration of action than native acyl-ghrelin (Moulin, Brunel et al. 2013, Vodnik, 
Štrukelj et al. 2016). From a pharmacokinetic perspective, increased half-life of synthetic 
compounds will lead to increased penetration into tissues and activation of the GHSR-1a for 
prolonged periods due to greater stability. In addition, synthetic derivatives are not converted 
to desacyl-ghrelin and avoid any potential counter effects. This therefore should lead to more 
predictable relationships of pharmacokinetics with pharmacodynamic effect. 
Pharmacokinetic data is sparse for synthetic ligands, with many trials solely reporting 
on pharmacodynamic outcomes (Table 1.2). This is largely due to the focus of the field of 
research on ghrelin shifting over time. The first clinical studies mainly focus on ghrelin and 
ghrelin ligands as GH secretagogues, thus solely measuring GH response and failing to 
measure serum ghrelin (Arvat, Maccario et al. 2001, Broglio, Benso et al. 2003). Indeed, it 
must be borne in mind that ghrelin had yet to be discovered for certain studies (Deghenghi, 
Cananzi et al. 1994, Patchett, Nargund et al. 1995, Ghigo, Arvat et al. 1996, Pihoker, Badger 
et al. 1997, Hansen, Raun et al. 1999, Phung, Sasaki et al. 2001). Originally, compounds such 
as Growth Hormone Releasing Peptide 6 (GHRP-6) and GHRP-2 were developed as 
somatotrophin secretagogues with the aim of treating GH deficiency syndromes such as 
pituitary dwarfism (Deghenghi, Cananzi et al. 1994, Ghigo, Arvat et al. 1996, Okada, Ishii et 
al. 1996, Pihoker, Badger et al. 1997, Torsello, Luoni et al. 1998, Lee, Vega et al. 2000, Roumi, 




ghrelin’s discovery, focus shifted towards the possibility of exploiting these compounds for 
disorders of appetite (Lawrence, Snape et al. 2002, Cowley, Smith et al. 2003, Horvath, 
Castaneda et al. 2003, Inui, Asakawa et al. 2004). With the increased appreciation of the role 
of ghrelin, research shifted to investigate its effects on the mesolimbic reward circuitry 
(Kawahara, Kawahara et al. 2009, Egecioglu, Jerlhag et al. 2010, Dickson, Egecioglu et al. 
2011, Skibicka, Hansson et al. 2011). More recently, ghrelin agonists have been explored as 
gastrointestinal prokinetics to treat idiopathic and diabetic gastroparesis, as well as post-
operative ileus (Sanger 2008, Charoenthongtrakul, Giuliana et al. 2009, De Smet, Mitselos et 
al. 2009). Preclinical studies are thus difficult to directly compare due to variable approaches 
to dosing and vastly different experimental setups and outcome. 
Nevertheless, the physiological mechanisms of appetite stimulation, body weight and 
other parameters for synthetic ligands (Table 1.2) are mediated through interaction with the 
GHSR-1a, and thus are broadly similar to ghrelin itself. Unfortunately, given the sparsity of 
comprehensive pharmacokinetic studies, many of parameters in Table 1.2 were taken from 
preclinical study data. No GHSR-1a antagonists or inverse agonists have been used clinically 
and there is a paucity of pharmacokinetic data available, hence they were not included in the 
scope for Table 1.2, however the reader is directed to a recent review for further information 
on these compounds (Vodnik, Štrukelj et al. 2016). Additionally, it is unwise to utilise 
pharmacodynamic outcomes as a surrogate measurement to compare ligand efficacy, due to 
heterogenous receptor-ligand interaction as discussed above (Sivertsen, Lang et al. 2011). For 
example, GH output is poorly correlated with orexigenic effect or body weight gain in vivo—
stimulation of GH without affecting food intake has been demonstrated (Torsello, Luoni et al. 
1998). The agonist ulimorelin fails to elicit any GH release after both central and peripheral 
administration (Hoveyda, Marsault et al. 2011). Anamorelin displays three times the potency 
of endogenous ghrelin in activating the ghrelin receptor in vitro (Pietra, Takeda et al. 2014). 
However, it is noted this greater potency does not translate to greater in vivo levels of GH 
response (Pietra, Takeda et al. 2014). Even minimal structural modifications of GH releasing 
peptide analogues affect the behavioural (food intake) but not GH-releasing properties of the 
analogue (Torsello, Luoni et al. 1998). Paradoxically, there have even been a number of 
reported GHSR-1a antagonists, which display orexigenic effects. Although the antagonist 
BIM-28163 blocks ghrelin-induced GHSR-1a activation, and prevents GH secretion in vivo as 




thought to be potentially due to action at a receptor other than the GHSR-1a (Halem, Taylor et 
al. 2005, Hassouna, Labarthe et al. 2013). Furthermore, GSK1614343 also increased food 
intake and body weight in vivo, but knockout of the GHSR-1a abolished this effect, confirming 
that the antagonist was working via this receptor (Costantini, Vicentini et al. 2011). Antagonists 
with agonistic properties in vivo may be explained by biased agonism (M'Kadmi, Leyris et al. 
2015). Vodnik and colleagues review several ligands which display biased agonism (Vodnik, 
Štrukelj et al. 2016). Individual drug-receptor interactions therefore determine distinct 
pharmacodynamic outcomes (Moulin, Ryan et al. 2007, Depoortere 2009). Different ligands 
can activate signalling cascades which may be more desirable and have the potential to be 
exploited for the development of more selective therapeutics (M'Kadmi, Leyris et al. 2015). 
This has led to examination of ligands, including inverse agonists, with selective effects for 
certain outputs. For example agonists for treating osteoporosis through GH secretion may have 
the adverse effect of increasing body weight (M'Kadmi, Leyris et al. 2015). Antagonists for 
GHSR-1a may be developed with the ability to decrease centrally-mediated food intake and 
adiposity, without inhibiting GH secretion. The potential of utilising biased agonism to achieve 
improved therapeutic efficacy warrants further investigation and has been highlighted in recent 





Table 1.2. Ghrelin agonists used clinically. The half-life, oral bioavailability and centrally-mediated effects have been summarised. To date, no 







Half Life Centrally Regulated Parameters Reported 
Growth Hormone 




(Walker, Codd et al. 
1990, Moulin, 
Brunel et al. 2013)  
0.3 h (Moulin, 
Brunel et al. 2013) 
↑ Food intake (Lawrence, Snape et al. 2002),  
↑ Body weight (Bowers, Momany et al. 1984, 
Lawrence, Snape et al. 2002),  
↑ Gastric emptying (Kitazawa, De Smet et al. 
2005),  
↑ Growth hormone (Bowers, Momany et al. 
1984, Deghenghi, Cananzi et al. 1994) 
Hexarelin Synthetic peptide 
<0.3% (Human) 
(Ghigo, Arvat et al. 
1994) 
1.15 h (Ghigo, 
Arvat et al. 1994, 
Roumi, Marleau et 
al. 2000) 
↑ Food intake (Torsello, Luoni et al. 1998),  
↑ Growth velocity (Imbimbo, Mant et al. 1994, 





Not reported, but 
has been dosed 
0.52 h (Pihoker, 
Kearns et al. 1998) 
↑ Food intake (Mericq, Cassorla et al. 2003, 






↑ Growth hormone (Bowers 1993, Pihoker, 
Kearns et al. 1998) 
Alexamorelin Synthetic peptide Not reported Not reported 
↑ Growth hormone (Broglio, Benso et al. 
2000) 
Ipamorelin Synthetic peptide 
1%–6% (Rat, Dog) 
(Ankersen, 
Johansen et al. 
1998) 
2 h (Gobburu, 
Agerso et al. 1999) 
↑ Growth hormone (Ankersen, Johansen et al. 
1998, Johansen, Nowak et al. 1999),  
↑ Body weight (Ankersen, Johansen et al. 
1998),  
↑ Gastointestinal motility (Polvino, Nelson et 
al. 2011) 
Capromorelin Small molecule 
65% (Carpino, 
Lefker et al. 2003) 
(Rat) (Khojasteh-
Bakht, O'Donnell J 
et al. 2005) 
2.4 h (Carpino, 
Lefker et al. 2003)  
↑ Growth hormone (Smith, Pong et al. 1996, 
Carpino, Lefker et al. 2003),  
↑ Body weight (Pan, Carpino et al. 2001),  
↑ Gastric emptying (Kitazawa, De Smet et al. 
2005) 
Relamorelin Synthetic peptide Not reported 
19.4 h (Lembo, 
Camilleri et al. 
2016) 
↑ Growth hormone (Palus, Schur et al. 2011),  
↑ Food intake, ↑ Body weight (Strassburg, 
Anker et al. 2008, Palus, von Haehling et al. 




↑ Gastric emptying (Shin, Camilleri et al. 
2013, Van der Ploeg, Laken et al. 2014) 
Macimorelin Small molecule 
Not reported, but 
has been dosed 
orally (Ali and 
Garcia , Garcia, 
Swerdloff et al. 
2013) 
3.8 h (Piccoli, 
Degen et al. 2007) 
↑ Growth hormone (Broglio, Boutignon et al. 
2002, Garcia, Swerdloff et al. 2013) 
Tabimorelin Synthetic peptide 
30%–35% (Rat) 
(Hansen, Raun et al. 
1999, Ankersen, 
Kramer Nielsen et 
al. 2000) 
20.8 h (Zdravkovic, 
Søgaard et al. 2000, 
Zdravkovic, 
Christiansen et al. 
2001) 
↑ Growth hormone (Ankersen, Kramer 
Nielsen et al. 2000, Zdravkovic, Søgaard et al. 
2000, Zdravkovic, Christiansen et al. 2001)  
↑ Body weight (Hansen, Raun et al. 1999) 
Anamorelin Small molecule 
Not reported, but 
has been dosed 
orally (Garcia, 
Boccia et al. 2007, 
Garcia and Polvino 
2007, Garcia and 
Polvino 2009) 
7 h (Garcia and 
Polvino 2009) 
↑ Growth hormone (Garcia and Polvino 2009, 
Garcia, Friend et al. 2013),  
↑ Food intake (Garcia, Boccia et al. 2007, 
Garcia and Polvino 2007, Garcia, Friend et al. 









et al. 1995, 
Svensson, Lonn et 
al. 1998, Adunsky, 
Chandler et al. 
2011) 
6 h (Guyda 2002) 
↑ Growth hormone (Patchett, Nargund et al. 
1995, Jacks, Smith et al. 1996, Adunsky, 
Chandler et al. 2011), ↑ Body weight 
(Prahalada, Block et al. 1999),  
↑ Fat free mass (Svensson, Lonn et al. 1998) 
Ulimorelin Synthetic peptide 
24% (Rat) 
(Hoveyda, Marsault 
et al. 2011) 
1.6 h  
(Venkova, Fraser et 
al. 2007, Fraser, 
Hoveyda et al. 
2008, Fraser, 
Venkova et al. 
2009) 
↑ Growth hormone (no effect), ↑ Food intake, 
↑ Gastrointestinal motility (Fraser, Hoveyda et 
al. 2008, Lasseter, Shaughnessy et al. 2008, 
Fraser, Venkova et al. 2009, Ejskjaer, 
Dimcevski et al. 2010, Hoveyda, Marsault et 




1.7.1 Clinical Status of synthetic Ghrelin Ligands 
An increasing number of GHSR-1a ligands are likely to be seen in the clinic in 
the near future. Interestingly, anamorelin was recently refused FDA and EMA 
approval for the treatment of cachexia associated with non-small cell lung cancer 
(Garcia 2017). This has led to some debate surrounding the appropriate clinical 
endpoints for establishing treatment efficacy as well as calls for a greater 
understanding of regulators of appetite. Much of this area is uncharted regulatory 
territory and as such the lack of precedent for FDA/EMA guidelines serves as an 
impediment to selecting and powering for primary outcomes. Currently however, 
anamorelin is being reassessed for different primary outcomes related to anorexia-
cachexia compared to the original ROMANA study, and may well attain regulatory 
approval in the future based on this (NCI 2018). Recently, Capromorelin has also been 
FDA-approved for veterinary use to stimulate appetite in dogs (Rhodes, Zollers et al. 
2017). Other GHSR-1a agonists are in the pipeline, albeit not solely for the indication 
of appetite modulation. The synthetic agonist macimorelin is in the process of gaining 
regulatory approval for the diagnosis of adult GH deficiency (Garcia, Biller et al. 
2018). Furthermore, phase 3 studies are underway for relamorelin in the treatment of 
diabetic gastroparesis (Allergan 2018). 
Enhancing efficacy through BBB penetration. 
BBB penetration per se does not seem to be a key criterion for effecting 
changes to the centrally- mediated processes of appetite stimulation, growth hormone 
output or adipogenesis. This is probably due to a hijacking of the endogenous 
mechanisms of transport for ghrelin across the BBB and is in line with the literature 
on mechanism of CNS access of ghrelin discussed in the earlier parts of this review 
(Banks 2002, Cabral, De Francesco et al. 2015). Despite its non-centrally penetrant 
action, anamorelin is in phase 3 trials for the treatment of cancer-anorexia-cachexia 
syndrome (Garcia, Boccia et al. 2015, Zhang and Garcia 2015). The compound elicits 
an orexigenic effect pointing to a central mechanism much in line with ghrelin’s 




for other non-centrally penetrant compounds (Torsello, Luoni et al. 1998, Laferrere, 
Abraham et al. 2005). Given the expression of the GHSR-1a in less accessible brain 
areas, particularly in relation to incentive salience, there is an impetus to investigate 
BBB penetrability of ghrelin ligands further. 
Preclinical work has already shown the potential benefits of BBB penetrant 
ghrelin agonists in other therapeutic areas. Activation of GHSR-1a in the spinal cord 
activates colonic motility. In the rat, severing the spinal cord at a thoracic level 
prevented defecation induced by the centrally penetrant agonist CP464709 (Shimizu, 
Chang et al. 2006). Critically, this stimulation of colorectal activity was evident after 
peripheral administration of the ghrelin agonist, indicating a direct action on GHSR-
1a in lumbosacral defecation centres. Furthermore, the lack of effect of peripheral 
ghrelin on the colon in vivo demonstrates the importance of BBB penetration (Trudel, 
Tomasetto et al. 2002). GSK 894281 is an orally bioavailable BBB-penetrant ghrelin 
agonist which causes a prompt and dose-related output of faecal pellets after 
administration (Shafton, Sanger et al. 2009). HM01 is another such agonist in 
preclinical trials as a colokinetic; again, its prokinetic action is attributed to its ability 
to cross the BBB and act on GHSR-1a’s present in the nerves of the lumbar section of 
the spinal cord (Naitou, Mamerto et al. , Karasawa, Pietra et al. 2014, Naitou, Mamerto 
et al. 2015, Borner, Loi et al. 2016). 
Centrally penetrant GHSR-1a antagonists reduced body weight in diet-induced 
obese (DIO) mice when administered for 10 days, while also improving glucose 
tolerance (Esler, Rudolph et al. 2007, Rudolph, Esler et al. 2007). Conversely, a non 
CNS-penetrating antagonist demonstrated comparatively mild effects on body weight, 
while retaining an effect on the peripherally regulated glucose tolerance. It has been 
postulated that the efficacy of these compounds on food intake and body weight 
appears to be correlated with their ability to antagonize central vs. peripheral GHSR-
1a’s in different animal models (Moran and Dailey 2009); YIL 870 and YIL 781 are 
quinazolinone-derived GHSR-1a antagonists which differ mainly in their ability to 
traverse the BBB. YIL 870 produces greater anorexigenic and weight reducing effects 
in diet-induced obese mice vs. the non-penetrant YIL 781, while both yielded a 




regulation (Esler, Rudolph et al. 2007). Robust evidence thus shows that for 
antagonists to be effective in regulating body weight they need to cross the BBB. 
Pharmacological evaluation in obesity-induced rats revealed that a BBB penetrant 
inverse agonist for the GHSR-1a effectively reduced weight gain (Takahashi, Funami 
et al. 2015). Ad libitum food intake was also reduced in mice treated with a BBB-
penetrant inverse agonist (AZ-GHS-38) while a lack of efficacy was obtained in mice 
treated with a non- BBB-penetrant inverse agonist (McCoull, Barton et al. 2014). 
Therefore, a crucial determinant of the anti-obesogenic potential of GHSR-1a inverse 
agonists and antagonists is their ability to traverse the BBB. 
The effect of ghrelin antagonists on the mesolimbic dopaminergic pathway has 
been investigated in the context of addictive-like behaviour. JMV 2959 is a centrally 
active GHSR-1a antagonist found to effectively reduce rewarding properties of 
addictive substances (Jerlhag and Engel 2011, Skibicka, Hansson et al. 2012, Engel, 
Nylander et al.). Systemic administration of JMV attenuated ghrelin-induced 
motivation to work for sugar pellet reward (Skibicka, Hansson et al. 2012) in an 
operant conditioning paradigm. It was found that cocaine and amphetamine-induced 
place preference and extracellular accumbal DA were attenuated by administration of 
JMV 2959. This demonstrates a role for the GHSR-1a in the pathogenesis of addiction, 
while also suggesting the importance of ligand access to less accessible brain areas. 
These findings also generalise to opioid-induced DA release (Sustkova-Fiserova, 
Jerabek et al. 2014, Engel, Nylander et al. 2015). Notably, Jerlhag and colleagues have 
also concluded that BBB penetrant GHSR-1a antagonists may have potential in 
alcohol use disorders (Jerlhag, Egecioglu et al. 2009). 
1.8 Hunger Is the Best Sauce—Targeting the Mesolimbic Reward 
Circuitry 
The old adage that “hunger is the best sauce” may provide a potential novel 
approach for appetite modulation therapies - food becomes more appealing the 
hungrier we are (Perello and Dickson 2015). This is an evolutionally-procured 
mechanism for survival in order to promote food intake beyond the immediate 
metabolic demand, to compensate for times of food scarcity (Lenard and Berthoud 




brain areas associated with reward, meant that it became implicated in food-reward 
directed behaviour (Egecioglu, Jerlhag et al. 2010, Skibicka, Hansson et al. 2011, 
Skibicka, Hansson et al. 2012). Consequently, the GHSR-1a may be a driver in the 
decision to eat palatable, calorie-dense foods, often beyond metabolic need. The role 
which ghrelin is purported to play at the interface between homeostatic and hedonic 
food intake regulation has been reviewed (Dickson, Egecioglu et al. 2011, Egecioglu, 
Skibicka et al. 2011, Schellekens, Dinan et al. 2013). We have previously summarised 
recent experiments examining ghrelin’s effect on rewarding food intake and 
preference (Schellekens, Dinan et al. 2013). It is now generally accepted that food 
intake is the result of an integrated multi-process neuro-circuit, involving the cortex 
and critically, the mesolimbic dopaminergic system—therefore, targeting GHSR-1a in 
the midbrain reward system, with BBB-penetrant ligands, may hold novel therapeutic 
potential. 
One of the key areas expressing the GHSR-1a in this respect is the VTA. The 
importance of dopaminergic VTA outputs in feeding has been well established (Wise 
2006, Fields, Hjelmstad et al. 2007, Narayanan, Guarnieri et al. 2010). Central ghrelin 
administration recruits dopaminergic neurons in the VTA and results in an elevated 
dopaminergic tone in the NAcc of mice, while more targeted intra-VTA administration 
robustly increases the intake of both standard chow (Naleid, Grace et al. 2005, 
Abizaid, Liu et al. 2006) and palatable food (Skibicka, Hansson et al. 2011, Skibicka, 
Shirazi et al. 2013). Incidentally, ghrelin administration into the medial prefrontal 
cortex also induces palatable-reward seeking behaviour in rats (Parent, Amarante et 
al. 2015). Microdialysis and electrophysiological studies in rodents have shown that 
peripheral ghrelin enhances dopaminergic neuronal firing, synapse formation and DA 
turnover in the NAcc. In animals, peripheral ghrelin treatment has increased locomotor 
activity and motivation to work for food, while also shifting food preference towards 
calorie dense and palatable foods (Jerlhag, Egecioglu et al. 2007, Egecioglu, Jerlhag 
et al. 2010, Perello, Sakata et al. 2010, Dickson, Egecioglu et al. 2011, Skibicka, 
Hansson et al. 2011, Skibicka, Hansson et al. 2012). Kawahara and colleagues showed 
that hunger in the absence of food creates an aversive neurocircuit in the reward 
pathway - dopamine outflow in the NAcc shell increased when food was present after 




2009). Intraperitoneal administration of ghrelin decreases the firing of dopaminergic 
neurons in the VTA in food-deprived Wistar rats (van der Plasse, van Zessen et al. 
2015). Therefore, peripheral ghrelin induces bimodal effects on the mesolimbic 
dopamine system depending on the food-consumptive status (Kawahara, Kawahara et 
al. 2009). For further detailed discussion of the preclinical studies in this area the 
reader is guided towards recent reviews (Andrews 2011, Perello and Dickson 2015). 
There is thus ample evidence to suggest that peripheral ghrelin is able to exert 
an effect on less accessible brain regions associated with reward and motivation, such 
as the VTA (Figure 1.5). The mechanism by which peripheral ghrelin achieves access 
to other subcortical brain areas which are spatially separated from the 
circumventricular organs has been debated. It is now widely believed that ghrelin itself 
is not synthesized in the brain (Sakata, Nakano et al. 2009, Furness, Hunne et al. 2011, 
Cabral, De Francesco et al. 2015). Jerlhag and colleagues have shown that ghrelin is 
able to access the VTA (Jerlhag 2008), while ghrelin has also been demonstrated to 
access the hippocampus (Diano, Farr et al. 2006). Since these however, tracer studies 
using radio-labelled ghrelin have only been able to show that peripheral ghrelin 
reaches the Arc at the level of the ME (Schaeffer, Langlet et al. 2013), and to a lesser 
extent the area postrema (Furness, Hunne et al. 2011). An evolutionally developed 
pathway has been argued to allow for selective transport of ghrelin across the BBB 
(Banks 2002, Banks, Burney et al. 2008). In vitro, human ghrelin exhibits saturable 
transport mechanics in the blood-to-brain as well as brain-to-blood directions in a rat 
cerebral microvessel endothelial model (Pan, Tu et al. 2006). An in vivo mouse model 
reported findings consistent with this (Banks 2002). Indeed, many other endogenous 
substrates have inherited carrier mediated transport systems, such as glucose and 
insulin (Schwartz, Sipols et al. 1990, Drewes 1998). Furthermore, there is evidence to 
show that access of ghrelin to the brain via diffusion can increase or decrease 
depending on the physiological/metabolic backdrop or state of hunger (Banks, Burney 
et al. 2008). Thus serum factors and physiological state are important determinants in 
the extent of the saturable ghrelin transport (Banks, Burney et al. 2008). Therefore, it 




The most likely mechanism of action of ghrelin in less accessible brain areas 
however, is through activation of neuronal populations via the permeable zones of the 
Arc and the area postrema. From here, ghrelin acts to stimulate neuronal projections 
to other appetite centres not adjacent to the ME, such as the lateral hypothalamus 
(Olszewski, Grace et al. 2003, Currie, Khelemsky et al. 2012). The LH is a key relay 
station for neuronal input to the VTA (Nieh, Matthews et al. 2015), and electrical 
stimulation of the LH induces voracious feeding even in well-fed animals (Stuber and 
Wise 2016). It receives multiple excitatory and inhibitory inputs from both cortical 
and subcortical structures, however of particular note is input from the adjacent Arc 
(Lutter and Nestler 2009). Differentially stimulating the neurons projecting from the 
Arc to the LH proves that homeostatic energy demands are met by Arc, but the LH is 
responsible for driving reward-motivated feeding (Stuber and Wise 2016). VTA 
dopaminergic neurons are modulated by the selectively expressed orexin 
neuropeptides in the LH (Harris, Wimmer et al. 2005). Thus, the LH and orexins play 
an important role in food and drug reward behaviours (Aston-Jones, Smith et al. 2010, 
Cason, Smith et al. 2010). Importantly, elevated peripheral ghrelin levels are known 
to communicate with the VTA to increase the rewarding value of food in an orexin-
dependent manner (Perello, Sakata et al. 2010, Sheng, Santiago et al. 2014). Therefore, 
in periods of hunger ghrelin is able to access the Arc to stimulate homeostatic feeding, 
while the LH is concomitantly activated, aided by its close proximity and connections 
with the Arc. The associated hedonic output is distinct from, yet intertwined with, 





Figure 1.5. Direct and indirect access of ghrelin to the mesolimbic circuitry The 
routes by which ghrelin and ghrelin ligands can traverse the blood-brain barrier 
(BBB). Direct activation of the mesolimbic circuitry can be attained by a centrally 
penetrant ghrelin agonist or by ghrelin which freely diffuses across the BBB. Indirect 
activation of mesolimbic circuitry is attained via the homeostatic mechanism through 
the “leaky” BBB capillaries at the median eminence and the area postrema. Ghrelin 
signalling initiating in the arcuate nucleus increases the rewarding value of food via 
orexin projections (red arrow) to the ventral tegmental area (VTA) from the lateral 
hypothalamus (LH). The nucleus tractus solitarius (NTS) displays connections with 
the hypothalamus, as well as the parabrachial nucleus (PBN), the laterodorsal 
tegmental area (LDTg) and pedunculopontine tegmental area (PPTtg), all of which 
have confirmed roles in either reward signalling (LDTg and PPTtg, blue arrow) or 
gustatory processes (PBN). Central penetration of ghrelin compounds may act directly 
on GHSR-1a expressed in these regions to modulate incentive salience of food (purple 
arrow). 
 
Another brain area of note for appetite regulation is the parabrachial nucleus, 
which is located in the hindbrain near the NTS (Saper and Loewy 1980, Cornwall, 




Arc, the NTS is spatially located near a permeable or “leaky” area of the BBB and 
sends glutamatergic signals to the parabrachial nucleus (PBN). Recent work has 
confirmed this region also receives GABAergic input from hypothalamic agouti-
related peptide neurons (Wu, Boyle et al. 2009). The PBN is an important site for 
processing of gustatory sensory information, with lesions of this area leading to 
disruption of hedonic feeding and taste-reactivity patterns (Grill, Friedman et al. 1995, 
Scalera, Spector et al. 1995, Spector, Scalera et al. 1995, Berridge and Robinson 2003). 
The PBN projects to several areas, notably the LH, paraventricular hypothalamus, and 
VTA (Jhamandas, Harris et al. 1992, Coizet, Dommett et al. 2010, Oliveira-Maia, 
Roberts et al. 2011, Abizaid and Horvath 2012). Afferent signals to the paraventricular 
nucleus of the hypothalamus exist which may be involved in tuning the behavioural 
response to rewarding food (Igelstrom, Herbison et al. 2010). Interestingly, the 
parabrachial nucleus itself expresses GHSR-1a and unsurprisingly this hedonic 
“hotspot” is therefore responsive to ghrelin treatment (Sárvári, Kocsis et al. 2014). 
Consequently, it is postulated that in periods of hunger plasma ghrelin conveys NTS-
dependent signalling to the PBN to exert an effect on feeding and reward behaviour 
(Skibicka and Dickson 2011, Wu, Clark et al. 2012). 
Other areas such as the laterodorsal tegmental area and pedunculopontine 
tegmental neurons express GHSR-1a and elicit excitatory input to the VTA (Jerlhag 
2008, Kim, Nakajima et al. 2009). The pedunculopontine nucleus is implicated in the 
motivational effects of drugs and food (Lanca, Adamson et al. 2000). Interestingly, in 
vitro work has demonstrated an excitatory effect of ghrelin on pedunculopontine 
neurons, suggesting a role in food reward (Kim, Nakajima et al. 2009, Kim, Nakajima 
et al. 2009). The laterodorsal tegmental area increases DA output in the NAcc via the 
VTA, thereby confirming a GHSR-1a dependant role in reward (Jerlhag, Egecioglu et 
al. 2006, Jerlhag, Egecioglu et al. 2007). 
1.8.1 Homeostatic “Gating” of the Reward System 
Two decades of research on the effects of exogenous ghrelin has clearly 
demonstrated the function of GHSR-1a mediated signalling at the level of both 




that ghrelin has ready access to sites involved in feeding initiation through permeable 
brain capillaries and tanycytes (Berthoud 2006), as well as vagal nerve communication 
(Date, Murakami et al. 2002, Cowley, Smith et al. 2003, Date, Shimbara et al. 2006, 
Date 2012). Hedonic and motivational aspects of food intake have also been 
investigated mechanistically through site-specific administration (Jerlhag, Egecioglu 
et al. 2007, Egecioglu, Jerlhag et al. 2010, Kawahara, Kaneko et al. 2013). The ability 
of ghrelin to communicate to less accessible GHSR-1a expressing brain areas such as 
the VTA, LH and parabrachial nucleus suggests an indirect neural mechanism (Cabral, 
Valdivia et al. 2014). This is indicative of modulation or “gating” of the motivated 
response for food by systemic signals of energy homeostasis (Ferrario, Labouèbe et 
al. 2016). 
The midbrain reward system is thus heavily dependent on homeostatic appetite 
regulation in the Arc and NTS, which constitute key “gatekeeping” structures to check 
the reward system under normal circumstances (Bouret, Gorski et al. 2008). Perello 
and colleagues confirmed that neural connections between the Arc and the VTA were 
responsible for peripheral ghrelin’s rewarding effect (Perello, Sakata et al. 2010). As 
we have seen however, preclinical and clinical studies have tended to use supra-
physiological doses of ghrelin which may artificially increase delivery across the BBB 
by saturable transport processes (Banks 2002) and diffusion from the 
circumventricular organs (Cabral, De Francesco et al. 2015). Elevated endogenous 
levels of ghrelin are able to elicit the same effects on hedonic aspects of food intake 
as high exogenous doses. This is due to the synergism of many systemic signals in 
energy-deprived states. The administration of high doses of a pleiotropic hormone may 
thus be leading to confounding compensatory mechanisms, particularly in relation to 
glucose homeostasis (Figlewicz, Evans et al. 2003, Chabot, Caron et al. 2014, Sheng, 
Santiago et al. 2014). Directly targeting the GHSR-1a expressed in the reward circuitry 
through enhanced BBB penetration may hold therapeutic potential. One could 
hypothesise that a centrally-penetrant ghrelin agonist may affect mesolimbic DA 
levels and incentive valuation of food more directly than non-penetrating ghrelin 
agonists, or even ghrelin itself, through direct action on the GHSR-1a expressed on 




Reward system activation: the key role of dopamine 
Dopaminergic neurons account for less than a hundredth of the total neuronal 
population of the brain, however they exert a profound effect on brain function (Arias-
Carrión, Stamelou et al. 2010). DA’s involvement in motor control, particularly in 
relation to Parkinson’s disease was the subject of original focus. Since then, the 
molecule’s involvement in the neurobiology of psychiatric disorders such as 
schizophrenia and attention deficit hyperactivity disorder (ADHD) has become 
increasingly apparent. Not least of these, is the pivotal role which DA plays in the 
brain’s reward system (R A Wise and Rompre 1989). Spatially, dopaminergic neurons 
are localized to the midbrain, forebrain and olfactory bulbs, although the majority of 
cells reside in the midbrain. Of particular interest to motivational and hedonic aspects 
of reward are those located in the VTA, while the nigrostriatal pathway plays the 
crucial role in voluntary movement control. The mesocorticolimbic pathway can be 
deconstructed to the mesolimbic and mesocortical pathways, both of which originate 
in the VTA and modulate emotional behaviours.  
DA facilitates the specific consolidation of experiences that are associated with 
reward, hence assuring repetition through assigning motivational salience to the 
experience (Arias-Carrión, Stamelou et al. 2010). Basic mechanisms of survival such 
as eating, drinking and reproduction are fundamentally underpinned by reward system 
functioning. Essentially, DA facilitates the selective reinforcement of initially random 
behaviours, which become associated with the attainment of an environmental 
stimulus. By biasing the consolidation of associations between rewards and otherwise 
insignificant stimuli, the process of learning occurs. Once the stimulus has been paired 
with the reward, the association can remain even after the reward has been devalued 
by the absence of appropriate drive states such as hunger or thirst (Changizi, McGehee 
et al. 2002), or due to DA system blockade (Dickinson, Smith et al. 2000). 
It is in this context that the phenomenon of eating for pleasure, rather than 
hunger, can be better understood. The rewarding properties of eating, particularly the 
consumption of palatable foods beyond metabolic demand are largely controlled by 




primitive drive to overconsume calories to compensate for times of deprivation (Wise 
2006, Wang, Volkow et al. 2009, Volkow, Wang et al. 2011, Waterson and Horvath 
2015). The initial associations forged by a reward system recognizing the apparent 
salience of energy-dense foods are robust and long lasting. However, these 
associations become harmful in the context of readily available high-calorie food in 
the Western world (Neel 1962). Bart Hoebel and colleagues drew comparisons 
between the recruitment of DA in the reward system by sugar, and drugs of abuse 
(Avena, Rada et al. 2008). The concept of food addiction and the role of DA has hence 
come to the fore in recent years. 
1.9 Microdialysis as a tool to investigate reward system activation 
DA signalling in vivo can be monitored in a number of ways – 
electrophysiologically, via recording of firing activity of the neurons, or by monitoring 
extracellular concentrations of DA. The latter can be performed using the techniques 
of microdialysis, voltammetry or brain imaging (e.g. PET) (Di Chiara 1990, Robinson, 
Venton et al. 2003). The temporal resolution of each of these techniques differs 
substantially, from milliseconds for electrophysiological recordings to minutes for 
microdialysis and PET. Essentially, these techniques have been proposed to quantify 
different modalities of DA signalling and should be interpreted accordingly in the 
literature.  
For tonic measurements, intracerebral microdialysis facilitates the measurement 
of free (unbound) substances in the extracellular fluid of many tissues. It has 
traditionally been used in the neuroscience field to quantify endogenous levels of 
neurotransmitters, such as DA, in the brain extracellular fluid, however the 
measurement of exogenous substances is also possible with this technique. Of 
particular use is that microdialysis samples can be collected in real time in conscious, 
freely-moving animals (Chefer, Thompson et al. 2009). Modern microdialysis 
techniques were introduced in the 1970’s by Ungerstedt and colleagues (Ungerstedt 
and Pycock 1974, Darvesh, Carroll et al. 2011). The pivotal component of this setup 
is the microdialysis probe, a small semi-permeable membrane which allows the free 




probe. The probe is constantly being perfused with dialysate solution which is 
physiologically identical to the extracellular fluid, normally CSF. The dialysate is 
constantly perfused at a defined flow-rate using a syringe micropump and hence the 
recovered analyte elutes out and can be expressed as concentration as a function of 
time as a result of the intervention. 
The active membrane of the probe can be accurately localized to a specific brain 
region of interest using stereotaxic surgery. At the level of the membrane, molecular 
diffusion takes place according to Fick’s law; the rate of diffusion is directly 
proportional to the concentration gradient (Bungay, Morrison et al. 1990). The amount 
of analyte in the perfusate will hence be proportional to the concentration of analyte 
in the area of interest. The perfusion fluid traverses the probe at a defined flow rate 
typically 0.5 - 5 µl.min-1. The outlet tubing allows for collection of the dialysate in an 
appropriate vial, which is subsequently stored and analysed using a suitable technique 
such as HPLC. The concentration of the analyte in the dialysate is directly proportional 
to the concentration in the extracellular fluid surrounding the active site of the probe. 
However, the dialysate concentration will always be lower than the actual 
concentration as there is not complete recovery from the probe – typically one would 
expect ~10% recovery per mm of active membrane window. The relationship between 
dialysate and periprobe concentrations is termed ‘probe recovery’ (Anderzhanova and 
Wotjak 2013). The recovery from each probe largely depends on factors such as 
perfusion flow rate, size of membrane window, properties of the specific analyte. 
Probe recovery can be estimated in vitro by immersing the probe in a solution of 
known concentration of analyte and comparing this to the concentration achieved in 





Figure 1.6. Microdialysis in the conscious, freely-moving rat. The microdialysis 
probe consists of a semi-permeable membrane at the tip of the probe which allows for 
free diffusion of analyte of interest into the probe perfusate in a concentration-
dependent manner. The probe is inserted through a surgically implanted guide 




1.10 Microdialysis, dopamine and ghrelin: current status  
Ghrelin is one of the key neurotransmitters which contributes to incentive 
salience of food via reward system activation (Perello, Sakata et al. 2010, Skibicka 
and Dickson 2011, Skibicka, Hansson et al. 2011, Schellekens, Finger et al. 2012, 
Skibicka, Hansson et al. 2012, Skibicka, Shirazi et al. 2013, Perello and Dickson 
2015). As discussed above, increases in circulating ghrelin such as those seen in a 
fasting period, are responsible for signalling an increase in appetite and hunger 
(Cummings, Purnell et al. 2001). A concomitant increase in the perceived palatability 
and motivation to work for food is observed. Furthermore, elevated ghrelin levels in 
the blood are linked with increased dopaminergic activity in the brain; fMRI in human 
subjects confirms enhanced activation of central reward circuitry induced by 
pleasurable food images, when these images are preceded by ghrelin administration 
(Malik, McGlone et al. 2008, Goldstone, Prechtl et al. 2014). Abizaid and colleagues 
reported that the GHSR-1a is expressed in key nodes of the reward circuitry such as 
the VTA, and demonstrated that ghrelin binds to VTA neurons, triggering 
dopaminergic neuronal activity, synaptic plasticity and increase turnover of DA. 
Ghrelin’s role in augmenting the incentive salience of food via the mesolimbic reward 
neurocircuitry has thus been highlighted (Andrews 2011, Perello and Dickson 2015)  
 Given the role of the mesocorticolimbic DA system in mediating both the 
rewarding properties of food intake, and the motor stimulation caused by food-seeking 
behaviour, a series of microdialysis publications investigated the effects of ghrelin on 
DA output in the midbrain reward circuitry. Previously published data showed that 
central administration of ghrelin modulates the in vivo DA levels in the NAcc (Jerlhag 
2006 & 2007). Furthermore, it was reported that intra-VTA administration of ghrelin 
initiates feeding which can be subsequently blocked with a ghrelin antagonist. Jerlhag 
and colleagues however, were the first to investigate ghrelinergic-manipulation of the 
mesolimbic pathway using in vivo microdialysis. Moreover, a GHSR-1a knockout 
model to show that DA output in the NAcc elicited by rewarding food is GHSR-1a 
dependent (Egecioglu, Jerlhag et al. 2010). Kawahara and colleagues also used 
microdialysis to describe the food-dependent effects of accumbal DA outflow 




Disorders of appetite: Current Status and Implications for 
ghrelin therapy 
Consequences of over- and under-eating constitute ever-expanding health 
problems that remain unanswered in modern society, despite education, public health 
campaigns and pharmacotherapy (Schellekens, Dinan et al. 2010, von Haehling and 
Anker 2014). Thus, there is an impetus to understand the physiological mechanisms 
underlying central appetite regulation and food intake in order to design novel 
treatment strategies for eating disorders. However, despite almost 20 years since it’s 
discovery by Kojima and colleagues, no specific ghrelin targeting anti-obesity drug or 
cachexia therapeutics are on the market for clinical use (Kojima, Hosoda et al. 1999). 
The literature on ghrelin illustrates a plethora of information, yet we are still faced 
with a paucity of success. As knowledge on ghrelin increased, the role of the hormone 
shifted from the key protagonist in feeding initiation to be considered as part of a 
spectrum of diverse physiological processes. The peripheral and central distribution of 
the GHSR-1a and the heterogenous nature of GHSR-1a signalling result in pleiotropic 
actions of ghrelin, many of which are still being investigated.  
Food intake and incentive valuation of food are centrally-mediated processes. 
Ghrelin or ghrelin ligands can access the brain from the periphery by circumventing 
the BBB at permeable locations adjacent to homeostatic appetite centres, and 
indirectly influence reward centres through neural connections stemming from these 
areas (Perello, Sakata et al. 2010, Ferrario, Labouèbe et al. 2016). The importance of 
GHSR-1a signalling in the mesolimbic dopaminergic pathway as a barometer for the 
incentive salience of food has been well described. However, the action of GHSR-1a 
signalling on reward areas is closely intertwined with homeostasis and is regulated in 
this respect (Cabral, De Francesco et al. 2015, Ferrario, Labouèbe et al. 2016). The 
peripheral metabolic confounders in systemic ghrelin therapy, particularly relating to 
glucose homeostasis, may be contributing to the lack of successful preclinical moieties 
translating to clinical practice (Su, Geng et al. 2016). BBB-penetrant ghrelin agonists 
should bypass the homeostatic “gating” at the level of the Arc and NTS. This means 




motivation and incentive valuation of food, such as the LH and VTA. Since the 
decision to eat is consciously made based on perceived palatability, centrally 
penetrating ghrelin agonists or indeed antagonists, could prove successful in 




1.11 Pre-cachexia and Cachexia 
The hypothalamic neural circuits controlling energy balance are well described 
above in Section 1.1. Dysregulation of these mechanisms in ageing  can lead to 
conditions of undereating and malnutrition, and appetite decline in the elderly is an 
important consideration for the healthcare industry (Chapman 2004, Hickson 2006, 
Malafarina, Uriz-Otano et al. 2013). Average life-expectancy has increased 
dramatically with recent years, due to better healthcare and nutrition. Conversely, 
appetite and food intake decrease with the normal ageing process. A number of 
physiological changes occur during ageing which disrupt the mechanisms of energy 
homeostasis and lead to reduced appetite and food intake, resulting in malnutrition and 
the loss of lean body mass (Evans, Morley et al. 2008, Stoyanova 2014). A resultant 
increased risk of acute or chronic illness, hospitalization and loss of independence 
leads to a greater burden on community and medical services.  A  ubiquitous decline 
in ghrelin levels is thought to be a major contributory factor to appetite reductions and 
weight loss (Chapman 2004, DeBoer 2008). This age-related phenomenon is dubbed 
the “somatopause” and results in decreased lean body mass (sarcopenia), frailty, and 
are linked to cardiovascular issues, as well as cognitive and sleep disorders. Moreover, 
the incidence of chronic conditions increases dramatically in older demographics, with 
an increased incidence of chronic diseases such as cancer, chronic obstructive 
pulmonary disease (COPD), congestive heart failure (CHF) and chronic kidney 
disease (CKD) – it is estimated that 80% of older adults suffer from at least one chronic 
condition. These conditions are known to disrupt the homeostatic energy regulation 
by decreasing appetite and increasing energy expenditure in patients.  
These physiological changes can result in the onset of pre-cachexia, defined as 
the presence of all the following criteria: (a) underlying chronic disease; (b) 
unintentional weight loss 5% of usual body weight during the last 6 months; (c) 
chronic or recurrent systemic inflammatory response; (d) anorexia or anorexia-related 
symptoms. In elderly patients, poor nutritional status in elderly patients hence 
complicates, and is complicated by, chronic diseases and is known to result in 
prolonged hospital stays, lessened independent living and poorer response to 




lower clinical outcomes (Malafarina, Uriz-Otano et al. 2013). Age-related 
malnutrition coupled with chronic illnesses cause a cascade of metabolic changes 
resulting in loss of lean and fat mass, and the development of cachexia (Chapman 
2004, DeBoer 2011, Malafarina, Uriz-Otano et al. 2013). Therefore, progression of 
illness and malnutritive status can result in cachexia, a multifactorial syndrome 
defined by an ongoing loss of skeletal muscle mass and functional impairment, that 
cannot be fully reversed by conventional nutritional support.  
Pharmacological strategies for increasing appetite in cachexia spans the use of 
corticosteroids, cannabinoids, megestrol and progestogens, thalidomide and 
gastrointestinal prokinetics (Radbruch L 2010, Aoyagi, Terracina et al. 2015). To date 
although promising results have been demonstrated these therapies are not without 
drawbacks. Caveats to current treatment strategies such as the above have been 
reviewed extensively (Argilés, López-Soriano et al. 2008, Evans, Morley et al. 2008, 
Argilés, López-Soriano et al. 2013, De Ng, Bruera et al. 2016). 
1.11.1 Neuronal alterations in cachexia 
Onset of cachexia is associated with a general increase in systemic 
inflammation and cytokine release, culminating in an increase in the basal metabolic 
rate and energy expenditure (Figure 1.7) (DeBoer 2011). Cancer and other chronic 
conditions also result in an increase in cytokine release, which are known to act on the 
central nervous system to alter the release and function of a plethora of 
neurotransmitters In particular, the hypothalamus is a major target for inflammatory 
cytokines (Grossberg, Scarlett et al. 2010). Neuronal inflammation, as reported by NF-
κB activation, is localized almost exclusively to the hypothalamus and brainstem 
following a systemic immune insult (Laflamme and Rivest 1999). This may be due to 
the permeable BBB at the level of the median eminence  which affords access of 
blood-borne signals to the central compartment. Neuronal response to inflammation 
results in local cytokine production in appetite centres, many of which express 
receptors for the same cytokines. Immediate early gene-activation as shown by c-Fos 
nuclear staining is detected in the Arc and paraventricular nucleus in response to 




1996). Therefore, anorexigenic effects of systemic inflammation are exerted through 
the hypothalamic centres responsible for energy balance. Feeding nuclei in the 
brainstem such as the NTS also display a robust induction of c-Fos and NF-κB in 






Figure 1.7. Physiological alterations in cachexia and potential of ghrelin therapy: 
The onset of cachexia is associated with various deleterious effects on appetite, 
metabolism, reward processing and systemic inflammation which results in a net 
catabolic effect in the body. Ghrelin exerts antagonistic effects to these. The hormone 
is orexigenic and somatotrophic, while also stimulating increases in gastrointestinal 
motility and reward system activation and decreasing systemic inflammation. 
Ghrelin treatment results in an increase in the expression and release of 
orexigenic agouti-related peptide (AgRP) and neuropeptide-Y (NPY), with a 
concomitant decrease in the expression of pro-opiomelanocortin (POMC). 
Downstream effects of this activation lead to increased food-seeking behaviour and a 
decrease in resting energy expenditure. Recent reviews have discussed the merits and 
limitations to date of ghrelin therapy (DeBoer 2008, DeBoer 2011). There are also 
various extra-hypothalamic effects of ghrelin pertaining to cachexia; specifically, 
reduced inflammation, cardiovascular effects, increase fat storage, gut motility and 
blood glucose homeostasis during fasting. Critically, the reward system is capable of 
overriding the hypothalamic “homeostatic” system of food intake regulation. This 




satisfy metabolic demand. It is known that motivation to seek out and consume food, 
as well as the perceived palatability of food is very low in cachectic states (Evans, 
Morley et al. 2008). Despite this, relatively little has been carried out on the impact of 
cachectic states on these important pathways. Immunohistochemistry of the NAcc, 
caudate putamen and other ventral striatal structures revealed FosB-positive neurons 
and/or prodynorphin or proenkephalin mRNA during cachexia-like states (Pourtau, 
Leemburg et al. 2011). The decision to eat is largely a top-down decision made through 
input of visual, gustatory, olfactory and emotional stimuli – these findings indicate 
that forebrain structures that are part of these decision-making networks are altered in 
tumour-associated cachexia syndrome and may contribute to the lack of compensatory 
eating in response to weight loss, a hallmark of this condition. 
1.12 Obesity, anorexia and binge eating disorders 
The primitive drive to overconsume calories in times of abundance in order to 
deal with long periods without food was a useful survival tool. However, this has 
become a redundant trait in the last century with the abundance of readily-available 
food in Western society (Neel 1962). Calorie overconsumption coupled with 
increasingly sedentary lifestyles has led to an obesity epidemic (WHO 2018). 
Synonymous with increased morbidity and mortality, obesity is widely seen as the 
largest and fastest growing public health concern of modern times (Isomaa, Almgren 
et al. 2001, Ng, Fleming et al. 2014, Martin, Mani et al. 2015, Seidell and Halberstadt 
2015, Tremmel, Gerdtham et al. 2017). As discussed in detail above, there are highly 
conserved neural pathways which exist to promote the consumption of calories surplus 
to metabolic requirements (Section 1). Those foods which are high in calories, 
typically palatable sugary foods, are potent instigators of reward system activation that 
trigger robust and long-lasting learned associations between the stimulus and reward. 
This leads to an overly-primed reward system which in turn exhibits increased 
anticipatory processing of rewards yet less pleasure is attained from the attainment of 
the reward (Volkow, Wang et al. 2012). In this context, the fundamental susceptibility 
of humans to the overconsumption of high-fat and high-sugar meals can be better 
understood. Conversely to cachexia, the underlying issues with obesity is not down to 




rewards which prime an effective neuronal pathway to promote overconsumption 
(Neel 1962, Waterson and Horvath 2015). Alterations in striatal dopaminergic 
signalling are thought to be a causative mechanism facilitating hyperphagia (Wise 
2006). Obese subjects show increased neural activity in reward and motivation 
circuitry when presented with pleasurable food images (Stoeckel, Weller et al. 2008). 
Indeed, it was found that activation of the NAcc was negatively correlated with body 
weight in these studies (Killgore and Yurgelun-Todd 2005). This suggests that the 
more food is consumed, the more sensitive the reward system is to pleasurable food 
images. The reactivity of obese neurocircuitry to food is thereby enhanced. 
Furthermore, it was found that obese individuals needed to consume more of the same 
food to get an equal consummatory reward, yet there is a comparative increase in the 
activation of cortical regions which process the anticipation of reward (Stice, Spoor et 
al. 2008, Stice, Yokum et al. 2010). In other words, there is enhanced anticipation and 
motivation to obtain the reward, but less pleasurable consequences to obtaining it. 
Thus over-anticipation and under-appreciation promotes overconsumption of food to 
redress the imbalance (Volkow, Wang et al. 2012). 
Anorexia nervosa (AN) and binge eating (BE) disorders warrant mention here 
also. A large body of literature has linked dysregulation in reward systems with eating 
disorders such as AN and BE, where there is a fundamental issue with food reward 
valuation and learning via their interactions with the mesolimbic dopamine system.  
Although the physiological mechanisms underlying these conditions are incompletely 
understood, a strong genetic predisposition has been reported (Cuesto, Everaerts et al. 
2017, Berner, Brown et al. 2018). These conditions have traditionally been treated as 
psychiatric disorders given the high prevalence of comorbid anxiety and obsessive 
compulsive disorder (OCD) in these patients (Walter H. Kaye, Cynthia M. Bulik et al. 
2004, Schalla and Stengel 2018). Though the prevalence of AN and BE are much 
lower than that of obesity, the impact to quality of life is considerable (Erskine, 
Whiteford et al. 2016). Indeed, AN is the psychiatric disorder with the highest degree 
of mortality (Walter H. Kaye, Cynthia M. Bulik et al. 2004, Agh, Kovacs et al. 2016). 
Many agents that were heralded as the answer to the obesity problem were 




of centrally acting sympathomimetics such as ephedrine derivatives and phentermine 
were withdrawn due to concerns over abuse potential and cardiovascular safety 
(Colman 2005). The serotonergic agent fenfluramine, the monoamine uptake inhibitor 
sibutramine and the CB1 antagonist rimonabant were withdrawn for links to cardiac 
issues (fenfluramine and sibutramine) and psychiatric problems 
(rimonabant)(Weintraub, Sundaresan et al. 1992, Luque and Rey 2002, Kirkham 
2009). For AN and BE, cognitive behavioural therapy (CBT) is the mainstay of 
treatment, with pharmacological management of comorbid symptoms such as anxiety, 
depression etc. (Walter H. Kaye, Cynthia M. Bulik et al. 2004, Halmi 2005). The 
altered feeding component is but one visible symptom of a complex neuropsychosocial 
disorder which is only in the process of being fully understood (Halmi 2013, Cuesto, 
Everaerts et al. 2017).  
1.13 Ghrelin as a pharmacological approach for disorders of 
appetite 
The neural network controlling food intake has proven to be one of the most 
deceptively complex machineries to manipulate. Ghrelin, when discovered in 1999, 
was heralded as the key to pharmacological manipulation of appetite and body weight. 
This endogenous hormone has become synonymous with research efforts in the 
appetite modulation field due to its key position in the mammalian neuraxis controlling 
energy balance, as a peripherally accessible hormone with centrally-mediated effects 
on appetite (Horvath, Diano et al. 2001). Ghrelin exerts a number of somatotropic and 
anti-inflammatory effects (Figure 1.7) and has shown promising results in clinical 
trials for CACS (Neary, Small et al. 2004, Nagaya, Kojima et al. 2006). Moreover, the 
synthetic ghrelin agonist anamorelin has shown promising results pre-clinically and 
clinically and is currently under regulatory consideration for this indication (Pietra, 
Takeda et al. 2014, Garcia, Boccia et al. 2015). Conversely, ghrelin’s role in the reward 
system has led to it being considered as a therapy for conditions of dysregulation of 
food reward such as obesity (Horvath, Castaneda et al. 2003). Elevated ghrelin in 
hunger increases the perceived palatability and motivation to work for a food reward, 
via mesolimbic system activation (Egecioglu, Jerlhag et al. 2010, Egecioglu, Skibicka 




studies (Asakawa, Inui et al. 2003), there is little evidence of sustained anorexigenic 
properties clinically. Furthermore, the pathophysiology of eating disorders is 
incompletely understood at present and ghrelin’s role in this respect remains unclear 
(Frank 2013, Cuesto, Everaerts et al. 2017, Schalla and Stengel 2018). A paradoxical 
elevation of ghrelin in AN has been described despite patients having no drive to 
consume food (Nedvidkova, Krykorkova et al. 2003, Monteleone, Serritella et al. 
2008). Moreover, patients are refractory to ghrelin therapy (Broglio, Gianotti et al. 
2004, Miljic, Pekic et al. 2006, Ogiso, Asakawa et al. 2011). Many of these studies 
however have ignored the acylation status of ghrelin (Ogiso, Asakawa et al. 2011). 
Des-acyl ghrelin is an important consideration and likely has important clinical 
sequelae, given that certain studies have found it to have contrasting effects to acyl-
ghrelin (Asakawa, Inui et al. 2005) and that there are documented differences in these 
in AN patients (Koyama, Yasuhara et al. 2010). Furthermore, genetic polymorphisms 
in the ghrelin and/or GOAT may hold the key to a therapeutic breakthrough given the 
association with increased prevalence of AN (Dardennes, Zizzari et al. 2007, Muller, 
Tschop et al. 2011).  
Targeting of the ghrelin system has high potential in the treatment of disorders 
of dysregulation in reward processing. Ghrelin is a contributor to reward system 
priming and promotes the incentive salience of food (Naleid, Grace et al. 2005, 
Skibicka and Dickson 2011, Schellekens, Finger et al. 2012, Perello and Dickson 
2015). Consequently, antagonizing this system has become a target for the overt 
activation of the mesolimbic pathway which causes, and is caused by, the 
overconsumption of palatable foods. Furthermore, ghrelin is part of the complex 
interplay of genetic and neurobiological factors underlying the pathogenesis and 
maintenance of eating disorders. Although it’s role in this respect is not as well 
understood, there is a growing body of evidence to suggest that although the etiology 
of these disorders may not be linked to ghrelin there may be a role for manipulation of 




From pharmaceutical to nutraceutical – opportunities for 
early intervention in cachexia. 
Current pharmaceutical therapy is limited to those patients diagnosed with 
cachexia and whom are already in a treatment-refractive state. There is growing 
interest in the area of nutraceuticals as prophylactic or complementary therapies for 
various illnesses (Santini, Tenore et al. 2017). The potential health benefits of the 
bioactive fragments which exist in many food and dietary proteins have long been 
known (Nongonierma and FitzGerald 2015). As such, a pre-emptive nutraceutical 
approach to treat pre-cachexia has been proposed to augment a weakening ghrelin axis 
in elderly and infirm cohorts (Howick, Wallace-Fitzsimons et al. 2018). 
Nutraceuticals or functional foods are a relatively new concept which sits at the 
interface of drugs and food. They may be defined as a “food or part of a food that 
provides benefits to health in addition to its nutritional content”. Nutraceuticals and 
functional foods adopted in the diet may aid in the prevention, or delaying the onset 
of, pathological conditions (da Costa 2017). Furthermore, they may provide an avenue 
to potentially delay initiation of pharmaceutical medicines in subjects with milder 
symptoms. In this respect, the phenomenon of age-related appetite reduction and pre-
cachexia is an important, unmet, clinical need (Chapman 2004). The initiation of 
routine pharmaceutical therapy is imprudent in many cases. However, the impact of 
poor nutrition on prognosis of co-morbid conditions, as well as on overall quality of 
life and independent living means that appropriate early interventions are needed 
(Malafarina, Uriz-Otano et al. 2013). Given the lack of suitable pharmacotherapy and 
the growing role of nutraceutical science, evidence-based dietary interventions to help 
delay the onset of a cachectic state due in comorbid illnesses may be a useful avenue. 
The pro-active targeting of the ghrelin system with dietary-derived bioactives may 
precede or supplement pharmacological treatment of clinically significant appetite 




1.14 Dairy-derived dietary bioactives 
Recent times have seen an increasing move towards harnessing the health 
promoting benefits of dairy-derived dietary constituents while providing scientific 
evidence to substantiate their claim (Hartmann and Meisel 2007). The utilisation of 
dairy-derived bioactives in appetite-related disorders is now becoming increasingly 
apparent (Nongonierma and FitzGerald 2015, Torres-Fuentes, Schellekens et al. 
2015).  In particular, the potential for bioactive protein hydrolysates and peptides to 
enhance health in conjunction with conventional pharmaceutical therapy is being 
investigated. Milk has been identified as one of the richest sources of bioactive 
fragments and there is a growing body of evidence that these can have positive effects 
on appetite and metabolism (Phelan and Kerins 2011, Schellekens, Nongonierma et 
al. 2014, Torres-Fuentes, Schellekens et al. 2015, Nilaweera, Cabrera-Rubio et al. 
2017). Dairy-derived proteins have been shown to contain bioactive peptide 
sequences with various purported health benefits, with effects ranging from the 
digestive system to cardiovascular circulation, immune system and central nervous 
system. Peptides fractions have been isolated with ACE-inhibitory action, and blood-
pressure lowering properties of these dairy-derived bioactives in vivo have been 
reported. Interestingly, the ability of dairy proteins to modulate metabolism and 
appetite has recently been reported. The ability of a dairy bioactive to enhance satiety 
and decrease food intake in vivo has been shown (Schellekens, Nongonierma et al. 
2014). Conversely, recent work has also shown another whey protein isolate to 
reduce the expression of satiating genes in the hypothalamus and increase food intake 
in rodents (Nilaweera, Cabrera-Rubio et al. 2017). Furthermore, a casein-derived 
bioactive fraction with specific serotonin-2C receptor (5-HT2C) agonist activity 
eliciting satiating properties in a rodent model has been described (Schellekens, 
Nongonierma et al. 2014). 
Bioactives that augment the ghrelin system have previously yielded anecdotal 
evidence of increased appetite, which has since been substantiated by animal and 
human studies.  Rikkunshito (RKT), a long-standing traditional Japanese herb has the 
ability to function as a ghrelin agonist (Fujitsuka and Uezono 2014). RKT has been 




syndrome (Terawaki, Sawada et al. 2014, Tsubouchi, Yanagi et al. 2014), while a 
retrospective analysis of cancer patients showed increases median survival time in 
patients receiving concomitant RKT with their treatment (Fujitsuka and Uezono 
2014). Chin-shin oolong tea, a popular tea in Taiwan, was empirically perceived to 
induce hunger, and subsequently was shown to increase food intake in rats (Lo, Chen 
et al. 2014). In vitro, an isolate from Emoghrelin Heshouwu, a Chinese traditional 
medicine, was shown to activate the ghrelin receptor and stimulate GH secretion in 
vitro, supporting a claim for its perceived therapeutic efficacy as an anti-aging 
supplement (Lo, Chen et al. 2015). Furthermore, work in our lab has described 
ghrelinergic bioactives derived from natural sources (Pastor-Cavada, Pardo et al. 2016, 
Torres-Fuentes, Pastor-Cavada et al. 2018). 
Naturally-derived ghrelin bioactives have clearly demonstrated anecdotal and 
experimental evidence of efficacy on food intake and gut motility. Dairy-derived 
peptides are increasingly recognized for their bioactive components which may 
bestow clinical benefits in the area of appetite and metabolism (Hartmann and Meisel 
2007, Torres-Fuentes, Schellekens et al. 2015). However, there exists a major 
knowledge gap to realizing the full potential of milk protein derived peptides in this 
respect. Identification and isolation of these bioactives, as well as elucidating their 
pharmacodynamic parameters are necessary to transfer their potential benefits into 
functional applications (Korhonen and Pihlanto 2003). An urgent need exists for the 
development of integrated, multidisciplinary research platforms to address the role and 
mechanism of action of milk protein-derived peptides in humans (Nongonierma and 
FitzGerald 2015). 
1.14.1 Oral peptide delivery – Formulation and release 
perspectives  
One of the research modalities critical to the success of bioactive peptides and 
other labile substances is pharmaceutical science (Brayden and Baird 2013, Gleeson, 
Ryan et al. 2016). There is undoubtedly an increasing amount of research on peptides, 
protein hydrolysates and other dietary-derived bioactive substances with a plethora of 




commercialization of these products, not least being the development of appropriate 
oral delivery systems to protect the bioactivity and physicochemical properties of the 
payload (McClements, Decker et al. 2009).Without appropriate delivery systems, 
promising nutraceuticals and bioactives are unlikely to provide the intended 
physiological benefit due to the various degradative barriers encountered in vivo, in 
addition to barriers to absorption from the gastrointestinal tract  (Brayden and Baird 
2013, Howick, Alam et al. 2018, Howick, Wallace-Fitzsimons et al. 2018). All of this, 
in addition to the need for cost-effective strategies for industrial scale-ups, means that 
the nutraceutical industry would benefit greatly from the experience of traditional 
pharmaceutical formulation perspectives to yield appropriate encapsulation platforms.  
Oral peptide delivery remains a bottle-neck in the transition of potentially 
effective therapeutics from bench to bedside (Brayden and Alonso 2016). 
Bioavailability of peptides is consistently poor due to the acidic and enzyme-mediated 
degradation in gut lumen, leading to loss of efficacy. The rapid degradation of 
bioactive peptide structures in vivo necessitates drug delivery technologies which 
protect the payload in the gastric compartment and allow for site specific delivery to 
the small and large intestine (Malik, Baboota et al. 2007). Indeed, oral peptide delivery 
has been the subject of intense research across the pharmaceutics field, with various 
approaches adopted to increase bioavailability and limited breakdown. Various 
formulation approaches have been adopted to protect peptides from degradation within 
the gastrointestinal tract and increase oral bioavailability, ranging from standard 
formulations containing functional excipients, to micro- and nano- based (colloidal) 
delivery systems (Lakkireddy, Urmann et al. 2016). These range from the use of 
absorption enhancers, enzyme inhibitors and mucoadhesive polymers, to the use of 
various formulation vehicles and cell penetrating peptides. However, commercial 
success in terms of an orally active peptide formulation has been limited to a few niche, 
high potency peptides which can achieve therapeutic efficacy with limited 
bioavailability (i.e. <1%) (Aguirre, Teijeiro-Osorio et al. 2016) Although limited 
success has been reported to date there have been a number of interesting 





Table 1.3. Summary of selected clinical approaches to enhance oral peptide delivery Drug delivery system approaches to enhance oral peptide. 
Drug delivery 
system 
Highlights Protein/peptide Status Reference 
Peptelligence™ • Enteric coated tablet for intestinal release.  
• Citric acid reduce intestinal pH microenvironment to 
prevent protease degradation of payload. 








et al. 2013) 
Mycapssa® • Transient Permeability Enhancer platform 
• Lipophilic suspension of drug and an absorption enhancer 
(e.g sodium caprylate or medium chain fatty acid) 





• Protein Oral Delivery (POD™) technology containing a 
protease inhibitor and an absorption enhancer (EDTA). Insulin, GLP-1 Phase II 
(Werle, 





GIPET® • Based on the use of medium-chain fatty acids, in particular 
sodium caprate, which is claimed to open tight junctions 
transiently. 
Insulin, GLP-1 Phase II 
(Halberg, 
Lyby et al. 
2019) 
Eligen® • SNAC (sodium salcaprozate) and 5-CNAC (N-(5-
chlorosalicyloyl)-8-aminocaprylic acid) used as absorption 









Brayden et al. 
2019) 
NOD® • Bioadhesive calcium phosphate nanoparticles 
Insulin Phase I 
(Mathur, 
Mathur et al. 
2018) 
PharmaFilm® • Surface modified gold nanoparticles complexed with 
peptide and embedded into a mucoadhesive film for buccal 
delivery. 
Insulin Phase II 
(Hassani, 
Lewis et al. 
2015) 
Oral-lyn™ • Micellar solution buccal spray combined with permeation 
enhancers, bile salts and sodium caprate. Insulin Phase II 
(Hassani, 






Regulation of appetite and energy balance is achieved via a complex array of 
neurobiological signals spanning the gut-brain axis, communicating reciprocally to 
maintain homeostasis. Disorders of appetite are responsible for significant morbidity 
and mortality. Ghrelin is the only known peripheral orexigenic hormone and as such 
holds therapeutic promise in the treatment of both under- and over-eating, however 
currently no ghrelinergic agents have reached the market. This thesis focuses on two 
distinct areas of research; firstly, the targeting of GHSR-1a using dietary peptides for 
early stage treatment of appetite disorders, and secondly, the investigation of biased 
signalling and biodistribution of synthetic ghrelin ligands to enhance the functional 
efficacy of GHSR-1a ligands. 
Aim 1: Investigate dairy-derived hydrolysate ability to activate GHSR-1a. 
Milk is one of the largest repositories for bioactive peptides, with numerous 
purported health benefits (Phelan and Kerins 2011). The potential applicability of 
dairy-derived bioactives in appetite-related disorders is becoming increasingly 
apparent (Nongonierma and FitzGerald 2015, Torres-Fuentes, Schellekens et al. 2015, 
Nilaweera, Cabrera-Rubio et al. 2017). GHSR-1a is a key peripherally-accessible 
target for appetite modulation. In vitro investigations into the ability of novel dairy 
hydrolysates to activate the GHSR-1a will be undertaken in order to assess their 
potential for a dietary based therapeutic in disorders of appetite (Chapter 2 & 3).  
Aim 2: Develop an appropriate gastro-protected formulation for oral delivery. 
Given the labile nature of peptide-based bioactives, appropriate encapsulation 
strategies are needed in order to translate in vitro potency from bench to bedside 
(Brayden and Baird 2013, Brayden and Alonso 2016, Gleeson, Ryan et al. 2016). 
Therefore, in order to realize a clinically viable bioactive product, appropriate steps 
must be taken in order to deliver the ghrelinergic bioactives from Aim 1 intact to the 




will protect the peptide payload from acid-denaturation in vivo while also being 
amenable to dosing in small animal studies (Chapter 2 & 3). 
Aim 3: Assess food intake in rodents after dosing with novel hydrolysate. 
Much nutraceutical and bioactive research to date lacks tangible in vivo 
evidence of effect. Proof-of-concept studies are needed in order to ascertain if in vitro 
bioactivity can translate to an effect in a physiological model. Therefore, food intake 
in a rodent model will be assessed after dosing of ghrelinergic hydrolysates under 
different modes of administration (Chapter 2 & 3), with the ultimate aim of enabling 
clinical studies to be carried out as part of the Food for Health Ireland research 
collaboration.  
Aim 4: Investigate biased signalling of synthetic ghrelin ligands on GHSR-1a. 
Growing evidence points to the significance of biased signalling of ghrelin 
ligands in exerting differential effects in vivo (M'Kadmi, Leyris et al. 2015, Mende, 
Hundahl et al. 2018, Ramirez, van Oeffelen et al. 2018). Largely ignored until recently, 
it is now thought that the ability of GHSR-1a ligands to preferentially activate varying 
downstream pathways may lead to the development of more effective, selective 
ghrelinergic therapies. Therefore, various cell-based assays will be utilized to compare 
and contrast the downstream signalling of two novel ghrelin ligands, anamorelin and 
HM01 in order to further characterize their pharmacodynamics (Chapter 4).  
Aim 5: Investigate the effects of novel ghrelin ligands on appetite and reward 
motivated behaviours. 
The mesolimbic circuitry is a key driver for reward-based feeding and may 
represent an underexploited machinery to manipulate food intake (Howick, Griffin et 
al. 2017). The GHSR-1a is expressed in key nodes of the reward system such as the 
VTA. Consequently, biodistribution of ghrelin ligands is increasingly recognized as 
an important determinant for in vivo efficacy based on ability to gain access to the 
CNS and reward areas (Howick, Griffin et al. 2017). Various appetite and reward 




1a agonists, anamorelin (non-BBB penetrant) and HM01 (BBB penetrant) in order to 
bolster the theory that central penetrance is an important determinant of in vivo 
potency.  
Aim 6: Investigate underlying mechanisms using c-Fos immunostaining and in vivo 
microdialysis. 
The neural mechanisms underlying appetite and reward behaviours after 
treatment with ghrelin have been well established. However, ghrelin’s ability to effect 
changes to the mesolimbic circuitry despite being limited to the periphery in vivo 
remains a point of debate in the literature (Cabral, De Francesco et al. 2015, Edwards 
and Abizaid 2017). Mechanistic investigation using c-Fos as a marker of neuronal 
activation ex vivo will be undertaken after treatment with anamorelin (non-BBB 
penetrant) and HM01 (BBB penetrant). Furthermore, extracellular DA levels in the 
NAcc will be quantified using in vivo microdialysis studies in conscious, freely 
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Recent times have seen an increasing move towards harnessing the health 
promoting benefits of food and dietary constituents while providing scientific 
evidence to substantiate their claim. In particular, the potential for bioactive protein 
hydrolysates and peptides to enhance health in conjunction with conventional 
pharmaceutical therapy is being investigated. Dairy-derived proteins have been shown 
to contain bioactive peptide sequences with various purported health benefits, with 
effects ranging from the digestive system to cardiovascular circulation, immune 
system and central nervous system. Interestingly, the ability of dairy proteins to 
modulate metabolism and appetite has recently been reported. 
The ghrelin receptor (GHSR-1a) is a G-protein coupled receptor which plays 
a key role in the regulation of food intake. Pharmacological manipulation of the 
GHSR-1a receptor has therefore received a lot of attention as a strategy to combat 
disorders of appetite and body weight, including age-related malnutrition and the 
progressive muscle wasting syndrome known as cachexia. In this study, a novel milk 
protein-derivative is shown to increase GHSR-1a-mediated intracellular calcium 
signalling in a concentration-dependent manner in vitro. Significant increases in 
calcium mobilization were also observed in a cultured neuronal cell line 
heterologously expressing the GHS-R1a. In addition, both additive and synergistic 
effects were observed following co-exposure of GHSR-1a to both the hydrolysate and 
ghrelin. Subsequent in vivo studies monitored standard chow intake in healthy male 
and female Sprague-Dawley rats after dosing with the novel casein hydrolysate 
(CasHyd). Taken together, evidence suggests that the provision of gastro-protected 
oral delivery of bioactive in vivo may aid in the progression of in vitro efficacy to in 
vivo functionality. This study thus provides valuable translational data supporting the 
development of an appetite-enhancing bioactive peptide derived from dairy. 
Keywords: ghrelin; ghrelin receptor; bioactive peptides; dairy; food intake; appetite; 












The potential health benefits of the bioactive fragments which exist within the 
matrix of many food and dietary components have long been known (Nongonierma 
and FitzGerald 2015). Milk has been identified as one of the richest sources of 
bioactive fragments and there is a growing body of evidence that these can have 
positive effects on appetite and metabolism (Phelan and Kerins 2011, Schellekens, 
Nongonierma et al. 2014, Torres-Fuentes, Schellekens et al. 2015, Nilaweera, 
Cabrera-Rubio et al. 2017) Many of these bioactives are proven to have various health 
benefits, with effects spanning the digestive, endocrine, cardiovascular, immune and 
nervous systems (Fitzgerald and Meisel 2003, Korhonen 2009). Identification and 
isolation of these bioactives, as well as elucidating their pharmacodynamic parameters 
are necessary to transfer their potential benefits into functional applications (Korhonen 
and Pihlanto 2003). The utilisation of dairy-derived bioactives in appetite-related 
disorders is now becoming increasingly apparent (Nongonierma and FitzGerald 2015, 
Torres-Fuentes, Schellekens et al. 2015). The ability of a bioactive to enhance satiety 
and decrease food intake in vivo has been shown (Schellekens, Nongonierma et al. 
2014). Conversely, recent work has also shown a whey protein isolate to reduce the 
expression of satiating genes in the hypothalamus and to increase food intake in 
rodents (Nilaweera, Cabrera-Rubio et al. 2017). However, more translational studies 
are required to provide insights into the merits and mechanisms of milk-derived 
bioactives to treat appetite-related disorders. 
The endogenous hormone ghrelin, a 28 amino acid peptide is one of the key 
factors involved in food intake regulation (Kojima, Hosoda et al. 1999). The ghrelin 
receptor (GHSR-1a) has thus been a therapeutic target for disorders of appetite 
(Müller, Nogueiras et al. 2015, Howick, Griffin et al. 2017). Particularly, focus has 
been on individuals with poor appetite secondary to co-morbid conditions such as 
cardiovascular disease, respiratory disease and cancer, who can suffer an advanced 
form of ‘wasting syndrome’ known as cachexia (DeBoer 2008). Ghrelin 
administration has shown potential as a therapy in cachectic patient cohorts, however 
therapy is expensive and necessitates intravenous administration (Miki, Maekura et al. 




ligands developed to date. The most promising of these, anamorelin, has shown robust 
effects on food intake in humans and is under regulatory review for the treatment of 
cancer-related cachexia (Temel, Abernethy et al. 2016). In any case, the initiation of 
pharmaceutical therapy is restricted to patients with co-morbid conditions such as 
cardiovascular disease, respiratory disease and cancer, who often display cachexia, 
and would not be routine in mildly reduced appetites, such as those seen in ageing 
populations. Nevertheless, a ubiquitous decline in ghrelin levels with age is a major 
contributory factor to appetite reductions and weight loss (Chapman 2004). Poor 
nutritional status in elderly patients is a complicating factor for chronic diseases and 
results in prolonged hospital stays, lessened independent living and poorer response to 
treatment, leading to an overall greater burden on global health infrastructures and 
lower clinical outcomes (Malafarina, Uriz-Otano et al. 2013). The phenomenon of 
age-related appetite loss hence represents an important, unmet, clinical need. Given 
the lack of suitable pharmacotherapy and the growing role of nutraceutical science, we 
suggest the potential role of a bioactive ghrelin agonist to help delay the onset of a 
cachectic state due in comorbid illnesses. The pro-active targeting of the ghrelin 
system with dietary-derived bioactives may precede or supplement pharmacological 
treatment of clinically significant appetite reductions.  
Bioactives that augment the ghrelin system have previously yielded anecdotal 
evidence of increased appetite, which has since been substantiated by animal and 
human studies. Rikkunshito (RKT), a long-standing traditional Japanese herb has the 
ability to function as a ghrelin agonist (Fujitsuka and Uezono 2014). RKT has been 
shown to reduce weight loss and increase food intake in mouse models of wasting 
syndrome (Terawaki, Sawada et al. 2014, Tsubouchi, Yanagi et al. 2014), while a 
retrospective analysis of cancer patients showed increased median survival time in 
patients receiving concomitant RKT with their treatment (Fujitsuka and Uezono 
2014). Chin-shin oolong tea, a popular tea in Taiwan, was empirically perceived to 
induce hunger, and subsequently was shown to increase food intake in rats (Lo, Chen 
et al. 2014). In vitro, an isolate from Emoghrelin Heshouwu, a Chinese traditional 
medicine, was shown to activate the GHSR-1a and stimulate GH secretion in vitro, 
supporting a claim for its perceived therapeutic efficacy as an anti-aging supplement 




H.procumbens was shown to act on the GHSR-1a and modulate appetite in an in vivo 
mouse model (Torres-Fuentes, Theeuwes et al. 2014). 
There is an impetus to provide dietary-incorporated, scientifically validated 
interventions for poor appetite at an early point, rather than initiating late-stage 
pharmaceutical therapy which is often expensive, ineffective and not without side-
effects. The proactive use of nutraceutical therapy as a preventative or complementary 
approach to traditional pharmacotherapy has been recently discussed (Santini, Tenore 
et al. 2017, Santini and Novellino 2018). There is an impetus for the integration of 
research disciplines to address the role and mechanism of action of milk protein-
derived peptides in health (Nongonierma and FitzGerald 2015). Specifically, 
investigation of dairy-derived bioactive fragments with the potential to positively 
affect appetite is warranted in order to inform their clinical usage. Furthermore, 
bioactive identification, enrichment and incorporation into appropriate delivery 
systems is required (Howick, Alam et al. 2018). Here, we describe a casein-derived 
milk hydrolysate (CasHyd) which potently activates the GHSR-1a in vitro. In addition, 
we demonstrate additive and synergistic effects of the hydrolysate with ghrelin. We 
also investigate the potential of this bioactive peptide to function as an appetite 
stimulant in vivo under different modes of administration. This study thus represents 
an interesting translational investigation of a novel dairy-derived appetite-stimulating 
bioactive targeting the GHSR-1a with promising potential for inclusion as a functional 
food ingredient in population groups with poor appetite who may be at risk of 





  Materials and Methods 
2.1 Materials 
Dairy-derived peptide hydrolysate (CasHyd) was provided by Food for Health 
Ireland (see section 2.2). Disposable plastic flexible gavage tubes were purchased from 
Instech Laboratories (Instech Laboratories, Inc. Plymouth Meeting, PA, USA). 
Standard chow (2018S Teklad Global 18 % Protein Rodent Diet) was procured from 
Harlan, UK. For encapsulation of bioactive, an aqueous pseudo-latex of EC 
(Surelease® Type B NF) was sourced from Colorcon Corp., Indianapolis, IN, USA. 
Microcrystalline cellulose (MCC, Avicel® PH-101 NF Ph. Eur.) was purchased from 
FMC Corp., Little Island, Cork, Ireland and pharmaceutical grade ethanol 96% (v/v) 
from Carbon Chemicals Group Ltd., Ringaskiddy, Cork, Ireland. For the Ca2+ 
mobilization assays, fetal bovine serum (3.3%) was obtained from Sigma-Aldrich, 
Arklow, Wicklow, F7524. Assay buffer was composed of 1x Hanks balanced salt 
solution, HBSS, Gibco™ 14065049 (Thermo Fisher Scientific™), containing 20 mM 
HEPES (Sigma-Aldrich, Arklow, Wicklow, H0887). The endogenous agonist, ghrelin 
(rat), was supplied by Tocris Bioscience, Avonmouth, Bristol, UK (Cat. No. 1465). 
2.2 Generation of CasHyd 
Sodium caseinate (NaCas, Kerry Group Plc, Listowel, Ireland) was suspended 
at 10 % (w/w) protein basis in water and dispersed under agitation at a pre-defined 
temperature and duration in an in-line mixer. Protein hydrolysis was carried through 
addition of food grade enzyme. The pH of hydrolysis was maintained at a constant pH 
for the duration of hydrolysis by addition of a hydroxide base (Microbio, Fermoy, 
Ireland). The enzyme was then inactivated by heat treatment through a plate and frame 
heat exchanger (Unison Engineering Services Ltd., Limerick, Ireland). Large 
molecular weight material and aggregates were removed from the hydrolysate through 
membrane separation or clarification steps. The clarified material was then filtered 
through 1 kDa spiral wound organic membranes (Synder Filtration, California, USA) 
and the permeate fraction (CasHyd) was dried in a single stage spray dryer (Anhydro 




2.3 Ca2+ mobilization assay for peptide GHSR-1a activity 
GHSR-1a mediated changes in intracellular Ca2+ were recorded on a High-
Throughput Cellular Screening System (Molecular Devices Corporation, Sunnyvale, 
California, USA). Ca2+ mobilization assays were performed according to a protocol 
modified from a previously described method (Pastor-Cavada, Pardo et al. 2016). 
Stably transfected Human Embryonic Kidney (HEK293A) cells overexpressing 
GHSR-1a were seeded in sterile 96-well microtiter plates with black-walled and clear-
bottomed wells (3904, Costar, Fisher Scientific, Dublin, Ireland) at a density of 2.5 x 
104 cells per well. Cells were then kept at 37°C in a humidified atmosphere containing 
5 % CO2 overnight. Twenty-four hours before the experiment, media was replaced 
with serum-free media (1 % non-essential amino acids). On the day of the assays, cells 
were allowed to incubate with 80 µL of 1xCa5 dye (R8186, Molecular Devices) in 
assay buffer (1x Hanks balanced salt solution - HBSS, supplemented with 20 mM 
HEPES buffer). CasHyd was dissolved in assay buffer (1x HBSS supplemented with 
20 mM HEPES buffer). Addition of the dissolved compounds (25 µL/well) was 
performed automatically. Fluorescent readings were taken for 120 seconds at 
excitation wavelength of 485 nm and emission wavelength of 525 nm. The percentage 
increase in cytosolic Ca2+ was deduced from the difference between maximum and 
baseline fluorescence and depicted as relative fluorescent units (RFU) normalized to 
maximum response (reading from 3.3 % fetal bovine serum (FBS)). Background 
fluorescence from assay buffer alone was subtracted from all readings. The 
endogenous agonist ghrelin (1465; Tocris) was also used as a positive control of Ca2+ 
influx. Data were analysed using GraphPad Prism software (PRISM 5.0; GraphPAD 
Software Inc., San Diego, California, USA). Sigmoidal concentration-response curves 
were generated using nonlinear regression analysis with variable slope. 
2.4 Calcium imaging 
Calcium imaging took place for HEK-GHSR-1a cells seeded on a 12 well plate 
at 2.0x105 cells/ml two days before the assay according to a previously described 
method (Pastor-Cavada, Pardo et al. 2016). The day before the assay media was 
swapped to serum-free. For the assay procedure, all media was removed from cells 




37oC with 7uM Fura 2-AM (F1221, Biosciences) in assay buffer. Upon calcium 
release, the fluorescent excitation maximum of the Fura-2 indicator undergoes a blue 
shift from 363 nm (Ca2+-free) to 335 nm (Ca2+-saturated), while the fluorescence 
emission maximum remains unchanged at 510 nm. Upon excitation at 340 nm and 380 
nm respectively, the ratio of the fluorescent intensity emissions at these excitations is 
correlated to the levels of intracellular calcium. Subsequently, media was replaced 
with assay buffer without Fura 2-AM. Cells were viewed and a field was selected 
under brightfield illumination (Olympus BX50WI). Standard digital epifluorescence 
system (Cell R, Olympus) was used to measure changes in intracellular calcium (Ca2+). 
Light at 340 and 380nm was generated using a Xenon/Mercury arc burner (MT20 
illumination system, cell R, Olympus), illuminating the cells and stimulating fura 2 
fluorescence. Hydrolysates or the endogenous GHS-R1a receptor agonist ghrelin (SP-
GHRL-1, Innovagen) were added and the excitation spectra at 380 nm (Ca2+-free) and 
340 nm (Ca2+-saturated) with fixed emission at 510 nm was recorded.  
2.5 HPLC characterisation of CasHyd 
CasHyd and its parent protein (NaCas) were analysed using size exclusion (SE) 
high-performance liquid chromatography using a TSK G2000SWXL 7.8 x 300 mm 
column (Tosoph Corporation, Japan). Analysis was carried out at isocratic conditions 
for 40 min; the mobile phase was 30 % v/v and 0.1 % v/v TFA in deionised water. 
Flow rate through the column was 0.5 mL/min. The total injection volume was 20 mL. 
Absorbance of the eluate was measured at 214 nm. The following molecular weight 
standards were used for calibration purposes: Tyr-Glu (310 Da), Leu-Trp-Mel-Arg 
(605 Da), bacitracin (1.4 kDa), aprotinin (6.5 kDa), a-lactalbumin (14.2 kDa) and 
bovine serum albumin (66 kDa). 
2.6 Cell culture, in vitro transfection and lentiviral transduction 
Hek293A and SHSY5Y cells were maintained in culture in high glucose 
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% heat 
inactivated fetal bovine serum and 1% non-essential amino acids in an atmosphere of 
95% air and 5% CO2 at 37 °C. Hek293A cells were transfected using lipofectamine 




Genecopeia) according to manufacturer's instructions. Cells stably expressing the 
GHS-R1a receptor with the C-terminal-EGFP fusion protein, were selected using 
geneticin (G418, Merck) as a selection antibiotic. Cell populations with the highest 
fluorescence were selected using flow assisted cell sorting (FACS). In addition, 
SHSY5Y cells were transduced to express the GHS-R1a receptor using a 3rd 
generation packaging, gene delivery and viral vector production system developed by 
Naldini and colleagues (Naldini, Blomer et al. 1996, Vigna and Naldini 2000, Follenzi 
and Naldini 2002, Follenzi and Naldini 2002). HIV-based lentivector (LV) particles 
expressing the GHS-R1a from a spleen focus-forming virus (SFFV) promoter in 
conjunction with an EmGFP sequence expressed as a separate protein after an internal 
ribosome entry site (IRES) were generated. Briefly, the GHS-R1a sequence was 
cloned into a HIV-based, replication deficient, lentiviral expression plasmid, pHR-
SIN-BX-IRES-EmGFP (kind gift of Adrian Thrasher, Institute of Child Health, 
London, United Kingdom), modified to exclude the shRNA U6 promoter. The GHS-
R1a gene was amplified, gel isolated using the Qiagen Gel Extraction Kit (#28706) 
and ligated into the lentiviral vector using BamHI and XhoI restriction sites, 
generating pHR-GHS-R1a-IRES-EmGFP. Lentivector (LV) GHS-R1a expressing 
particles, pseudotyped with the vesicular stomatitis virus G [VSV-G] were produced 
using 293T-17 cell following transient cotransfection of the cloned expression 
constructs, pHR-GHS-R1a-IRES-EmGFP, the packaging construct, pCMVR8.91 
and the envelope construct, pMD.G –VSVG. SHSY-5Y cells were transduced with 
the GHS-R1a expressing lentiviral vectors diluted in transduction media, consisting of 
DMEM with 2% heat-inactivated FBS, 1% NEAA and an additional 8μg/ml 
polybrene® (Sigma; #H9268). Fluorescence was monitored using flow cytometry as 
indicator of receptor expression.  
2.7 Cumulative Food intake studies 
Male and female Sprague-Dawley (SD) rats were purchased from Envigo, UK. 
Rats were 7 to 8 weeks-old when received at the facility. Animals were group-housed 
(4 rats per cage) in standard holding cages with controlled light-dark cycle (12-h light; 
lights on at 7:00 a.m.) and in a temperature- (21 ± 1°C) and humidity-controlled (55 ± 




Rodent Diet, Envigo, UK) were available ad libitum. All experiments were in full 
accordance with the European Community Council directive (86/609/EEC) and 
approved by the Animal Experimentation Ethics Committee of University College 
Cork (B100/3774). Animals were habituated to experimental conditions for a week 
prior to experiments taking place. On experimental day, animals were administered 
their respective treatment at the onset of the light phase and then placed in individual 
cages for duration of food intake monitoring. Food intake was then recorded by 
weighing the chow at defined intervals. For the gastro-protected pellets, animals were 
food restricted for a period of 4 hrs before a pre-weighed quantity of chow was added 
to the cages. The dosing system for pellets consisted of a flexible PVC gavage tube 
which was filled with a pre-weighed quantity of blank or active pellets. After insertion 
of the dosing tube a guidewire was used to administer the dose of pellets directly into 
the stomach. 
2.8 Pellet preparation by extrusion-spheronisation 
Requisite quantities of CasHyd and MCC were combined in a ratio of 33:67 
and manually blended for 1 minute. A Kenwood planetary mixer (KM005, Kenwood 
Ltd., Hampshire, UK) was then used to further dry blend the mixture for 5 minutes at 
a minimum agitation setting. The dry powder blend was gradually wetted by adding 
deionized H2O, under constant agitation by the planetary mixer. The granulation end-
point was achieved upon addition of a cumulative amount of deionized H2O equivalent 
to 45 % (w/w) of the dry powder blend.  The granulate was immediately extruded at 
an extrusion speed of 17 – 19 rpm using a sieve extruder (Caleva® Extruder 20, Caleva 
Process Solutions, Sturminster Newton, Dorset, UK). Screen thickness and aperture 
diameter were both 1 mm. The extrudate was then placed into a Caleva® Spheroniser 
250 for 90 seconds at 1500 rpm (Caleva Process Solutions, Sturminster Newton, 
Dorset, UK). Pellets were collected and dried using high flow air in a microfluid bed 





2.9 Pellet film coating 
Film coating was performed in a laboratory scale microfluid bed system in 
bottom-spray mode. Nozzle air was set to 16-17 psig and airflow was 310 – 335 
L/minute. Coating solution, an 11% (w/w) aqueous pseudo-latex of EC (Surelease® 
Type B), was fed at a constant rate (1.0 gram/minute). Prior to coating, the Surelease 
polymer was allowed to homogenise for 30 minutes under constant agitation. 
Uncoated pellets were charged to the coating vessel and pre-heated for 10 minutes 
with an inlet air temperature of 80 °C, such that the sufficient drying could be obtained 
of the coating polymer. This was achieved at an outlet air temperature of ~ 50 °C. The 
amount of coating polymer required for film coating was calculated as a theoretical % 
weight gain based on a pre-based on the weight of uncoated pellets at the start of 
coating. The microfluid bed coating system was constantly monitored to ensure that 
appropriate air flow and drying was maintained in the coating chamber.  
2.10 pH susceptibility tests 
CasHyd was dissolved in deionized H2O and acidified with HCl to the requisite 
pH (pH 1, 3, 5 and untreated), using a pHenomenal® 1000L pH meter and electrode. 
Acidified CasHyd solutions were incubated for 30 minutes under gentle agitation. 50 
µL of each sample was removed and added to 950 µL of Ca2+ assay buffer and pH 
checked to confirm that acidity was neutralized before samples were added to cells. 
2.11 In vitro dissolution studies 
Dissolution testing (USP Type 1) was performed, using a basket-type 
dissolution apparatus (DISTEK, Inc., Model 2100C, North Brunswick, NJ, USA). 
Simulated gastric fluid sine pepsin (SGFsp) (pH 1.2, 500mls) was used as dissolution 
media. Dissolution bath temperature was kept at 37 °C and 50 rpm agitation speed. 
Sampling was conducted at various timepoints. After each sample an equal volume of 




2.12 Peptide quantification assay 
The bicinchoninic acid (BCA) assay was performed using a BCA assay kit 
(Thermo Fisher Scientific™ Pierce™ BCA Protein Assay, Catalog Number 23225) 
according to a well-established method. A 2 mg/ml stock solution of CasHyd in SGFsp 
was used to prepare a series of dilutions for preparation of a standard curve (2, 1, 0.5, 
0.25, 0.125, and 0.0625 mg/mL, respectively). 25 µL of each sample obtained during 
dissolution testing, and standards were plated on a 96-well plate. After the dissolution 
experiment was completed, remaining pellets were removed, crushed, and quantified 
as above in order to confirm all peptide was released from the formulation. Working 
reagent was prepared by mixing BCA assay Reagent A with BCA assay Reagent B in 
a ratio of 50:1. The working reagent (200 µL) was then transferred to each well. The 
plates were then covered and incubated at 37 °C for 30 minutes. Spectrophotometric 
analysis was performed at 562 nm and quantity of peptide in each sample was 
quantified from standard curves and expressed as a % of total peptide in the pellets. 
2.13 Data Analysis 
Data were analysed and graphs generated using both GraphPad Prism software 
and Microsoft Excel software. For in vitro cell screening and dissolution work, all 
means were calculated from the results of at least three independent experiments 
carried out in triplicate. For the in vitro calcium mobilization assays, standard error of 
the mean (SEM) is depicted, the dissolution result reports standard deviation (SD). For 
in vivo food intake, measurements between groups were analysed using a one-way, 
repeated measures ANOVA followed by estimation of parameters. If data was non-
spherical as determined by Mauchly’s test for sphericity, a Huynh-Feldt correction 
was applied for data analysis. Graphs are expressed as mean ± SEM. Statistical 






2.14  Activity of CasHyd on ghrelin receptor overexpressing cell line. 
The activity of the casein-derived hydrolysate, CasHyd, on the GHSR-1a was 
analysed  using an intracellular Ca2+ mobilization assay, as a measure of downstream 
GHSR-1a signalling activation (Schellekens, van Oeffelen et al. 2013), in HEK293A 
cells stably expressing the GHSR-1a tagged with an enhanced green fluorescent 














































Figure 2.1. A Concentration response curve of novel casein-derived hydrolysate. 
Concentration response curve for the casein-derived hydrolysate, CasHyd measured 
in GHSR-1a over-expressed in HEK293A cells. B Activity of CasHyd in wild-type 
(HEK293A-WT) cells, 5HT2C receptor (HEK293A-5HTR2C) and a fully edited form of 
5HTR2C (HEK293A-5HTR2C -VSV) expressing cells. Intracellular Ca
2+ increase was 
depicted as a percentage of maximal Ca2+influx in relative fluorescence units (RFU) 
as elicited by control (3.3% FBS). Graph represents mean ± SEM of at least three 
























































Table 2.1. Activity of CasHyd and Ghrelin on GHSR-1a over-expressing HEK293A 
cells 
Compound EC50 Emax1 
Ghrelin 0.25 µg/ml 132.5% 
CasHyd 0.27 mg/ml 148.9% 
1 Intracellular Ca2+ increase reported as a percentage of maximal Ca2+influx in 
relative fluorescence unit (RFU) as elicited by control (3.3% FBS). 
CasHyd stimulated calcium mobilization in cells expressing GHSR-1a in a 
concentration-dependent manner, with the EC50 = 0.27 mg/ml and efficacy (Emax) 
reaching 148.9 %. The potency of CasHyd was 1000-fold lower than that for the 
endogenous receptor ligand, ghrelin (EC50 = 0.25 µg/ml, Emax = 132.5%). Considering 
CasHyd is a mixture of different peptides not all of which are likely to elicit 
bioactivity, the activation found here on the GHSR-1a indicates promising ability to 
modulate the receptor. Efficacy of CasHyd was normalized to the maximal response 
of the positive control (3.3% FBS, Emax = 100%). Critically, the concentration response 
curve shows that the hydrolysate has GHSR-1a agonist activity, while no Ca2+ influx 
was observed in wild-type HEK293A cells (HEK293A-WT) not expressing the 
GHSR-1a. Furthermore, no activity was observed in 5HT2C (HEK293A-5HTR2C) 
receptor-expressing cell line, nor in the edited from of the 5HTR2C, (HEK293A-
5HTR2C -VSV), compared to treatment with control (FBS), which gives maximal 
intracellular Ca2+ mobilization in all tested cell lines. Food intake and adiposity are 
altered in vivo when the 5-HT2C receptor RNA is fully edited, suggesting a potential 
role for 5-HT2C editing in eating disorders (Schellekens, Clarke et al. 2012). Together, 
these results show to our knowledge for the first time, the promising potential of the 
novel CasHyd to specifically modulate the GHSR-1a.  
 
2.15 Calcium imaging on ghrelin receptor overexpressing cell line 
Next, the GHS-R1a mediated calcium response of the HEK-GHSR-1a cells to 
ligand exposure was investigated using calcium imaging. Following addition of 
500nM ghrelin an increased fluorescence peak is observed indicating calcium influx 




CasHyd (1.5mg/ml), but to a lesser extent than was seen upon ghrelin addition (Figure 
2.2A). Calcium influx is evident through the shift in fluorescence from pink to blue 
(Figure 2.2B), indicating calcium release from intracellular stores resulting in an 
excitation shift from 340nm to 380nm. This further corroborates the calcium 
mobilization results obtained.  
 
  
Figure 2.2. Specific activation of heterologously expressed GHSR-1a in HEK293A 
cell-line. Calcium imaging of HEK cells (60x magnification) heterologously 
expressing the GHS-R1a. Cells were seeded for 48 hours into wells at a density of 
2.0x105 cells/ml, and loaded for 1 hr with the UV-excitable fluorescent calcium 
indicator, Fura-2AM, and the 340nm/380nm ratio is recorded after addition of 500nM 
ghrelin or 1.5 mg/ml CasHyd. Traces represents the average of three independent 
experiments, dotted lines indicative of SEM. 
 






























2.16 HPLC characterization of CasHyd 
 
Figure 2.3. Size exclusion HPLC for CasHyd fraction compared with parent casein 
protein. Molecular weight distribution of CasHyd and parent protein, Sodium 
Caseinate (NaCas), expressed as absorbance over time on HPLC chromatogram.  
Size exclusion chromatography carried out on the whole unhydrolysed protein, 
Sodium Caseinate (NaCas) versus the hydrolysate, CasHyd, shows no overlap in the 
molecular weight distribution after enzymatic hydrolysis. The unhydrolysed parent 
protein, NaCas, showed 85.9% of total proteins to be >25kDa molecular weight, 
whereas 86.0% of CasHyd is below 1kDa in size. This shows the extent of hydrolysis 
which takes place yielding a mixture of vastly different peptide fractions to the parent 
casein protein. In addition, the high level of hydrolysis of CasHyd yielding a majority 










































NaCas      (% 
Area)   
CasHyd     (% 
Area) 
>25 kDa <14.66 85.9 0.0 










5kDa – 1kDa 19-21.35 0.0 14.0 
<1kDa >21.35 0.0 86.0 
 
 
2.17 GHSR-1a activation by CasHyd in neuronal cells in vitro. 
Next, the activity of CasHyd was assessed in the neuroblastoma cell line, 
SHSY-5Y, engineered to overexpress the GHS-R1a as a native receptor (no 
fluorescent tag) using lentiviral vectors. A calcium mobilization response following 
exposure to the endogenous ligand, ghrelin, as well as the dairy-derived hydrolysate, 
CasHyd, was observed in both engineered cell lines. We also demonstrate hydrolysate-
mediated calcium mobilization in neuronal cells endogenously expressing the GHS-

























































Figure 2.4. Specific activation of tagged and untagged GHS-R1a receptor in 
neuronal cells. Both CasHyd (3mg/ml) and ghrelin (100nM) elicited a GHS-R1a 
mediated calcium influx in the neuronal-like cell line (SHSY-5Y-GHSR-1a_-IRES-
EGFP) and HEK-GHSR-1a-EGFP cells generated to express the receptor using 
lentiviral vectors. Graphs represent the mean +/− SEM of a representative experiment 
with each concentration point performed in triplicate. Intracellular calcium increase 
was depicted as a percentage of maximal calcium increase as elicited by control 
(100nM ghrelin)(IRES – Internal ribosome entry sites, EGFP – enhanced green 





2.18 Additive and synergistic effects of the novel dairy-derived 











































































Figure 2.5. Additive GHS-R1a activation following co-treatment of ghrelin and 
CasHyd. Additive calcium mobilization is observed following co-treatment of HEK 
cells stably expressing the GHS-R1a with 33nM of ghrelin and CasHyd. Graphs 
represent the mean +/− SEM of a representative experiment of three independent with 
each concentration point performed in triplicate. Intracellular calcium increase was 
depicted as a percentage of maximal calcium increase as elicited by control (100nM 
ghrelin). Statistically significant differences are calculated using a one-way analysis 
of variance (ANOVA) followed by Bonferroni post-hoc test for multiple comparisons 
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Ghrelin (3.3nM) + CasHyd
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Figure 2.6. Additive and synergistic effects of GHS-R1a activation following co-
treatment of ghrelin and CasHyd. Additive and synergistic effects are observed 
following co-treatment of HEK cells stably expressing the GHS-R1a with hydrolysate 
and 30nM or 10nM ghrelin (A) or hydrolysate and 3.3nM or 1.1nM ghrelin (B). 
Intracellular calcium increase was depicted as a percentage of maximal calcium 
increase as elicited by control (100nM ghrelin). Graphs represent the mean +/− SEM 
of a representative experiment of three independent with each concentration point 




indicating an additive effect are calculated using a one-way analysis of variance 
(ANOVA) followed by Bonferroni post-hoc test for multiple comparisons and depicted 
as ***p<0.001, **p<0.01 and *p<0.05. Statistically significant differences of a 
synergistic effect are depicted as; $ p<0.001, & p<0.01 and # p<0.05. 
Potential additive or synergistic effects between ghrelin and the novel dairy-
derived hydrolysate on GHS-R1a activation were investigated. Cells stably expressing 
the GHSR1a were exposed to different concentrations of ghrelin (100nM-3.7nM) and 
CasHyd (3-0.5mg/ml). Increases in intracellular calcium could be observed following 
all concentrations of hydrolysate and a dose dependent calcium influx for ghrelin 
(Figure 2.5). However, no synergistic effects were observed. A small additive effect 
was observed for cells treated with a suboptimal concentration of ghrelin (33nM) and 
all three concentrations of CasHyd but this did not reach statistical significance. 
However, when analysing the effect on calcium mobilization using lower 
concentrations of CasHyd (0.1mg/ml and 0.03 mg/ml) clear additive effects could be 
observed with 30nM and 10nM ghrelin (Figure 2.6A). In addition, additive calcium 
mobilization was observed following co-treatment of 0.3 mg/ml CasHyd and 3.3nM 
or 1.1 nM ghrelin (Figure 2.6B). Moreover, synergistic effects were observed when 
cells were co-treated with the two lowest concentrations of CasHyd (0.1mg/ml or 






2.19 Cumulative food intake studies after intraperitoneal injection of 
peptide solution 











































Saline injection (n = 12)


























































2.0 Saline injection (n = 12)


















Figure 2.7. Cumulative food intake following intraperitoneal administration of 
dairy derived peptide hydrolysate. Cumulative food intake (CFI) (regular chow) 
intake in male (A) and female (C) sprague-dawley rats was determined following 
intraperitoneal injection with 50mg kg-1 body weight of CasHyd over 6 hours. The 
food intake per time bin is also illustrated for males (C) and females (D). Data 
presented as mean ± SEM. 
In food intake studies following an intraperitoneal injection of CasHyd 50mg 
kg-1 in 0.9% saline, or control, there were no significant differences noted in the 
amount of food consumed between groups, normalized to body weight. Examination 
of individual time bins yielded no overall differences at any timepoint. Hence, we 





2.20 Cumulative Food Intake studies after oral administration of 
peptide solution 
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Figure 2.8. Cumulative food intake following oral administration of unencapsulated 
dairy protein-derived hydrolysates. Food (regular chow) intake in male (A) and 
female (B) sprague-dawley rats was determined following oral gavage with 50mg kg-
1 body weight of CasHyd over 6 hours. Cumulative food intake (CFI) was determined 
at regular intervals after oral gavage. The food intake per time bin is also illustrated 
(B and D). Graphs represents the mean ± SEM. Statistical significance was determined 
using repeated measures ANOVA and estimation of parameters for food intake. 
Pairwise comparisons were carried out using Tukey’s post-hoc test, while independent 
samples t-test was used for each individual timebin; statistical significance is depicted 
as **p < 0.01 and *p < 0.05. 
In cumulative food intake (CFI) studies following an oral gavage of a 50 mg 
kg-1 dose of peptide solution, there were significant increases noted in the amount of 
food consumed relative to control in both males and females, normalized to body 




Pairwise comparisons also reveal trends at 3 and 5 hours post dose, and a significant 
increase at 4 hours compared to control for the female cohort. The most significant 
change in food intake was in the 5-6 hour time bin for both males and females (B, D). 
The GHSR-1a is located on vagal nerve terminals in the gastrointestinal tract, 
throughout the small and large intestine (Howick, Alam et al. 2018), potentially 
explaining the increased efficacy of the oral route versus IP via potential local GHSR-
1a stimulation. 












































Figure 2.9. GHSR-1a agonist, CasHyd, displays pH dependent activity. Reduction in 
hydrolysate-mediated GHSR-1a activation following exposure to acidic pH confirms 
the need for an oral delivery mechanism. Graph represents three independent 
experiments carried out in at least triplicate (Control = CasHyd not exposed to acidic 
pH, RFU = Relative Fluorescence Units). 
CasHyd was exposed to varying degrees of acidic pH for a time representative 
of minimum gastric residence time in the fasted state (minimum 30 minutes (Tuleu, 
Andrieux et al. 1999)Howick, 2018 #1307). A pH-dependent loss in peptide activity 
is observed for CasHyd, confirming the need to develop a gastro-resistant formulation 
to minimize exposure to gastric acid before progression to further in vivo efficacy 




2.22 Delivery system (pellet) characterization work 
Since CasHyd is susceptible to acidic pH, the peptide was incorporated into a 
gastro-protected delivery system (coated pellets) in order to minimize exposure to the 
stomach in vivo. Simulated release profile assessment of CasHyd from the formulation 
was carried out in vitro in order to assess whether the coating applied to the pellets 
was able to delay release. USP Type 1 (Basket) dissolution studies were carried out in 
gastric conditions (simulated gastric fluid, SGFsp, pH 1.2) in order to confirm a 
delayed release of peptide from the pellets. Pellets displayed a delayed release of 
peptide load over 60 minutes, confirming the functionality of the delivery system 
(Figure 2.10). 


















Figure 2.10. Dissolution study of gastro-protected CasHyd pellets. USP Type 1 
(Basket) dissolution studies (50 rpm, 37.5 °C) showed gastro-protected release in 



































































Figure 2.11. CasHyd retains bioactive functionality after encapsulation. Activity of 
CasHyd after encapsulation was determined relative to activity of non-encapsulated 
CasHyd in GHSR-1a- expressing cells. Activity was quantified as being 75 % for 
uncoated pellets and 60% for coated pellets (representative of three independent 
experiments carried out in triplicate). 
Due to the likely fragile nature of the peptide hydrolysate (Howick, Alam et 
al. 2018), we quantified the impact of the encapsulation processing conditions on 
bioactivity. Activity of CasHyd in the encapsulated pellets was determined relative to 
activity of non-encapsulated CasHyd peptide in the GHSR-1a overexpressing cells, as 
described above. Activity was quantified as being 75 % for uncoated pellets and 60% 





2.24 Cumulative food intake studies after oral administration of 
peptide encapsulated in gastro-protective pellets 

















































































Figure 2.12. Cumulative food intake following oral administration of gastro-
protective pellets containing casein-derived hydrolysate. Food (regular chow) intake 
in male (top) and female (bottom) Sprague-Dawley rats was determined following oral 
gavage with 35mg kg-1 dose of encapsulated CasHyd over 6 hours. Cumulative food 
intake (CFI) was determined at regular intervals, beginning 4 hours after oral gavage 
of the coated pellets containing CasHyd, or an equivalent weight of blank pellets. The 
food intake per time bin is also illustrated. Graphs represents the mean ± SEM. 
Statistical significance was determined using repeated measures ANOVA and 
estimation of parameters for food intake. Pairwise comparisons were carried out 
using Tukey’s post-hoc test, while independent samples t-test was used for each 
individual timebin; statistical significance depicted is notated as **p < 0.01 and *p < 
0.05. 
In food intake studies following an oral gavage of casein hydrolysate 




no overall significant increases noted in the amount of food intake for males or 
females, however a trend towards an overall increase is noted at the 6 hour timepoint 
for both. A significant increase in amount of food consumed was observed in the 4-
5hour time bin for the male cohort also. However, the orexigenic effect seen after oral 






Ghrelin and the growth hormone secretagogue receptor, or GHSR-1a, play an 
important role in energy balance and appetite regulation (Schellekens, Dinan et al. 
2010, Howick, Griffin et al. 2017). Many studies have reported potent appetite-
stimulating effects of both peripheral and central administration of ghrelin (Tschop, 
Smiley et al. 2000, Wren, Seal et al. 2001). Furthermore, natural analogues of ghrelin 
have provided anecdotal and, more recently, experimental evidence of a positive effect 
on appetite and energy balance in susceptible population groups (Fujitsuka and 
Uezono 2014). Hydrolysates of milk proteins, both casein and whey, are increasingly 
recognized for their bioactive components which may bestow therapeutic benefits on 
appetite (Hartmann and Meisel 2007, Nongonierma and FitzGerald 2015, Torres-
Fuentes, Schellekens et al. 2015, Nilaweera, Cabrera-Rubio et al. 2017). A casein-
derived bioactive fraction with specific serotonin-2C receptor (5-HT2C) agonist 
activity eliciting satiating properties in a rodent model has been described 
(Schellekens, Nongonierma et al. 2014). In this study, we demonstrated that a novel 
casein hydrolysate displayed intrinsic GHSR-1a agonist activity which translated to 
an effect on increasing food intake in vivo in rats.  
The dairy hydrolysate, CasHyd, dose-dependently and specifically increased 
intracellular Ca2+ in HEK293A cells heterologously expressing the GHSR-1a. We 
have previously reported ghrelin agonistic effects of a whey-based protein derivative 
in the same in vitro system (Howick, Alam et al. 2018). The CasHyd described here, 
displays superior potency (0.27 mg/ml) compared to the whey derived fraction, 
however it is considerably less than the endogenous GHSR-1a ligand (0.25 µg/ml), 
ghrelin (Figure 2.1). This is likely reflective of the fact that CasHyd is a mixture of 
peptides, only some, or one, of which may be active on GHSR-1a. Additionally, the 
in vitro activity is specific, with negligible effects on WT, 5HTR2C or the fully edited 
form of 5HTR2C. The activity of CasHyd is also shown to be both additive and 
synergistic to native ghrelin in vitro (Figure 2.5,2.6). Furthermore, the activity of 
CasHyd was assessed in the neuroblastoma cell line, SHSY-5Y, engineered to 
overexpress the GHS-R1a receptor as a native receptor (no fluorescent tag) using 




endogenous ligand ghrelin as well as the dairy-derived hydrolysate was observed in 
both this cell line, and that of HEK293A (Figure 2.4). This reinforces the GHS-R1a 
activating potential of the hydrolysate. Moreover, hydrolysate mediated GHS-R1a 
activation was obtained in a cultured neuroblastoma cell line expressing the GHS-R1a. 
This provides promising evidence to further examine CasHyd activity on GHSR-1a in 
a physiologically relevant environment using primary cultured neuronal cells. HPLC-
SEC contrasted the size differences of the parent casein protein and CasHyd, 
confirming the efficacy of the hydrolyzation process (Figure 2.3). The high presence 
of low molecular weight peptide sequences (<1kDa, Table 2) is critical to the 
bioactivity reported in these assays.  
This is the first instance that a casein-derived peptide has been shown to have 
GHSR-1a agonist properties in vitro. Furthermore, this in vitro activity has been 
demonstrated to translate to an increase in food intake in vivo in a rodent model. We 
show that CasHyd displays evidence of enhancing food intake in healthy SD rats. Male 
and female rats treated orally using a solution of CasHyd at a dose of 50mg/kg showed 
a three-fold increase in food intake over the six hour experiment (Figure 2.8), however 
this is tempered by a relatively low quantity of food consumed overall. Time bins 
illustrate a significant elevation in both groups in the 5-6 hour timepoint, potentially 
indicative of a prolonged/delayed systemic effect. Interestingly, following 
intraperitoneal injection of CasHyd (50mg/kg dose), neither male nor female rats 
displayed a significant increase in food intake relative to control (Figure 2.7). The 
apparent success of oral delivery of the bioactive peptide relative to injection may be 
reflective of the distribution of the GHSR-1a in vivo, which is heavily expressed in the 
gastrointestinal tract and involved in neuronal signalling to appetite centres in the brain 
(Howick, Alam et al. 2018).  
Despite the apparent increase in food intake after oral gavage of CasHyd, in 
vitro assays confirm that acidic pH, comparable to that experienced in the gastric 
conditions, is detrimental to CasHyd bioactivity (Figure 2.9). The ability of bioactive 
peptides to elicit a beneficial effect in vivo is hence likely to be highly dependent on 
the use of a gastro-protective delivery system (de Vos, Faas et al. 2010, Gleeson, Ryan 




research strategies for bioactive materials (Brayden and Baird 2013, Gleeson, Ryan et 
al. 2016). Therefore, we sought to develop a gastro-protective formulation to minimize 
acid-mediated degradation of the casein fraction and enhance delivery to the small 
intestine. A coated pellet formulation was established, utilizing extrusion-
spheronisation for pelletisation, followed by coating with an ethylcellulose-based 
polymer using fluidized bed technology. CasHyd encapsulated in a coated oral 
delivery vehicle (pellets) showed a trend towards an increase in food intake in female 
rats (p=0.054), and male rats (p=0.097) at the 6-hour timepoint, although overall no 
significant differences are noted. Furthermore, the absolute amount of food consumed 
in the experimental period is higher after dosing with pellets (Figure 2.12) compared 
with CasHyd solution (Figure 2.8), which may be reflective of the bulk volume of 
pellets; it may be that dosing pellets which slowly disintegrate in the intestine creates 
a paradoxical increase in food intake, thereby confounding any comparisons to orally 
dosed solutions. Furthermore, the orally dosed pellets impact on the timing of the 
release of bioactive which may in itself lead to different effects i.e. the immediate 
availability of the peptide in the stomach vs the gradual release from slowly dissolving 
pellets. 
Overall, although food intake results showed high variability, these initial 
proof-of-concept studies represent promising results. The increase in food intake after 
oral gavage of CasHyd is tempered by efforts to substantiate the claim as an appetite 
stimulant by incorporating it into a gastro-protected vehicle; these efforts did not find 
any such increase. Further discussion on the study limitations is therefore merited, 
specifically in relation to the suitability of the experimental setup for assessing food 
intake, and peptide release characteristics from the delivery system.  
Firstly, although the food intake model described has been reported in previous 
studies involving a bioactive peptide, food intake in rodents is inherently variable, and 
susceptible to change by a multitude of factors. Inter-experimental variability is 
evident in the differing absolute amount of food consumed between studies. Healthy, 
normophagic rats were used in this study; this makes it difficult to observe any 
increases in food intake given that metabolic drive would generate a healthy appetite 




normally would be asleep – circadian fluctuations may serve here as a confounder to 
assessing true appetite. Furthermore, the dosing procedure exerted a degree of restraint 
stress upon the animals, while there is a risk of minor local injury to the oesophagus 
in gavaged rats which is also likely to impact on food intake. Secondly, the bioactive 
hydrolysate itself is likely to be highly fragile in vivo, due to low gastric pH (discussed 
above), as well as intestinal peptidases. Variability in results may well be a 
consequence of systemic breakdown. Thirdly, in the case of pelletized CasHyd, the 
delivery system design incorporated the peptide into a gastro-protected pellet which 
exerted a degree of processing stress on the peptide, resulting in a loss of ~40% 
bioactivity. The bulk effect of solid pellets also seems to have imparted a default 
increase in food intake in both males and females compared to oral solution. While 
this formulation was useful as proof of concept, process optimization is required to 
minimize activity losses, reduce bulk volume and tailor the release profile further in 
vivo.  
Despite the above described caveats to this study, hitherto, a lot of evidence 
substantiating nutraceutical and bioactive health claims comes from in vitro 
bioinformatics, with many lacking tangible in vivo evidence of effect (Li-Chan 2015, 
Nongonierma and FitzGerald 2015). Therefore, evidence is needed to further support 
the claim of dairy-derived bioactives for appetite modulation. Our novel casein-
derived bioactive peptide, CasHyd, shows promising results translating a specific in 
vitro bioactivity with high potency, to a promising biofunctional effect on food intake 
in vivo, suggesting overall success of this proof of concept study. Given a more 
suitable platform for assessment of food intake, and/or an optimized oral delivery 
mechanism to improve stability during formulation, a considerable potential to 
increase food intake in vivo by targeting intestinal GHSR-1a exists. 
The area of bioactives for appetite modulation is of growing commercial 
interest and has the potential to address an unmet clinical need by providing an 
evidence-based, dietary incorporated, early intervention for conditions of undereating. 
CasHyd is a GHSR-1a agonist which represents a novel nutraceutical approach to 




order to fully elucidate its clinical merit, while technology to retain and enhance 





This work describes a dairy-derived peptide with potent activity on the GHSR-
1a in vitro. In vivo preclinical studies with this bioactive peptide show its potential to 
act as an appetite stimulant after oral administration. CFI was increased three-fold after 
6 hours in male and female SD rats after a single oral dose. However, while activity 
of CasHyd was eliminated following exposure to gastric pH, administration of CasHyd 
in a gastro-protected pellet formulation only showed a trend towards increased food 
intake in both males and females. Variable results may be reflective of the suboptimal 
release of peptide coupled with loss of bioactivity in vivo, and/or potential lack of 
suitability of the model to assess subtle appetitive changes in a normophagic rat cohort. 
Overall, high in vitro efficacy on the GHSR-1a has translated to evidence of an effect 
on food intake in vivo. Therefore, we consider this study a valuable contribution to the 
growing body of evidence for nutraceuticals and nutraceutical encapsulation 
platforms, which serves as a useful reference for further investigations in preclinical 












































































Figure S1. Enzyme Linked Immunosorbent Assay for Growth Hormone, total GLP-
1 and Corticosterone: 4 hours post-dosing with CasHyd pellets animals were 
euthanized and trunk blood collected for analysis. Growth Hormone (GH), Total 
Glucagon-Like Peptide (GLP-1) and Corticosterone (Cort). No significant differences 
were detected between the treatment and control animals 4 hours post-dosing with 
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There is an impetus to provide appropriate sustained release oral delivery 
vehicles to protect biofunctional peptide loads from gastric degradation in vivo. This 
study describes the generation of a high load capacity pellet formulation for sustained 
release of a freely water-soluble dairy-derived hydrolysate, FHI-2571. The activity of 
this novel peptidic ghrelin receptor agonist is reported using in vitro calcium 
mobilization assays. Conventional extrusion spheronization was then used to prepare 
peptide-loaded pellets which were subsequently coated with ethylcellulose (EC) film 
coats using a fluid bed coating system in bottom spray (Wurster) mode. Aqueous-
based EC coating dispersions produced mechanically brittle coats which fractured due 
to osmotic pressure build-up within pellets in simulated media. In contrast, an 
ethanolic-based EC coating solution provided robust, near zero-order release in both 
USP Type 1 and Type 4 dissolution studies. Interestingly, the functionality of aqueous-
based EC film coats was restored by first layering pellets with a methacrylic acid 
copolymer (MA) subcoat, thereby hindering pellet core swelling in acidic media. 
Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) was utilized as a 
complementary technique to confirm the results seen in USP dissolution studies. 
Retention of activity of the ghrelinergic peptide hydrolysate in the final encapsulated 
product was confirmed as being greater than 80%. The described pellet formulation is 
amenable to oral dosing in small animal studies in order to assess in vivo efficacy of 
the whey-derived ghrelinergic hydrolysate. In more general terms, it is also suitable as 
a delivery vehicle for peptide-based bioactives to special population groups e.g. 





Graphical Abstract. Graphical synopsis of Chapter 3 
Introduction 
Oral peptide delivery remains a bottle-neck in the transition of potentially 
effective therapeutics from bench to bedside (Brayden and Alonso 2016). 
Bioavailability of peptides is consistently poor due to the acidic and enzyme-mediated 
degradation in gut lumen, leading to loss of efficacy. The rapid degradation of 
bioactive peptide structures in vivo necessitates drug delivery technologies which 
protect the payload in the gastric compartment and allow for site specific delivery to 
the small and large intestine (Malik, Baboota et al. 2007). Various formulation 
approaches have been adopted to protect peptides from degradation within the 
gastrointestinal tract and increase oral bioavailability, ranging from standard 
formulations containing functional excipients, to micro- and nano- based (colloidal) 
delivery systems (Lakkireddy, Urmann et al. 2016). However, commercial success in 
terms of an orally active peptide formulation has been limited to a few niche, high 
potency peptides which can achieve therapeutic efficacy with limited bioavailability 




systems encompass a large proportion of the efforts to translate peptide functionality 
in vitro to the clinical setting. However, various limitations exist to these respective 
approaches: the former typically involves complex processing steps leading to peptide 
degradation (Witschi and Doelker 1998, Yin, Lu et al. 2008), while the latter displays 
poor loading capacity (1-5%), variable release characteristics and limited scalability 
(Redhead, Davis et al. 2001, Jain, Khar et al. 2008). Furthermore, stresses during 
processing, including shear forces, exposure to organic solvents and excessive drying 
time will adversely impact on peptide stability, as well as interactions with 
hydrophilic/hydrophobic interfaces. There is thus an impetus to develop more suitable 
oral delivery platforms to enable assessment of in vivo efficacy for peptidic 
compounds showing promise in the in vitro setting. 
The main aim of this study is the encapsulation of a novel bioactive peptide 
using a traditional multiparticulate formulation approach. These coated pellets are 
intended for use pre-clinically to investigate bioactive functionality in rodents. In 
addition, from a clinical utility perspective, pelletised dosage forms offer numerous 
advantages such as flexible dosing and ease of administration in special population 
groups. Conventional formulations such as coated pellets are widely used in the 
pharmaceutical industry to obtain suitable release profiles for a variety of active 
pharmaceutical ingredients (API) (Lecomte, Siepmann et al. 2004, McGinity and 
Felton 2008) . Millimetre size-range pellets have notable advantages compared to sub-
micron and colloidal delivery approaches. A narrower particle size distribution allows 
for homogeneous film formation and more reproducible release profiles. Higher 
peptide loading can typically be achieved by inclusion of a pelletisation aid such as 
microcrystalline cellulose. The process is readily scalable to industrial size, while 
critically this represents a flexible dosing platform ranging from pre-clinical proof of 
concept studies, to clinical dosing in special population groups, i.e. paediatric and 
geriatric patients. Fluid bed coating technology holds many advantages for coating 
peptide-loaded matrix pellets. This is a well-established process that allows for simple 
and efficient polymer layer deposition and subsequent reliable delayed/sustained drug 
release, depending on the nature of the functional polymeric coat applied. 
Furthermore, the processing conditions are mild relative to other methods such as pan 




are fluidized by high flow air, while an atomized coating solution or suspension is 
pulsed onto the pellets. As liquid coating material is deposited and simultaneously 
dried, the latent heat of evaporation of solvent means that the microenvironment of 
each individual pellet is considerably lower than the pre-heated inlet air (El Mafadi, 
Picot et al. 2005, Poncelet D 2009).  
The therapeutic potential of bioactive peptides for treating many health 
problems, including appetite-related disorders, is becoming increasingly apparent 
(Torres-Fuentes, Schellekens et al. 2015). Recent work in rodents has demonstrated 
the ability of whey protein isolate to reduce the expression of satiating genes in the 
hypothalamus, thereby increasing energy intake (Nilaweera, Cabrera-Rubio et al. 
2017). This study describes a novel peptidic dairy hydrolysate, FHI-2571, with ghrelin 
receptor agonist activity. Ghrelin, a 28-amino acid containing peptide, is produced in 
the stomach and functions as an endogenous appetite-stimulant (Kojima, Hosoda et al. 
1999, Nakazato, Murakami et al. 2001, Howick, Griffin et al. 2017).  The ghrelin 
receptor has thus been a pharmacological target to reduce appetite in obesity as well 
as to stimulate food intake in conditions of malnutrition and cachexia (wasting 
syndrome) (Schellekens, Dinan et al. 2010, Howick, Griffin et al. 2017). While the 
precise site of action of ghrelin is still open to some debate (Howick, Griffin et al. 
2017), the high prevalence of the ghrelin receptor throughout the small and large 
intestinal mucosa is thought to facilitate communication with appetite centres in the 
brain via the vagus nerve (Date 2012), and thus may hold potential as a local 
therapeutic target (Lakkireddy, Urmann et al. 2016).  
Overall, this study aims to first assess the in vitro efficacy of a novel ghrelin 
receptor agonist, FHI-2571, and investigate a formulation approach to progress this 
bioactive to in vivo studies. To overcome the acidic and proteolytic degradation of this 
whey-derived hydrolysate in the stomach and upper intestine, we have developed a 
sustained-release oral delivery system to minimize exposure to gastric acid and 
intestinal peptidases. In vitro release profiles of FHI-2571 in traditional USP 
dissolution tests, confirmed using BARDS, demonstrate the capability of our 




the small intestine in vivo. Activity assays confirm that the peptide retains good 




Materials and Methods 
3.1 Materials 
Dairy-derived peptide hydrolysate (FHI-2571) was provided by Food for 
Health Ireland (see section 2.2). Methacrylic acid and ethyl acrylate copolymer type 
C (MA, Acryl-EZE® II) and ethylcellulose (EC) (Ethocel™ Standard 20 Premium) 
were both purchased from Colorcon Corp., Dartford, Kent, UK, while aqueous 
pseudo-latex of EC (Surelease® Type B NF) was sourced from Colorcon Corp., 
Indianapolis, IN, USA. Microcrystalline cellulose (MCC, Avicel® PH-101 NF Ph. 
Eur.) was purchased from FMC Corp., Little Island, Cork, Ireland. Pharmaceutical 
grade ethanol 96% (v/v) was procured from Carbon Chemicals Group Ltd., 
Ringaskiddy, Cork, Ireland. Unless otherwise stated, only deionised water was used 
in this study. For the Ca2+ mobilization assays, fetal bovine serum (3.3%) was obtained 
from Sigma-Aldrich, Arklow, Wicklow, F7524. Assay buffer was composed of 1x 
Hanks balanced salt solution, HBSS, Gibco™ 14065049 (Thermo Fisher 
Scientific™), containing 20 mM HEPES (Sigma-Aldrich, Arklow, Wicklow, H0887). 
The endogenous agonist, ghrelin (rat), was supplied by Tocris Bioscience, 
Avonmouth, Bristol, UK (Cat. No. 1465). 
3.2 Generation of FHI-2571 
A dairy-peptide hydrolysate was prepared by a method similar to a previously 
published method (Mukhopadhya, Noronha et al. 2015). Briefly, bovine milk derived 
whey protein (80 % w/w protein, Carberry Group, Ballineen, Cork, Ireland) was 
suspended at 10 % protein (w/w) in reverse osmosis-treated water and agitated 
continuously at 50 °C for 1 h in a jacketed tank. The pH was adjusted using a NaOH 
4.0 N solution (VWR, Dublin, Ireland). A bacterial food-grade enzyme preparation, 
was added to the protein solution until 7-12 % degree of hydrolysis was achieved. The 
enzyme was then inactivated by heat-treatment and the resultant hydrolysate solution 




3.3 Ca2+ mobilization assay for peptide ghrelin receptor activity pre- 
and post-encapsulation 
Ghrelin receptor mediated changes in intracellular Ca2+ mobilization were 
monitored on a FLIPR Tetra High-Throughput Cellular Screening System (Molecular 
Devices Corporation, Sunnyvale, California, USA). Ca2+ mobilization assays were 
performed according to the manufacturer’s instructions and modified from a 
previously described method (Pastor-Cavada, Pardo et al. 2016). Human Embryonic 
Kidney (HEK293A) cells stably transfected with the ghrelin receptor were seeded in 
black 96-well microtiter plates at a density of 3 x 104 cells/well and maintained 
overnight at 37 °C in a humidified atmosphere containing 5 % CO2. Twenty-four hours 
before the experiment, media was replaced with serum-free media containing 1 % non-
essential amino acids (NEAA). On experimental day cells were incubated with 80 µL 
of 1xCa5 dye in assay buffer (1x Hanks balanced salt solution - HBSS, supplemented 
with 20 mM HEPES buffer) according to the manufacturer’s protocol (R8141, 
Molecular Devices Corporation, Sunnyvale, CA). Addition of compound (40 µL/well) 
was performed by the FLIPR Tetra, and fluorescent readings were taken for 120 
seconds at excitation wavelength of 485 nm and emission wavelength of 525 nm. The 
relative increase in cytosolic Ca2+ was calculated as the difference between maximum 
and baseline fluorescence and depicted as percentage relative fluorescent units (RFU) 
normalized to maximum response (100 % signal) obtained with 3.3 % fetal bovine 
serum (FBS). Background fluorescence was recorded in cells in assay buffer alone and 
subtracted from RFUs.  All compounds and hydrolysates used in experiments were 
prepared in assay buffer. FBS (3.3 %) and the endogenous agonist ghrelin (1465; 
Tocris) were used as positive controls of Ca2+ influx. Responses were considered as 
positive when Ca2+ influx exceeds 20% compared to control. Data were analysed using 
GraphPad Prism software (PRISM 5.0; GraphPAD Software Inc., San Diego, 
California, USA). Sigmoidal concentration-response curves were generated using 
nonlinear regression analysis with variable slope. 
3.4 Pellet preparation by extrusion-spheronisation 
Initial process optimization studies, focusing on pellet production, trialled a 




of FHI-2571 content from 50% afforded a robust pellet with minimal generation of 
fines at 33% peptide loading (data not shown). Therefore, requisite quantities of FHI-
2571 and MCC were combined in a ratio of 33:67, respectively, and manually blended 
for 1 minute. The powder was then added to a Kenwood Major planetary mixer 
(KM005, Kenwood Ltd., Hampshire, UK), fitted with a ‘K’ blade mixing arm, and dry 
blended at minimum setting for 5 minutes. The resultant dry powder blend was 
granulated by addition of deionised H2O, under constant agitation by planetary mixer 
at minimum setting. A homogenous dispersion of moisture was ensured, by adding 
deionisedH2O periodically from an atomizer every 15 seconds. Mixing was stopped 
every 2-3 minutes, to scrape material down from the sides of the mixing vessel. The 
granulation end-point was achieved upon addition of a cumulative amount of 
deionisedH2O equivalent to 45 % (w/w) of the dry powder blend.  The granulate was 
immediately extruded at an extrusion speed of 17 – 19 rpm using a sieve extruder 
(Caleva® Extruder 20, Caleva Process Solutions, Sturminster Newton, Dorset, UK). 
Both the screen thickness and aperture diameter were 1 mm. The extrudate was 
subsequently spheronized for 1.5 minutes at a speed of 1500 rpm, using a Caleva® 
Spheroniser 250 (Caleva Process Solutions, Sturminster Newton, Dorset, UK) 
equipped with a cross-hatch friction plate having a diameter of 22.5 cm. Resulting 
pellets (c. 100 g) were dried in a laboratory scale microfluid bed system (Vector Corp., 
Marion, IA, USA) at 40 °C for 20 minutes and then stored at room temperature in an 
airtight container until further testing took place.  
3.5 Pellet film coating 
Film coating was performed in a laboratory scale microfluid bed system, 
equipped with a Wurster funnel insert, in bottom-spray mode. Both nozzle air (16.6 – 
16.7 psig) and airflow (310 – 335 L/minute) were adjusted to maximum setting. Liquid 
feed rate (gram/minute) and spray pattern parameters varied, depending on the film 
coating polymer mixture (see Table 1). Various coating polymer mixtures were 
prepared; a concentrated 25 % (w/w) aqueous pseudo-latex of EC (Surelease® Type 
B) was diluted to 11 % (w/w), using deionised H2O water. Dissolution of EC 
(Ethocel™ Standard 20 Premium) in 96 % (v/v) EtOH to produce a 5 % (w/w) 




vigorous agitation. Dry methacrylate powder (Acryl-EZE® II) was gradually 
dispersed in deionised H2O water to produce a 10 % (w/w) coating mixture. All of the 
coating polymer mixtures were subjected to constant agitation at 900 rpm, for not less 
than 30 minutes, using a magnetic stirrer at room temperature. Agitation of the 
polymer coating mixtures (750 – 850 rpm at room temperature) was maintained during 
film coating procedures. Uncoated pellets were charged to the coating vessel (25 – 50 
g, pellet load), and the coater reassembled. Pellets were pre-heated in-situ, for 
approximately 10 minutes (inlet air temperature 80 °C; outlet air temperature ~ 50 °C), 
prior to commencing film coating. The amount of coating polymer required for film 
coating was based on a pre-determined weight gain, based on dry uncoated pellet mass.  
Table 3.1. Coating parameters. Coating parameters employed during the film 
coating with methacrylic acid and ethyl acrylate copolymer type C (Acryl-EZE® II), 
aqueous dispersion of ethylcellulose (Surelease® Type B), and organic solution of 




10 % (w/w) 
Acry-LEZE® II 
in water 
11 % (w/w) 
Surelease® Type B 
in water 
5 % (w/w) 
Ethocel™ 
in 96 % (v/v) 
EtOH 
Liquid Feed Rate 
(g/minute) 
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The duration of the film coating process was determined by the theoretical 




The vessel containing the coating polymer mixture was weighed before and after the 
coating process, to determine the actual weight of coating solution sprayed onto the 
pellets. The microfluid bed coating system was visually monitored to ensure that a 
steady uniform flow of pellets was maintained within the spray chamber.  
 
3.6 pH susceptibility tests 
Powdered FHI-2571 (6 g) was dissolved in 100 ml of deionised H2O and 
aliquoted into 4 x 25 ml samples. Next, 3 M HCl was added to bring the individual 
solutions to the requisite pH (pH 1, 3, 5 and untreated), using a pHenomenal® 1000L 
pH meter with a pHenomenal® 221 pH electrode. After pH was adjusted, samples 
were incubated for 30 minutes under gentle agitation. Finally, 50 µL of each sample 
was removed and added to 950 µL of Ca2+ assay buffer and neutralization of acidic 
pH confirmed before samples were added to cells. 
3.7 In vitro dissolution tests 
3.7.1 USP Type 1 (Basket) Dissolution studies 
Dissolution testing (USP Type 1) was performed, using a basket-type 
dissolution apparatus (DISTEK, Inc., Model 2100C, North Brunswick, NJ, USA) with 
500 mL of both simulated gastric fluid sine pepsin (SGFsp) (pH 1.2) and simulated 
intestinal fluid sine pancreatin (SIFsp) (pH 6.8) as dissolution media. Dissolution bath 
temperature was maintained at 37 ± 0.5 °C. Impeller shaft speed was 50 rpm. 
Dissolution medium sampling was conducted at predefined timepoints (10, 20, 40, 60, 
90, 120, 180, 240, 300, and 360 minutes) from a location not less than 1 cm from the 
vessel wall and midway between the top of the rotating impeller and dissolution media 
surface. After sampling, an equal volume of dissolution medium was added to the 




3.7.2 USP Type 4 (Flow-through) Dissolution studies 
An Erweka® flow-through apparatus (Model DFZ 720, ERWEKA GmbH, 
Germany), equipped with a HKP 720 piston pump and 22.6 mm diameter cells, was 
used to perform USP type 4 dissolution studies. The temperature of the water bath was 
maintained at 37 °C. Experiments were carried out over six hours using the closed 
loop system at a flow rate of 4 ml/minute. The dissolution media was composed of 
100 mL SGFsp for the first two hours. SGFsp was then replaced with 100 mL of SIFsp, 
after two hours. Samples (1 mL) were taken at the same time intervals as for USP Type 
1 dissolution (described above). After sampling, an equal volume of dissolution 
medium was added to the dissolution vessel 
3.8 Peptide quantification assay 
The bicinchoninic acid (BCA) assay was performed using a BCA assay kit 
(Thermo Fisher Scientific™ Pierce™ BCA Protein Assay, Catalog Number 23225) 
according to a previously published method.  Diluted stock samples were made using 
a 2 mg/ml stock solution of FHI-2571 in SGFsp. Using this stock solution, a serial 
dilution was performed to afford six 0.1 mL solutions with concentrations of 2, 1, 0.5, 
0.25, 0.125, and 0.0625 mg/mL, respectively. This method was repeated, using SIFsp. 
A 25 µL volume of each sample obtained during dissolution testing (see section 2.6.) 
was then transferred to a 96-well plate. After the dissolution experiment was 
completed, peptide not released from the formulation was determined. Remaining 
pellets were removed, physically crushed and redissolved in the relevant media. The 
quantity of liberated peptide was determined using the BCA assay. Working reagent 
was prepared by mixing BCA assay Reagent A with BCA assay Reagent B in a ratio 
of 50:1. The working reagent (200 µL) was then transferred to each well. The plates 
were then covered and incubated at 37 °C for 30 minutes. Spectrophotometric analysis 
(Flexstation II Multiplate Fluorometer, Molecular Devices, Sunnyvale, California) 
was performed at 562 nm. A standard curve was made by plotting the average blank-
corrected absorbance (562 nm) for each BCA assay standard versus concentration 





3.9 Electron microscopy 
Samples were mounted onto aluminium stubs using double sided carbon tape. 
All samples were sputter coated with a 5 nm layer of gold palladium (80:20) using a 
Quorum Q150 RES Sputter Coating System (Quorum Technologies, UK), before 
being examined using a JEOL JSM 5510 Scanning Electron Microscope (JEOL Ltd., 
Japan) in the BioSciences Imaging Centre, Department of Anatomy & Neuroscience, 
UCC. Digital electron micrographs were obtained of areas of interest. 
3.10  Broadband Acoustic Resonance Dissolution Spectroscopy 
A Broadband Acoustics Resonance Dissolution Spectroscopy (BARDS) , as 
described previously by Fitzpatrick et al. (Fitzpatrick, Evans-Hurson et al. 2014) was 
used to investigate the BARDS responses (BARDS ACOUSTIC SCIENCE LABS, 
Cork, Ireland). A sample size of 0.1 g was used in each experiment. Testing was 
performed under acidic conditions, using 25 mL simulated gastric fluid (SGFsp pH 
1.2) as solvent. The stirrer rate was set to 300 rpm. Prior to testing, temperature (c. 
25.5 °C), relative humidity (c. 47%), and pressure (c. 1025 mbar) were recorded. 
Before sample addition, steady state resonances were recorded for 30 s, while the 
magnetic follower was in motion. Spectra were recorded using a microphone (Sony 
ECM-CS10, range 100 Hz – 16 kHz) for 560 – 1300 s. The frequency time course of 
the fundamental frequency curve is shown as manually extracted data from the 
recorded acoustic response. All experiments were performed in triplicate (n = 3) and 
average values with error bars representing the standard deviation are presented.  
3.11  Data Analysis 
Data were analysed and graphs generated using both GraphPad Prism software 
and Microsoft Excel software. All means were calculated from the results of at least 
three independent experiments carried out in triplicate. For the in vitro calcium 
mobilization assays, standard error of the mean (SEM) is depicted, while all 






3.12 A dairy-derived peptide exhibits ghrelin receptor agonist 
activity in vitro. 

















































































Figure 3.1A. Concentration response curve of novel whey-derived hydrolysate. 
Concentration response curves for the endogenous ghrelin receptor ligand, ghrelin, 
the whey-derived hydrolysate, FHI-2571 and the parent whey protein concentrate 
(WPC) measured in ghrelin receptor over-expressing HEK293A cells. Intracellular 
Ca2+ increase was depicted as a percentage of maximal Ca2+influx in relative 
fluorescence unit (RFU) as elicited by control (3.3% FBS). Graph represents mean ± 






activity of test compounds on wild-type cells. Activity of control (FBS), ghrelin (1uM), 
FHI-2571 (3mg/ml) and parent whey protein concentrate (WPC) (3mg/ml) in wild-
type (HEK293A-WT) cells (representative of three independent experiments carried 
out in triplicate). 
 
The activity of the whey-derived hydrolysate, FHI-2571, on the ghrelin 
receptor was shown using intracellular Ca2+ mobilization, as a measure of downstream 
ghrelin receptor signalling activation (Schellekens, van Oeffelen et al. 2013), in 
HEK293A cells (human embryonic kidney cells) stably expressing the ghrelin 
receptor tagged with an enhanced green fluorescent protein (GHSR-1a-EGFP) (Figure 
3.1A). FHI-2571 hydrolysate stimulated calcium mobilization in cells expressing 
ghrelin receptor in a concentration-dependent manner, with the EC50 = 1.1mg/ml and 
efficacy (Emax) reaching 205%.  The potency of FHI-2571 is 1000-fold lower 
compared to the endogenous receptor ligand, ghrelin (EC50 = 2.84µg/ml). 
Interestingly, the maximal response attained for FHI-2571 hydrolysate is higher 
compared to ghrelin (Emax = 150%). Efficacy of both compounds was normalized to the 
maximal response of the positive control (3.3% FBS, Emax = 100%). Critically, the 
concentration response curve shows that the FHI-2571 hydrolysate has ghrelin 
receptor agonist activity, while the un-hydrolysed parent whey protein concentrate 
(WPC) fails to elicit appreciable activity in the same assay (Figure 3.1A). Furthermore, 
no Ca2+ influx was observed in wild-type HEK293A cells (HEK293A-WT) not 
expressing the ghrelin receptor, when exposed to the FHI-2571 hydrolysate, while 
treatment with control (FBS) resulted in a non-specific maximal intracellular Ca2+   
mobilization in this cell line (Figure 3.1B), indicating the specificity of FHI-2571 




3.13 pH susceptibility of FHI-2571 





































Figure 3.2. Ghrelin receptor agonist, FHI-2571 displays pH dependent activity. 
Graph represents three independent experiments carried out in at least triplicate. 
Reduction in FHI-2571-mediated ghrelin receptor activation following exposure to 
acidic pH confirms the need for an oral delivery mechanism (Control = FHI-2571 not 
exposed to acidic pH (3mg/ml), RFU = Relative Fluorescence Units) 
The FHI-2571 hydrolysate was exposed to varying degrees of acidic pH for a 
time representative of minimum gastric residence time in the fasted state (minimum 
30 minutes (Tuleu, Andrieux et al. 1999)). A pH dependent loss in peptide activity is 
observed for the whey-derived FHI-2571 (Figure 3.2), confirming the requirement for 
a protective film coat to minimize exposure to gastric acid before progression to in 
vivo efficacy studies.  
3.14 Aqueous-based Ethylcellulose dispersion yields a mechanically 
weak film coating 
USP Type 1 (Basket) dissolution studies were carried out in both simulated 
gastric conditions (simulated gastric fluid, SGFsp, pH 1.2) in order to assess the release 
profile of peptide from the pellets. Pellets displayed burst release of the peptide, with 
> 80 % release over the first 60 minutes. This occurred independent of coating 
thickness, as 10 % coating represented no additional benefit to the 5 % (Figure 3.3). 
Visual investigation showed film disintegration or “shelling” occurred within 20 




mechanical strength of the film coat produced from aqueous dispersion-based 
fluidized coating (Lecomte, Siepmann et al. 2004, Siepmann, Siepmann et al. 2008). 
An aqueous-based dispersion is hence an unsuitable coating approach to achieve 
sustained delivery of whey-derived FHI-2571 hydrolysate. 




















Figure 3.3. Dissolution study of aqueous-based Ethylcellulose and FHI-2571 
hydrolysate pellets. USP Type 1 (Basket) dissolution studies (50 rpm, 37.5 °C) 
showed a burst release in simulated conditions with >80% release over the first hour 
in both uncoated and coated FHI-2571 hydrolysate pellets following exposure to 
Simulated Gastric Fluid sine pepsin (SGFsp) pH 1.2 (A). Graph represents three 
independent experiments carried out in triplicate. Macroscopic investigation showed 
an unexpected disintegration or “shelling” of the coat from the pellets, resulting in 







3.15 Towards pellet coating achieving sustained release of peptide - 
Ethanolic solutions of ethylcellulose vs. aqueous dispersion based 
dual-coat 
Two alternative strategies were employed to circumvent the observed film 
disintegration for EC coats prepared using aqueous-based EC dispersions (Figure 3.4). 
Firstly, an ethanolic solution of EC was prepared and applied to the pellets. The EC 
coated pellets prepared from ethanolic solutions achieved near-zero order delayed 
release in simulated USP Type 1 (Basket) dissolution studies carried out in SGFsp.  
Due to the drawbacks associated with organic solvent use (Muschert, Siepmann et al. 
2009, Srivastava and Mishra 2010), an aqueous-based dual coat approach was trialled 
as an alternative. A pH-resistant methacrylic acid copolymer subcoat was applied to 
the pellets in order to prevent water ingress to the pellet core under acid conditions. 
Interestingly, this aqueous-based dual coat approach achieved a similar delayed 
release profile as the organic EC coat. 



















Figure 3.4. Dissolution study of FHI-2571 hydrolysate pellets with ethanolic-based 
ethylcellulose film coat and aqueous-based dual coat. Two different approaches were 
taken to circumvent the phenomenon of "shelling" as a result of coating with an 
aqueous dispersion of EC. 1) An organic solution of EC was applied to create a more 
robust coat, and 2) a methacrylic acid copolymer was layered beneath the aqueous 
EC to form a functional acid-resistant subcoat. USP Type 1 (Basket) dissolution 
studies (simulated gastric fluid, SGFsp, pH 1.2) showed effective delayed release for 
both organic EC and aqueous dual-coated pellets. Graph represents three 





3.16 Scanning electron microscopy investigation of whole and cross-
sectioned pellets  
  
  
Figure 3.5. Scanning Electron Microscope (SEM) images of whole pellets.  SEM 
images of uncoated (A), aqueous ethylcellulose (EC) coated (B), ethanolic EC coated 










Figure 3.6. Scanning Electron microscope (SEM) images of cross-sectioned pellets. 
Aqueous EC coated pellets have a distinctly porous coat which allows for water 
ingress and increased osmotic pressure within the pellet, leading to swelling and 
rupture of the film coat (A,B). Organic EC coated pellets display a more complete, 
non-porous coat (C,D), while the aqueous dual coated pellets show a distinct double 








Figure 3.5 represents SEM images of uncoated, aqueous EC coated, ethanolic 
EC coated and dual-coated pellets (A, B, C & D, respectively). Notably, images reveal 
no obvious structural cracks or pores on the surface of the coated pellets which may 
explain the fluid ingress and film coat rupture in the aqueous-based EC coated pellets. 
Figure 3.6 presents the SEM images obtained from cross-sectioned pellets with the 
various film coats. The aqueous EC coated pellet displays a porous cross-sectioned 
coat (Figure 3.6B). The porous nature of this coat can also be seen in the outer layer 
of the dual coated pellets (Figure 3.6F). By contrast, the ethanolic-based EC coat is 
distinctly non-porous and waxy in appearance (Figure 3.6D) while the methacrylate-
based subcoat is also visibly non-porous (Figure 3.6F). The porous nature of the 
aqueous-based EC coat is likely responsible for the osmotic-induced fluid ingress to 
the pellet core, and subsequent film disintegration. Both the ethanolic based EC coat 
and the methacrylate based subcoat are functionally resistant to water ingress in 
simulated gastric conditions. This is attributable to the non-porous substructure 





3.17 Investigation of peptide release in pH transfer model  
A pH transfer model was utilized in order to investigate whether there was any 
appreciable difference in release when intestinal pH was introduced to the pellets after 
2 hours exposure to SGFsp (pH 1.2) conditions (Figure 3.7). Predictably the aqueous 
EC-coated pellets display a burst release of peptide with > 80 % release in the first 
hour. Notably, the dual-coated EC pellets retain a sustained release profile after the 
transition from acid pH, to intestinal pH (pH 6.8). In contrast to the release profiles 
observed under USP Type 1 conditions, the ethanolic-based EC coat also displays a 
faster release rate compared to the dual-coat. This difference in release patterns 
between Type 1 and Type 4 may be attributed to different flow patterns and agitation 
between the systems. 
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Figure 3.7. Modelling of release profiles in a pH transition setup. USP Type IV 
(Flow-through) dissolution experiments were carried out using 22.6 mm diameter 
cells to quantify FHI-2571 release in a pH-transfer model (pH 1.2 to pH 6.8). A closed 
loop system maintained at 37 °C recirculated 100 ml of media at 4 ml/minute for the 
duration of the experiment (adapted from a previous study (Keohane, Rosa et al. 
2016). This yielded a predictable sustained release for both organic EC coated and 
dual-coated pellets. Graph represents three independent experiments carried out in 






3.18 Broadband Acoustics Resonance Dissolution Spectroscopy 
(BARDS) 
 
Figure 3.8. Fundamental curve frequency of coated pellets in SGF. Fundamental 
curve frequency time course of uncoated (Δt = 167 s), aqueous-based EC coated (10% 
w/w) (Δt = 790 s), dual-coated (MA and aqueous EC, 10% w/w, respectively), and 
organic-based EC (10% w/w) pellets, containing FHI-2571, in 25 mL SGFsp (pH 1.2). 
This data is representative of three independent experiments carried out, and 
demonstrates the comparable integrity of the dual-coated pellets with that of the 
organic-based EC pellets, in low pH conditions. Δt denotes the time at which minimal 
frequency reached (release) is reached.  
As expected in the case of uncoated pellets, a distinct change in real-time 
compressibility of the solvent is evident immediately after addition of the pellet to the 
solvent with the fundamental curve approaching its respective frequency minimum 
within 170 seconds (Figure 3 8).  This reflects the rapid disintegration/dissolution of 
the pellets lacking a protective film coat. In the case of both the dual-coated pellets 
and organic-based EC-coated pellets, there is no noticeable dissolution/disintegration 
event, following addition to the acidic solvent in the vessel (SGFsp pH 1.2). This 
spectral observation was confirmed by visual inspection; both the dual-coated pellets 
and organic-based EC-coated pellets remained intact during testing and no 
disintegration was observed. In the case of the aqueous-based EC coated pellets, a 
distinct change in solvent compressibility was observed from 400 seconds, indicating 
that the coated pellets undergo a dissolution/disintegration event here under acidic 
conditions. This was also evident visually in the solvent vessel with pellets undergoing 
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disintegration, where the frequency minimum is observed at 780 seconds. This result 
indicates that the aqueous-based EC pellets do not remain intact in an acidic 
environment and further support findings from previous dissolution experiments (see 





3.19 Ghrelin receptor activity post-encapsulation 
In order to quantify the impact of processing conditions on bioactivity of the 
peptide cargos, activity of the encapsulated peptide in vitro was reassessed. Activity 
of the FHI-2571 hydrolysate liberated from the encapsulated product was determined 
relative to activity of non-encapsulated FHI-2571 peptide in the ghrelin receptor 
overexpressing cells, as before. Activity was quantified as being greater than 80% for 










































Figure 3.9. FHI-2571 retains bioactive functionality after encapsulation. Activity of 
FHI-2571 after encapsulation was determined relative to activity of non-encapsulated 
FHI-2571 on ghrelin receptor overexpressing HEK293A cell line (representative of 
four independent experiments carried out in at least triplicate). Activity was quantified 





Dairy-derived peptides are increasingly recognized for their bioactive 
components which may bestow clinical benefits (Hartmann and Meisel 2007, Torres-
Fuentes, Schellekens et al. 2015). Peptides fractions have been isolated with ACE-
inhibitory action, and blood-pressure lowering properties of these dairy-derived 
bioactives in vivo have been reported. Furthermore, a casein-derived bioactive fraction 
with specific serotonin-2C receptor (5-HT2C) agonist activity eliciting satiating 
properties in a rodent model has been described (Schellekens, Nongonierma et al. 
2014). Ghrelin and the growth hormone secretagogue receptor (GHSR-1a) or ghrelin 
receptor, play an important role in energy balance and appetite regulation 
(Schellekens, Dinan et al. 2010, Howick, Griffin et al. 2017). Many studies have 
reported potent appetite-stimulating effects of both peripheral and central 
administration of ghrelin (Tschop, Smiley et al. 2000, Wren, Seal et al. 2001). In this 
study, we identified a milk whey-derived hydrolysate with intrinsic ghrelin receptor 
agonist activity. The dairy hydrolysate, FHI-2571, dose-dependently and specifically 
increased intracellular Ca2+ in HEK293A cells heterologously expressing the ghrelin 
receptor in vitro, while the unfractionated parent whey elicited negligible effects on 
the receptor (Figure 3 1A). In vivo, the ghrelin receptor is present throughout the small 
and large intestine, acting remotely via the vagus nerve to communicate with appetite 
centres in the brain (Date, Kojima et al. 2000, Date 2012). Given the appropriate oral 
delivery mechanism, a potential to increase food intake in vivo by targeting intestinal 
ghrelin receptor therefore exists.  
Given the acidic and peptidase rich environment of the gastrointestinal tract, 
as well as the barriers to epithelial absorption, development of appropriate delivery 
platforms to improve in vivo efficacy of bioactive peptides is required (Brayden and 
Alonso 2016, Gleeson, Ryan et al. 2016). Microspheres and microcapsules are one 
such approach, however degradation of peptide due to complex processing steps is a 
concern (Witschi and Doelker 1998, Yin, Lu et al. 2008). Furthermore, there is an 
ever-increasing interest in nano-sized formulations (Date, Hanes et al. 2016). Nano-
based approaches offer a platform to traverse membrane barriers and deliver peptide 




pharmacokinetic profiles (Griffin, Guo et al. 2016). However, much work remains to 
be done in order to elucidate the mechanisms of action and safety profiles of nano-
formulations. Critically, despite the exciting advances in the micro- and nano- fields, 
none are yet proven as a viable, industrially scalable delivery approach to achieve both 
high loading of peptide, and a predictable release pattern. On the other hand, there are 
limited examples of conventional mm-sized pellets being used to deliver peptide 
payloads, despite the approach being widely used in formulation of small organic drug 
molecules. This is traditionally due to the poor permeation of peptides across the 
intestinal barrier, extensive first-pass metabolism and short half-life in the body, not 
to mention the high concentration of peptidases present in the upper small intestine. In 
the case of the bioactive peptide under investigation here, FHI-2571, its 
pharmacological target, the ghrelin receptor, is found throughout the small and large 
intestine on vagal afferent terminals located just beyond the mucosal brush border 
(Date, Kojima et al. 2000), while a substantial proportion of the hydrolysate size 
fraction is < 1 kDa, meaning that paracellular transit to these nerve terminals is 
possible (Griffin and O'Driscoll 2011). The ghrelin receptor is also located in the 
myenteric plexus of rodent and human gastrointestinal tract (Takeshita, Matsuura et 
al. 2006), furthering the case for enhancing the delivery of the peptidic payload to the 
intestinal lumen. Therefore, we sought to develop a simple, high loading sustained 
release delivery vehicle to protect the ghrelinergic peptide from acid exposure in the 
gastric compartment and upper small intestinal breakdown, to facilitate in vivo proof-
of-concept studies.  
Firstly, the need for a gastro-protected delivery vehicle was validated by 
exposing FHI-2571 to acidic pH, which predictably abolished the bioactivity of this 
compound on the ghrelin receptor in a progressive manner (Figure 3.2). Polymeric 
film coating of active pharmaceutical ingredient (API)-loaded core pellets  has been 
widely utilized, with predominantly aqueous based functional polymer coatings 
(Siepmann and Siepmann 2013).  EC is the most commonly-used coating polymer. It 
is non-toxic and biodegradable, and achieves predictable, pH independent release 
profiles due to drug diffusion across a water-insoluble membrane (Ozturk, Ozturk et 
al. 1990). Generally, aqueous EC colloidal dispersions are preferred as a coating 




Srivastava and Mishra 2010). Moreover, it is possible to achieve higher percentages 
of solid content in aqueous dispersions; the high viscosity of organic solutions of EC 
is a limiting step for coating media (Lecomte, Siepmann et al. 2004). Therefore, 
coating time can be excessively lengthened when organic solutions are used. 
In our study, aqueous-based EC dispersion failed to provide us with a 
sufficiently robust film coating during release testing. Burst release of peptide was 
observed (> 80 % in the first 60 minutes) in USP Type-1 and USP-Type 4 apparatus. 
Macroscopic and microscopic investigation showed that the polymer coating fractured 
after exposure to aqueous media, allowing peptide to freely-diffuse out of the matrix 
system though fluid-filled cracks, rather than diffusing through the polymeric coat. 
This was attributed to the mechanism of film coat formation for a coating dispersion. 
During the fluid bed coating process, evaporation of solvent on the surface of the 
particles leads to sequential, layered polymer chain packing. These discrete polymer 
particles interact with one another via relatively weak Van der Waals interactions. 
Aqueous solubility is a major factor affecting osmotic pressure within coated pellets 
in contact with dissolution media. Osmotic pressure is a driving force for water ingress 
into pellets, increasing the intra-particulate volume and outward pressure on the 
coating film. Furthermore, migration of API into the film coat during the fluid-bed 
coating process has also been reported (Melegari, Bertoni et al. 2016). Therefore, the 
high aqueous solubility of the peptide may lead to leaching into the EC coat, creating 
water soluble pores which affords easier ingress of water into the pellet core, thereby 
causing swelling and an increased intra-particulate pressure. Considering the high 
loading of peptide in our system (33%), this problem is compounded leading to pellet 
swelling and film fracture. 
Here, we demonstrate the mechanical integrity of two alternative film coating 
approaches, which both provide time-dependent release of a bioactive peptide in the 
in vitro setting. This is particularly useful in the context of sustained delivery of 
hydrophilic peptides. Initial burst release has been reported from some reservoir 
devices, which tapers over time due to a reducing concentration in the reservoir 
(Dekyndt, Verin et al. 2015). Organic solutions of the film coating polymer lead to 




the polymer chains in solution, which, upon removal of the solvent phase, cross-link 
and form a robust, physically-bonded polymeric meshwork (Lecomte, Siepmann et al. 
2004). This is supported by SEM images (Figure 3.6) which show a distinct porous 
nature to the cross sectioned aqueous-based film coat (Figure 3.6B), compared to a 
more complete, non-permeable structure seen in the ethanolic-based film coat (Figure 
3.6D). Consistent with the impervious nature of the coat show in SEM cross-sections, 
FHI-2571 -loaded pellets coated with an ethanolic solution of EC displayed near-zero 
order release in both USP Type 1 (Basket) and USP Type 4 (Flow-through) dissolution 
setups (Figures 3.4 & 3.7).  
Due to the drawbacks associated with organic-based coating solutions, an 
aqueous -based coating approach to achieving an appropriate release profile of active 
peptide was desirable. Increased efficiency of aqueous EC film coats has been 
demonstrated by allowing a curing step to take place post-encapsulation, which 
typically involves extended periods of exposing the product to high temperature and 
humidity – water is an efficient plasticizer for many polymers (Kucera, Felton et al. 
2013, Siepmann and Siepmann 2013). However, in this study an extended period of 
exposure to such harsh conditions was not possible due to the probability of peptide 
hydrolysis. Furthermore, layered multi-particulates have been used successfully by 
Siepmann and colleagues to provide reliable zero-order release of water-soluble agents 
(Dekyndt, Verin et al. 2015). However, this involved incorporating the drug into the 
film coating layer itself. The potential to incorporate a peptide-based bioactive into 
such coating solutions, rather than the pellet matrix itself, is limited due to high risk 
of denaturation.  
Dual coated pellets have been used before to increase the functionality of the 
outer coat and optimize release profiles. In this study, an acid resistant methacrylic 
acid (MA) co-polymer was proposed, which was layered beneath the aqueous EC coat 
in order to provide an impermeable seal-coat in acid conditions. This may be 
considered atypical, given that a pH dependent polymer would normally form the outer 
layer in dual-coated systems. The acid-resistant layer was initially trialled as an 
overcoat of the aqueous EC coating, which limited burst release in acid conditions. 




overcoat occurred, with subsequent “shelling” of the EC subcoat (data not shown). 
This was due to the swelling of the pellet core combined with the mechanically brittle 
subcoat formed by the aqueous-based EC dispersion. USP-Type 1 dissolution studies 
for our dual-coated pellets in SGFsp display a near-zero order release profile 
comparable to organic EC pellets (Figure 3.4). This is consistent with the insolubility 
of methacrylic acid below pH 5.5, which likely prevented osmotic fluid ingress into 
the pellet core, and subsequent pellet swelling and film fracture. Furthermore, USP-
Type 4 dissolution studies, also show a delayed release profile after transitioning to 
intestinal media (pH 6.8) (Figure 3.7). This may be considered surprising given the 
solubility of the methacrylate copolymer above pH ~ 5.5. The intact EC overcoat in 
this case is likely hindering the access of the intestinal buffer to the surface of the 
subcoat, thereby reducing the rate at which the subcoat can dissolve.  The advantage 
to the MA applied as a subcoat is therefore two-fold, initially it prevents the ingress of 
fluid to the pellet core and subsequent pressure-induced film fracture. Secondly, the 
limited exposure of intestinal media to the MA subcoat due to the intact EC overcoat 
serves to slow the overall dissolution of the film coat. 
BARDS was utilized to confirm the release profiles obtained from the 
compendial dissolution methods (Figure 3.8). This is an emerging technology used to 
explore the changes in compressibility of a solvent that occurs during dissolution. 
During an experiment, the introduction of the pellets into the BARDS system causes 
changes in the speed of sound in the dissolution medium, which can be monitored 
acoustically. The dissolution process thus generates a change in the resonance 
frequency time course of the solvent in the vessel. BARDS analysis has previously 
shown successful application in the analysis of powder blend uniformity (Fitzpatrick, 
Scanlon et al. 2012) and the profiling of enteric-coated drug delivery systems 
(Fitzpatrick, Evans-Hurson et al. 2014). 
Of vital importance to this work was to confirm that the active peptide retains 
its bioactivity post-encapsulation, as protein aggregation or denaturation may occur 
during formulation. In fluid-bed coating, inlet air temperature is partially negated due 
to the latent heat of evaporation of the coating polymer solvent during the spraying 




temperature at the surface of individual pellets than would be suggested by the process 
parameters themselves. In our study, peptide liberated from the pellet formulation 
displays > 80 % activity of the untreated peptide. Compared to alternative methods of 
encapsulation which have been used for peptides incorporating solvent-based 
methods, we consider this to be a reasonable retention of activity in light of our 
processing conditions.  
In conclusion, a multiparticulate sustained release formulation approach for 
delivery of a ghrelin agonist peptide is described. Aqueous-based EC film coats 
applied to pellets in the millimetre size range are porous and mechanically brittle, 
leading to disintegration or “shelling” of the coat in aqueous media. Here, we observed 
that the high loading of a freely soluble ghrelin agonist peptide enhanced the problem 
of film disintegration due to increased osmotic pressure and pellet swelling. To 
overcome this, we provide near zero-order release by taking two alternative 
approaches: 1) Organic EC based solution can be applied to the pellets, or 2) an 
aqueous dispersion of a pH dependent MA co-polymer may be introduced as a subcoat 
to the aqueous EC. This provides an impermeable seal coat in gastric conditions which 
prevents fluid ingress into pellets, thereby preventing pressure-induced EC layer 
fracture and allowing the EC polymer to function as originally intended. Both 
processes allow the ghrelinergic peptide to retain sufficient activity after 
encapsulation. In conclusion, we designed a successful delivery formulation for a 
peptide based ghrelinergic dairy-derived bioactive hydrolysate. This delivery platform 
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The ghrelinergic system, comprising of the neuroendocrine peptide, ghrelin, 
and its receptor, the growth hormone secretagogue receptor (GHSR-1a), have been 
steadily investigated as therapeutic targets in the treatment of metabolic and appetite 
disorders. Despite nearly 2 decades of concerted efforts, the outcomes of this field of 
research have been disappointing. It is becoming increasingly clear that ghrelinergic 
signalling has both unexpected and unexploited complexities in its pharmacology, 
which have likely been hindering research efforts. While native ghrelin activates the 
full complement of GHSR-1a pathways, synthetic GHSR-1a ligands display biased 
signalling and functional selectivity, which have a significant impact on the intended 
and indeed, unintended, therapeutic effects. Furthermore, the widespread expression 
of the GHSR-1a in vivo has led to increasing consideration of the biodistribution of 
GHSR-1a ligands. Here, we investigate anamorelin and HM01, two novel synthetic 
GHSR-1a ligands with promising effects on food intake in preclinical and clinical 
studies. Downstream signalling pathways of both are compared in calcium 
mobilization, IP-one, internalization and β-arrestin recruitment assays. We describe a 
novel divergent activation of central reward circuitry by anamorelin and HM01 using 
c-Fos immunostaining as well as behavioural effects in food intake and reward 
paradigms.  
Interestingly, we found a paradoxical reduction in reward-related behaviour 
for anamorelin and HM01 treated animals in our chosen paradigms. The work 
highlights the critical importance to consider signalling bias in relation to future 
ghrelin-based therapies. In addition, central access of GHSR-1a ligands, particularly 
to reward areas of the brain, remains a crucial factor in eliciting potent appetite-
stimulating effects. The precise characterization of downstream ghrelinergic signalling 
and biodistribution of novel GHSR-1a ligands will be decisive in their successful 
development and will allow predictive modelling and design of future synthetic 





Since its discovery in 1999, efforts to exploit ghrelin’s orexigenic capacity for 
disorders of appetite have been met with limited success. Endeavours in the appetite 
modulation field have found the growth hormone secretagogue receptor (GHSR-1a) 
to be an elusive target with a deceptively complicated pharmacological profile 
(Howick, Griffin et al. 2017). Ghrelin, the endogenous ligand for GHSR-1a, is a 
peripherally-produced endogenous hormone which acts centrally as a key mediator in 
the neuroendocrine control of food intake, metabolism and adiposity (Tschop, Smiley 
et al. 2000, Nakazato, Murakami et al. 2001). The primary site of production and 
release is the stomach (Kojima, Hosoda et al. 1999), with plasma levels of ghrelin 
peaking in anticipation of a meal, while the arcuate nucleus of the hypothalamus (Arc) 
is the main site of action for effecting an increase in food intake (Cummings, Purnell 
et al. 2001, Nakazato, Murakami et al. 2001, Cowley, Smith et al. 2003). The 
orexigenic effects of ghrelin are mediated via activation of its target G-protein coupled 
receptor, the GHSR-1a, which has been conclusively demonstrated across species 
(Wren, Small et al. 2000, Cummings, Purnell et al. 2001, Nagaya, Uematsu et al. 2001, 
Wren, Seal et al. 2001, Mericq, Cassorla et al. 2003, Chen, Trumbauer et al. 2004, 
Druce, Wren et al. 2005, Schmid, Held et al. 2005, Wynne, Giannitsopoulou et al. 
2005). As such, the GHSR-1a represents a promising therapeutic target for conditions 
of under-eating such as Cancer Anorexia Cachexia Syndrome (CACS) (Nass, Gaylinn 
et al. 2011, Howick, Griffin et al. 2017), as well as over-eating and obesity (Soares, 
Roncon-Albuquerque et al. 2008, Schellekens, Dinan et al. 2010). Treatment with 
ghrelin has shown promising results on food intake and lean body mass maintenance 
in preclinical animal models of CACS, as well as clinically (Nagaya, Uematsu et al. 
2001, Wynne, Giannitsopoulou et al. 2005). However, the short half-life and ready 
deactivation in vivo into des-acylated ghrelin means that the pharmacokinetics of the 
ghrelin peptide are not optimal to provide sustained increases in appetite (Delhanty, 
Neggers et al. 2012, Delhanty, Neggers et al. 2014). 
Numerous synthetic ghrelin ligands have been developed over the years with 
the aim of providing sustained, desirable alterations in appetite (Vodnik, Štrukelj et al. 




recognized complexity in GHSR-1a pharmacology (Howick, Griffin et al. 2017, 
Ramirez, van Oeffelen et al. 2018). GHSR-1a elicits various downstream signalling 
pathways which are ligand-dependent, while also exhibiting a high degree of basal, 
ligand-independent activity (Ramirez, van Oeffelen et al. 2018). Largely ignored until 
recently, these differences in the functional selectivity of ghrelin ligands can have an 
impact on the ultimate effect observed in vivo (M'Kadmi, Leyris et al. 2015, Mende, 
Hundahl et al. 2018). There is growing evidence that selectively activating GHSR-1a 
signalling with pathway-specific ligands may lead to the development of more 
successful candidates to treat appetite disorders, while minimising off-target effects. 
Recent literature has described the importance of biased ligand signalling. 
Importantly, it has already been shown that Gq blockade specifically is responsible for 
eliciting a decrease in food intake (Mende, Hundahl et al. 2018). Thus, there is a 
growing impetus for characterisation of the signalling pathway(s) activated by 
individual ligands, and their subsequent contribution to the observed behavioural 
effect.  
Hence, given the lack of a successful ghrelin-based therapeutic to date, an 
appreciation of the pleiotropic pharmacodynamics of the GHSR-1a is crucial. The 
biodistribution of ghrelin ligands also has a significant role to play in determining in 
vivo effects (Howick, Griffin et al. 2017). While the hypothalamus is the traditional 
site of action for food intake and body weight regulation, the GHSR-1a is also 
expressed in key nodes of the reward system and contributes to so-called “pleasurable” 
eating beyond metabolic demand (Abizaid, Liu et al. 2006, Zigman, Jones et al. 2006). 
Indeed, ghrelin treatment has been shown to increase the motivation to work for a food 
reward in rodents, as well as shifting the preference from standard chow towards 
palatable, calorie-dense foods (Shimbara, Mondal et al. 2004, Egecioglu, Jerlhag et al. 
2010, Skibicka, Hansson et al. 2011). Ghrelin’s ability to effect this despite a lack of 
apparent ability to gain access to the brain is a source of ongoing debate in the field 
(Cabral, De Francesco et al. 2015, Edwards and Abizaid 2017). Therefore, the 
biodistribution of the GHSR-1a in areas not immediately accessible to the peripheral 
circulation has given rise to the theory that central penetrance of ghrelin ligands would 
be advantageous, for example by increasing the access of ghrelin ligands to the 




More detailed mechanistic research is required to inform the 
pharmacodynamics and biodistribution of ghrelin ligands, in order to fully elucidate 
their therapeutic merit in disorders of appetite. This paper provides in vitro and in vivo 
characterization of two novel, synthetic GHSR-1a agonists, anamorelin (non-BBB 
penetrant) and HM01 (BBB penetrant), previously demonstrated to exhibit a high 
GHSR-1a potency and selectivity, good oral bioavailability and longer half-lives than 
ghrelin (approximately 7 and 4.5 hours respectively).  Both have already shown 
promising results on food intake and lean body mass maintenance in preclinical animal 
models of cachexia (Pietra, Takeda et al. 2014, Borner, Loi et al. 2016). Here, we 
characterize and compare the signalling pathways of anamorelin and HM01 to native 
ghrelin on the GHSR-1a in vitro.  Furthermore, the divergent neuronal activation 
underlying the ligands is explored using c-Fos immunohistochemistry, while effects 
on appetite and reward-motivated behaviour is also assessed. Knowledge of the 
downstream signalling pathways of GHSR-1a, and an appreciation of the role of 
GHSR-1a in the reward system is crucial to predicting the effect observed in vivo. 
Taken together, this paper provides novel insights into key factors, which are poised 





Materials and Methods 
4.1 Cell lines and reagents 
Fetal bovine serum (3.3%) was purchased from Sigma-Aldrich, Arklow, 
Wicklow, F7524. Assay buffer consisted of 1x Hanks balanced salt solution, HBSS, 
Gibco™ 14065049 (Thermo Fisher Scientific™), supplemented with 20 mM HEPES 
(Sigma-Aldrich, Arklow, Wicklow, H0887). The endogenous agonist, ghrelin (rat), 
was obtained from Tocris Bioscience, Avonmouth, Bristol, UK (Cat. No. 1465). 
Synthetic ghrelin agonists HM01 and Anamorelin were kindly provided by Helsinn 
Therapeutics, Lugano, Switzerland.  
4.2 In vitro assays for GHSR-1a mediated signalling  
4.2.1 Ca2+ mobilization assay 
This method has been described in detail in Section 3.3 above. 
4.2.2 IP-one mobilization assay 
The detection of IP-one was performed in HEK293A cells expressing GHSR-1a, 
according to the manual’s instruction from Cisbio (Codolet, France). Briefly, 24 hours 
before experiment, growth media was replaced with serum free DMEM containing 1% 
NEAA. Directly before the experiment cells were manually disrupted by scraping in 
PBS and centrifuged for 3 minutes at 200 x g. A cell pellet was then suspended in 
assay buffer (146 mM NaCl, 1 mM CaCl2, 10mM HEPES, 0.5 mM MgCl2, 4.2 mM 
KCl, 5.5 mM glucose) containing 50 mM LiCl. For the stimulation step, 35 µL of cell 
suspension was pipetted into a flat bottom 96-well plate at the density of 3 x 105/well 
containing the appropriate compound solution, and incubated for 30 minutes at 37 °C. 
Following this, 15 µL of IP1-d2 conjugate and 15 µL of anti-IP1 cryptate conjugate in 
lysis buffer were added and incubated for 1 h in room temperature, followed by 
fluorescent measurement. After 1 h of incubation at room temperature, the 
fluorescence at 620 nm and 665 nm was read with the use of FlexStation (Molecular 




ratio multiplied by 104 and depicted as percentage of relative fluorescent units (RFU) 
normalized to maximum response (100% signal) obtained for non-stimulated cells. 
This was then converted to demonstrate the proportional dependence of the signal to 
the level of endogenous IP-one in the sample. 
4.2.3 Internalization assay 
Ligand-mediated GHS-R1a receptor translocation was quantified by 
monitoring the EGFP fluorescent trafficking away from the cellular membrane into 
vesicles within the cytosol, as per a previously described protocol (Torres-Fuentes, 
Pastor-Cavada et al. 2018). Cells were seeded in 96-well plate at density of 2.5 x 104 
cells/well and incubated for 48 hours at standard culture conditions. 24 hours before 
the experiment, media was replaced with serum free DMEM containing 1% NEAA. 
Cells were incubated with different concentrations of GHSR-1a receptor ligands for 
60 minutes in 37oC. After treatment, cells were fixed with 4% paraformaldehyde in 
phosphate buffer saline (PBS) for 20 minutes, and washed two times with PBS. Cells 
were imaged on the GE Healthcare IN Cell Analyzer 1000 (GE Healthcare Life 
Science, Buckinghamshire UK) and receptor trafficking analysed using the IN Cell 
Analyzer Developer Toolbox V1.6 Software (GE Healthcare). The intracellular EGFP 
intensity increase was normalized to Buffer B. 
4.2.4 Beta-arrestin recruitment assay 
PathHunter® eXpress GHSR-1a U2OS β-Arrestin-1 GPCR Assay (93-
0242E3CP5S, Discoverx, Fremont, CA) was used to analyse the effects of GHS-R1a 
receptor ligands on both basal and agonist-mediated β-Arrestin-1 recruitment. 
Procedures were performed according to the manufacturer's instructions. Briefly, 
cryopreserved PathHunter® eXpress GHSR-1a U2OS cells were plated at a density of 
2.5 x 103 cells/well of the 96-well plate. After 48 hours incubation at standard culture 
conditions, cells were treated with GHS-R1a receptor ligands for 60 minutes. 
Luminescent signal was read with the use of Synergy 2 (Biotek Instruments, 





Male Sprague-Dawley rats (8 weeks) and C57Bl/6 mice (8 weeks) were 
purchased from Envigo, United Kingdom for use in in vivo behavioural experiments. 
All animals were housed in group cages at 21 ± 1°C, humidity (55± 15 %), outside air 
ventilation (15±5 cycles/h) with a 12-h light/dark cycle. Animals were acclimatized 
for at least 1 week before use in experiments. Animals were provided standard chow 
(Teklad Global 18 % Protein Rodent Diet, Envigo, UK) and tap water ad libitum. All 
experiments were performed in accordance with European guidelines following 
approval by University College Cork Animal Ethics Experimentation Committee 
(B100/3774). 
4.2.6 Ex vivo c-Fos immunohistochemical analysis 
Rats were randomly allocated to one of four treatment groups (saline, ghrelin 
0.3mg/kg, anamorelin 3mg/kg or HM01 3mg/kg)(Wren, Small et al. 2001, Pietra, 
Takeda et al. 2014, Naitou, Mamerto et al. 2015). On the morning of experiment, 
animals were administered with a single IP injection of the relevant compound and 
individually housed and left undisturbed for a period of 2 hours, after which a lethal 
dose of anaesthetic was administered, and the animals perfused with chilled 
phosphate-buffered saline followed by 0.4% paraformaldehyde (PFS) fixative. Brains 
were removed and stored in a 0.4% PFA for 24 hours, after which they were 
transferred to a 30% sucrose solution for a period of 1 week. Brains were then snap 
frozen in liquid nitrogen and stored at -80C until sectioning. Sections from the 
requisite brain areas (20 µm) were cut in a Leica cryostat (model CM100), thaw-
mounted on microscopic glass slides and stored at -80 C until further processing. AP 
coordinates were verified microscopically for replicate slices using the stereotaxic 
atlas. Before staining, sections were rehydrated in Phosphate Buffered Saline (PBS; 
0.01M) for 5 minutes. Endogenous peroxidase activity was removed by immersing the 
sections in a 0.24% H2O2. Slides were washed in PBS containing 0.2% Triton-X-100 
(PBS-T) twice for 5 minutes each. To block unspecific binding, slides were incubated 
in blocking solution (PBS containing 0.2% Triton R X-100 and 3% normal goat serum 




c-Fos (#2250, Cell Signalling Technology, 1:10,000 in PBS) containing 0.2% Triton 
R X-100 and 3% GS solution was applied for 24 h at 4C. The secondary antibody 
(biotinylated goat-anti rabbit, Vector Laboratories, 1:200 in PBS containing 0.2% 
Triton R X-100) was applied for 2 hours at room temperature. Sections were then 
incubated in avidin-biotin complex (ABC) reagent using a kit for 90 minutes (ABC 
Vectastain R , Burlingame, CA, USA) for 1 h at room temperature. After this, sections 
were washed in PBS-T and incubated with the chromogen (0.5mg/ml 
Diaminobenzidine, DAB) for up to 5 minutes, or until a brown colour started to 
develop. Sections were counterstained with cresyl violet for 10 minutes and 
subsequently dehydrated in a series of alcohol solutions before clearing in histolene 
and mounting of DPX. c-Fos positive cell counts were averaged per animal from a 
defined frame size from at least three slices (maximum of five slices) and used for the 
calculation of group means.Photomicrographs were taken at 20x magnification, using 
a digital camera system (Olympus BX53 upright microscope, Olympus Life Science). 
 
4.3 Behavioural Experiments 
4.3.1 Cumulative Food Intake 
All animals were habituated to single housing conditions and procedures for 
up to 5 days prior to experimental day. Rats were randomly allocated to one of four 
treatment groups (Saline, Ghrelin 0.3mg/kg, Anamorelin 3mg/kg or HM01 3mg/kg). 
On the morning of experiment, animals were individually housed for 30 minutes, after 
which they were administered with a single IP injection of the relevant compound. 
Thereafter, food intake was monitored hourly for a period of 7 hours by quantifying 
the amount of leftover food. The amount of food consumed at 24 hours post-dose was 
also recorded. Cumulative change in food intake, as well as an hourly breakdown of 
the time course of food intake was evaluated. 
4.3.2 Saccharin Preference Test 
Rats were individually housed with ad libitum access to standard chow and 




HM01 3mg/kg). Each rat was habituated to two water bottles in the cage for up to 8 
hours a day over 4 days to familiarize the rats to drinking from two bottles. During 
training, one bottle contained water while the other contained a 0.1% saccharin 
solution, a concentration shown in the literature studies to provide a robust but not 
maximal saccharin preference (Sclafani, Bahrani et al. 2010). During the habituation 
phase, the bottles were alternated in order to prevent a side-bias from confounding 
results. Bottles were weighed before and after each habituation session to monitor for 
a preference establishment. On the experimental day, animals placed into individual 
cages and injected IP at the onset of the light phase. Ad libitum access to water, 0.1% 
saccharin solution and standard chow was available throughout the experiment. 
Consumption of/preference for saccharin was monitored over a 24 hour period.  
4.3.3 Female Urine Sniffing Test 
The protocol for assessing female urine sniffing behaviour in male C57Bl/6 
mice was carried out as per Malkesman et. al (Malkesman, Scattoni et al. 2010). Mice 
were randomly allocated to one of three treatment groups (saline, ghrelin, anamorelin 
3mg/kg or HM01 3mg/kg). One week before the test, mice were placed into individual 
cages in order to remove the effect of single housing on the day of the experiment. On 
the experimental day, rodents were transferred to a dark room illuminated with a red-
light. 1 hour before the test, mice were habituated to the presence of a cotton-tipped 
applicator extending into the home cage. Then, 30 minutes before the test mice were 
given an intraperitoneal (IP) injection with the appropriate treatment or saline control. 
The following protocol took place for each mouse; a 3 minute exposure to a cotton tip 
dipped in 60µL sterile water, during which the experimenter left the room and video 
was recorded for later analysis of duration of interaction, total number of interactions 
and latency to interact. This was followed by an inter-trial interval of 45 minutes 
during which no cotton tip was in the cage. Lastly, a 3 minute exposure to a cotton tip 
dipped in 60µL of urine, freshly collected from a cohort of female mice in estrous, was 





4.4 Data Analysis 
Data were analysed and graphs generated using both GraphPad Prism software 
and Microsoft Excel software. All means were calculated from the results of at least 
three independent experiments carried out in triplicate. For the in vitro calcium 
mobilization assays, standard error of the mean (SEM) is depicted, while all 
dissolution results report standard deviation (SD). For the c-Fos immunostaining, a 
Kruskal-Wallis analysis with Dunn’s post-hoc test for multiple comparisons was used 
to determine statistical significance. A repeated measures ANOVA with Tukey’s post-
hoc test for multiple comparisons was used to determine significance in the food 






4.5 Potency and efficacy profiles of Anamorelin and HM01 
The GHSR-1a exerts ligand-dependent biased signalling and upon activation 
can send downstream signalling via Gαq- dependent signalling, which is critical for 
food intake behaviour (Mende, Hundahl et al. 2018). The agonist activity of HM01 
and anamorelin on the GHSR-1a was measured using an intracellular Ca2+ 
mobilization assay, as a measure of downstream GHSR-1a signalling in HEK293A 
cells (human embryonic kidney cells) stably expressing the GHSR-1a tagged with an 
enhanced green fluorescent protein (GHSR-1a-EGFP) (Figure 4.1) (Schellekens, van 
Oeffelen et al. 2013),. Interestingly, both HM01 (EC50 = 8.8 x10
-10 M) and anamorelin 
(EC50 = 1.1x10
-8 M) display higher potencies compared to the endogenous receptor 
ligand, ghrelin (EC50 = 4.5x10
-8 M). In addition, the maximal response attained for 
both ligands (HM01 Emax = 117%, Anamorelin Emax = 129%) is the same as compared 
to ghrelin (Emax = 127%).  















































Figure 4.1. Concentration response curve of novel GHSR-1a ligands. Concentration 
response curves for the endogenous GHSR-1a ligand, ghrelin, and the synthetic 
GHSR-1a ligands, HM01 and anamorelin measured in HEK293A cells stably 




maximal Ca2+influx in relative fluorescence unit (RFU) as elicited by control (3.3% 
FBS). Graph represents mean ± SEM of at least three independent experiments 
performed in triplicate. 
4.6 IP-one mobilization assay 
Next, the inositol-phosphate one (IP-one) assay was carried out to confirm the 
efficacy of the synthetic ligands on the Gαq signalling-pathway as seen with the Ca2+ 
mobilization assay. Again, anamorelin and HM01 produced a stronger concentration-
dependent agonist effect compared to ghrelin. The potencies of both HM01 (EC50 = 
2.3 x10-10 M), and anamorelin (EC50 = 5.2 x10
-9 M) were higher compared to that 
obtained with ghrelin (EC50 = 3.1 x10
-8 M). Interestingly, the maximal response 
attained for both ligands (HM01 Emax = 106%, anamorelin Emax = 111%) is the same 
as compared to ghrelin (Emax = 111%).  























Figure 4.2. Inositol phosphate one (IP-one) accumulation after treatment with 
ghrelin and novel ghrelin ligands. Fluorescence intensity (IP-one accumulation) 
increases in a concentration-dependant manner for the endogenous GHSR-1a ligand, 
ghrelin, and the synthetic GHSR-1a ligands, HM01 and anamorelin measured in 
GHSR-1a expressing HEK293A cells. Intracellular IP-one accumulation was depicted 
as a percentage of maximal Ca2+influx in relative fluorescence unit (RFU) as elicited 
by control (3.3% FBS). Graph represents mean ± SEM of at least three independent 
experiments performed in triplicate. 
4.7 Internalization assay 




endosomal vehicles were evaluated. Desensitization and internalization provide a 
pivotal feedback loop preventing overstimulation through the GHSR-1a (Ramirez, van 
Oeffelen et al. 2018). Clear GHSR-1a internalization was observed after treatment 
with ghrelin, anamorelin and HM01. The internalization was dependent on the 
concentration of ligand used; Ghrelin EC50 = 5.3 x 10
-9 M, anamorelin EC50 = 2.7 x 10
-
8 M, HM01 EC50 = 2.3 x 10
-10 M. The pattern of potencies is aligned with those reported 
above, but interestingly the Emax reached by anamorelin (126%) is much higher than 
that of ghrelin (74%) and HM01 (69%) as a percentage of control (3.3% FBS) (Figure 
4.3).  


































Figure 4.3. Internalization of GHSR-1a after treatment with ghrelin or novel 
GHSR-1a ligands. Cytoplasmic EGFP intensity, as a measure of the GHSR-1a-EGFP 
internalization, increases in a concentration-dependant manner for ghrelin as well as 
for the synthetic GHSR-1a ligands, HM01 and anamorelin, measured after a 1 hour 
incubation period in HEK293A-GHSR-1a cells. Graph represents mean ± SEM of at 
least three independent experiments performed in triplicate. 
4.8 β-arrestin recruitment assay 
The intracellular protein, β-arrestin, functions in the desensitization of GPCRs 
and in the control of their intracellular trafficking(Bologna, Teoh et al. 2017, Ramirez, 
van Oeffelen et al. 2018). Here, β-arrestin recruitment was assessed after pre-treatment 




mediated GHSR-1a internalization, as reported above. As expected, ghrelin (EC50 = 
2.3 x 10-8 M), anamorelin (EC50 = 1.9 x 10
-8 M) and HM01 (EC50 = 2.3 x 10
-9 M) 
increase the recruitment of β-arrestin in a concentration dependant manner. Critically 
this result aligns with the previously observed ligand-mediated GHSR-1a 
internalization results as the Emax reached by anamorelin (153%) is again much higher 
than that of ghrelin (107%) and HM01 (89%). 
 






















































Figure 4.4. Recruitment of β-arrestin after treatment with ghrelin or novel GHSR-
1a ligands Luminescent signal intensity (β-arrestin recruitment) increases in a 
concentration-dependant manner for ghrelin and the synthetic GHSR-1a ligands, 
HM01 and anamorelin measured in HEK293A-GHSR1a cells. The β-arrestin 
recruitment was depicted as a percentage of maximal agonist response as elicited by 
control (3.3% FBS). Graph represents mean ± SEM of three independent experiments 









 Potency (EC50) [M] Efficacy (Emax) % 
Assay Ghrelin Anamorelin  HM01 Ghrelin Anamorelin  HM01 
Ca2+ mobilization 4.5x10-8 1.1x10-8 8.8x10-10 127.1 129.4 116.6 
IP-one assay 3.2x10-8 5.2x109 2.3x10-10 111.1 110.9 105.7 
Internalization 5.3x10-9 2.7x10-8 2.3x10-10 69.3 125.7 73.7 




4.9 c-Fos immunohistochemistry 
Next, neuronal activation was quantified using c-Fos immunohistochemical 
staining. Predictably animals treated with ghrelin, anamorelin and HM01 
demonstrated a significant elevation in arcuate neuronal activation compared to saline 
vehicle. Interestingly, divergent activation profiles were obtained for HM01 vs. 
anamorelin; a significant increase in immunoreactivity was noted in the LH, VTA and 
NAccSh for HM01, all of which are key areas in the reward pathway which are not 
peripherally accessible. Kruskal-Wallis with Dunn’s post-hoc test for multiple 
comparisons was used to determine statistical significance ((A):Kruskal-Wallis (KW) 
statistic =12.04, p=0.0072, (B) KW =13.14, p=0.0043, (C) KW = 8.046, p=0.0451, 
(D) KW=11.67, p=0.0086). The spatial separation of the peripherally active 
anamorelin is a limiting factor to the activation of brain areas not immediately 
accessible to the peripheral circulation. This strongly indicates the importance of 






















































































































































































































































































Figure 4.5. Effect of ghrelin, HM01 and anamorelin on c-Fos expression in 
homeostatic and reward centres. c-Fos expression levels were quantified in Arc (A), 





0.3mg/kg body weight of ghrelin, or 3mg/kg of anamorelin or HM01. Representative 
images of arcuate nucleus staining for c-Fos neuronal activation at 20x magnification 
(E). Kruskal-Wallis with Dunn’s post-hoc test for multiple comparisons was used to 





4.10 Cumulative Food Intake 
In vivo effects of the novel ligands were assessed in an acute food intake 
paradigm. Since manipulation of the ghrelinergic system is known to stimulate food 
intake, the amount of standard rodent chow consumed was monitored over a 24-hour 
period after administration of a ghrelin ligand or control (Figure 4.6). Repeated 
measures analysis revealed an overall effect of time (p=<0.001, df =1, F=289.081), 
treatment*time (p=<0.001, df = 3, F=257.615) and treatment (p=<0.001, df=3, 
F=19.623). Tukey’s post hoc test for multiple comparisons showed a significant effect 
of ghrelin (p=0.018), Anamorelin (p=0.012) and HM01 (p<0.001) compared to 
vehicle. Interestingly, multiple comparisons revealed there was a statistically 
significant effect observed between HM01 and both ghrelin (p= <0.001) and 
anamorelin (p=<0.001). Analysis of cumulative food intake 24 hours post-dose 
showed an overall effect of treatment (p=0.018, df=3, F=3.943). The orexigenic effect 
of HM01 was sustained at the 24-hour timepoint, while anamorelin maintains a trend 
(p=0.061). Ghrelin’s orexigenic effect is not sustained after 24 hours, in agreeance 
with previous studies (Finger, Schellekens et al. 2011, Schellekens, De Francesco et 
al. 2015). Post-hoc analysis showed that ghrelin’s effect tapered after 4 hours. 


























































Figure 4.6. Cumulative food intake following intraperitoneal administration of 
ghrelin, HM01 and anamorelin. Food (regular chow) intake in male sprague-dawley 
rats was determined following intraperitoneal (IP) injection with 0.3mg/kg body 
weight of ghrelin, or 3mg/kg of anamorelin or HM01 over 7 hours. Cumulative food 
intake (CFI) was determined at regular intervals after dosing. There was an overall 
effect of time (p=<0.001, df =1, F=289.081) and treatment*time (p=<0.001, df = 3, 
F=257.615) on food intake. Tukey’s post hoc test for multiple comparisons showed a 
significant effect of ghrelin (p=0.018), Anamorelin (p=0.012) and HM01 (p<0.001) 
compared to vehicle, while pairwise comparisons were used to delineate significant 
timepoints.  (A). Comparison of cumulative food intake 24 hours post-dose shows an 
overall effect of treatment (p=0.018, df=3, F=3.943), with a significant elevation in 
food intake 24 hours post-dose for HM01, while a trend is observed for anamorelin 
(p=0.061) and ghrelin is no longer significant (B). Graphs represents the mean ± 
SEM. Statistical significance was determined using repeated measures ANOVA for 
overall effect of treatment, time and time*treatment.Tukey’s post-hoc test  was used  
for multiple comparisons, while pairwise comparisons carried out for individual 






4.11  Saccharin Preference test 
Next, naïve rats were individually housed in cages with ad libitum access to 
food and habituated to a 2-bottle choice paradigm with the choice of normal drinking 
water or drinking water containing 0.1% saccharin. At the onset of the experiment rats 
were IP injected with either saline, anamorelin or HM01. Overall fluid consumption 
did not differ between experimental groups (Figure 4.7B). However, there was a 
significant effect of treatment (p=0.0056, df=2, F=9.727) over a 24 hour period 
revealed by ANOVA at the same timepoint (pairwise comparisons; Anamorelin 
p=<0.001, HM01 p=0.035). Furthermore, repeated measures ANOVA showed an 
overall effect of time (p=<0.001, df=3, F=11.115) and treatment*time (p=0.044, df=6, 
F=2.366) over the experiment (Fig 4.7A). The preference for saccharin was 
significantly  reduced in rats treated with ghrelin ligands anamorelin and HM01 as 




































































Figure 4.7. Paradoxical effect of HM01 and Anamorelin on intake of a rewarding, 
non-caloric saccharin solution. Preference for a 0.1% saccharin solution vs. regular 
water in male sprague-dawley rats was determined following intraperitoneal (IP) 
injection with 0.3mg/kg body weight of ghrelin, or 3mg/kg of anamorelin or HM01 
over a 24 hour period. Saccharin preference was determined at regular intervals after 
dosing. Overall significant reduction in the preference for saccharin solution was 
observed for anamorelin vs. saline (p= <0.01) and for HM01 (p= <0.05)(overall 
significant effect of treatment (p=0.0056, df=2, F=9.727) over a 24 hour period) (A). 
No overall differences in fluid consumption was observed between treatment groups 
(B). Graphs represents the mean ± SEM. A repeated measures ANOVA using Tukey’s 
post-hoc test was used to determine overall statistical significance; depicted as **p < 






4.12 Female Urine Sniffing test 
The female urine sniffing test (FUST), typically used to assess anhedonia and 
depressive-like characteristics in rodents (Malkesman, Scattoni et al. 2010, Burokas, 
Arboleya et al. 2017), can be used as a surrogate for reward system assessment in a 
natural, non-invasive approach that is not confounded by differences in metabolic 
status, calories and/or gustation. HM01 treated mice had a significantly lower number 
of sniffing interactions with a female urine stimulus than control mice, in addition to 
displaying an increased latency to sniffing (Figure 4.8). There was no difference in 
either the number of interactions or the latency to sniffing between anamorelin and 
control. These results indicate that HM01-treated mice show aversive-like behaviour 
towards a rewarding stimulus, indicating a paradoxical reward-related deficit induced 
by the compound. Noteworthy, anamorelin, though displaying the same trend in the 

















































































Figure 4.8. Effect of ghrelin, HM01 and Anamorelin on female urine sniffing test. 
Interaction of male C57/Bl6 mice with a rewarding odour (female urine) was 
determined following intraperitoneal (IP) injection with 0.3mg/kg body weight of 
ghrelin, or 3mg/kg of anamorelin or HM01. An overall significant increase in the 
latency to first interaction with female urine reward (A), as well as a decrease in the 
total number of discrete interactions with the stimulus was observed for HM01(B). A 
one-way ANOVA using Tukey’s post-hoc test was used to determine overall statistical 







Due to its ability to increase food intake and promote adiposity, ghrelin and 
the GHSR-1a have been pharmacological targets for disorders of appetite such as 
CACS (DeBoer 2011, von Haehling and Anker 2014). Ghrelin treatment provides a 
reliable orexigenic and anabolic effect across species, however, since it’s discovery by 
Kojima and colleagues in 1999, only one ghrelin agonist, anamorelin, is close to 
gaining regulatory approval for CACS (Garcia 2017). Potential barriers to therapeutic 
success to date have been recently reviewed (Howick, Griffin et al. 2017). One such 
barrier to the success of ghrelin therapeutics is the ligand-dependent biased signalling 
exerted by the GHSR-1a, which, upon activation, sends downstream signalling via 
Gαq- dependent, Gαi/o-dependent or β-arrestin-dependent signalling (Ramirez, 
Oeffelen et al. , M'Kadmi, Leyris et al. 2015). Moreover, the expression of the GHSR-
1a in vivo has led to increasing consideration of the biodistribution of GHSR-1a 
ligands (Howick, Griffin et al. 2017, Mohammadi, Pietra et al. 2018). Here, we 
investigate anamorelin and HM01, two novel synthetic GHSR-1a ligands. Though 
these ligands have already shown promising effects on food intake in preclinical and 
clinical studies, their biased signalling and biodistribution in relation to appetite and 
reward remains unexplored. 
Firstly, GHSR-1a activation by anamorelin and HM01 was investigated in the 
context of predicting functional outcome based on downstream signalling.  Though 
native ghrelin activates the full complement of signalling, differences in functional 
selectivity of synthetic ligands toward diverse signalling pathways can have a crucial 
impact on the ultimate effect observed in vivo. Recent evidence has highlighted the 
behavioural significance of this promiscuous signalling; Gαq-dependent downstream 
signalling was pinpointed as the major effector in relation to food intake (Mende, 
Hundahl et al. 2018).  Here, the previously unassessed signalling behaviour of 
anamorelin and HM01 were assessed using calcium mobilization, IP-one, β-arrestin 
recruitment, and receptor internalization assays. As expected, both ligands produced a 
strong agonist effect on the calcium mobilization assay compared with ghrelin, in a 
concentration-dependent manner. The IP-1 assay confirmed the efficacy of the 




assay. As for the Ca2+ mobilization assay, anamorelin and HM01 produced a strong 
agonist effect compared with ghrelin, in a concentration-dependent manner. 
Desensitization and internalization of the receptor into endosomal vesicles provides a 
pivotal feedback loop preventing overstimulation through the GHSR-1a. Predictably, 
clear GHSR-1a internalization was observed after treatment with ghrelin, anamorelin 
and HM01. The internalization was concentration dependent with a pattern of 
potencies aligned with those reported above, but interestingly the Emax reached by 
anamorelin (126%) is much higher than that of ghrelin (74%) and HM01 (69%). This 
indicates likely GHSR-1a desensitization and amelioration of the in vivo effect after 
treatment with anamorelin, but not HM01. Furthermore, β-arrestin which also 
functions in the desensitization of GHSR-1a aligns with the previous internalization 
results as the Emax reached by anamorelin (153%) is again much higher than that of 
ghrelin (107%) and HM01 (89%).  
Further to pharmacodynamic differences, biodistribution of ghrelin ligands is 
an important consideration and is poised to play a key role in future ghrelin research 
given the widespread GHSR-1a expression in key nodes of the reward system 
(Edwards and Abizaid 2017, Howick, Griffin et al. 2017). Native ghrelin 
administration exerts differential effects on neuronal activation depending on whether 
it is administered peripherally or centrally(Edwards and Abizaid 2017). It follows that 
HM01, a centrally penetrant compound, would have a differing neuronal activation 
profile to anamorelin or native ghrelin due to differing distribution in vivo. Indeed, it 
has recently been shown that HM01 has a more potent colokinetic effect compared to 
a peripherally active GHSR-1 ligand due to its central penetrance (Mohammadi, Pietra 
et al. 2018). In line with this, significantly elevated c-Fos immunoreactivity, 
potentially indicative of greater neuronal activation, was noted for HM01 in the LH 
and the VTA, both of which are key areas in the reward pathway which are not 
peripherally accessible. Furthermore, the NAccSh showed elevated activity for HM01 
only and not ghrelin or anamorelin. c-Fos staining also expectedly showed elevated 
activation in the Arc for ghrelin, anamorelin and HM01.This c-Fos activation profile 
indicates a divergent activation of reward-related areas with a brain penetrant ghrelin 
agonist. This bolsters the theory that central penetrance could lead to greater efficacy 




Both anamorelin and HM01 show high potency on Gq signalling which is 
known to be the main signalling pathway responsible for eliciting changes in food 
intake (Mende, Hundahl et al. 2018). Therefore, in vivo effects of the ligands were 
assessed in an acute food intake paradigm. Dose selection of anamorelin and HM01 
was based upon previous publications, while ghrelin was chosen as a positive control 
based on the seminal paper by Wren et. al (Wren, Small et al. 2001, Pietra, Takeda et 
al. 2014, Mohammadi, Pietra et al. 2018). The amount of standard rodent chow 
consumed after administration of a GHSR-1a ligand, or saline vehicle, was monitored 
over a 24-hour period (Figure 4.6). The orexigenic effect exerted by ghrelin, 
anamorelin and HM01 are consistent with the c-Fos activation profiles in 
hypothalamic arc sections. Notably, HM01 elicits a robust elevation in food intake 
compared to both ghrelin and anamorelin. It is tempting to speculate that the greater 
efficacy of HM01 in this respect may be due to the BBB penetrability of HM01 
compared to the non-penetrant anamorelin. In line with this, HM01 elicits greater 
activation in the LH and the VTA compared to anamorelin. Moreover, there is no 
greater magnitude of arcuate neuronal activation by HM01 than anamorelin or ghrelin.  
Furthermore, there were no appreciable differences between the ligands on GH output 
(Figure 14, Appendix B) while a higher dose (10mg/kg) of anamorelin and HM01 
failed to elicit greater increases in food intake over the 7-hour time frame (data not 
shown), indicating a plateau in the orexigenic effect of both compounds. One obvious 
caveat to this speculation is the higher potency of HM01 in in vitro assays, therefore 
further studies must be carried out in order to conclusively prove this theory. 
Nevertheless, this is the first time that both ligands have been compared head to head 
over an acute period in a food intake paradigm. 
Next, behavioural effects of anamorelin and HM01 were investigated on the 
reward system using the Female Urine Sniffing Test (FUST) and Saccharin Preference 
Test (SPT) paradigms. Ghrelin treatment has been shown in the literature to increase 
the preference for a saccharin solution in rodents (Disse, Bussier et al. 2010). A non-
caloric 0.1% saccharin was used as it was a concentration previously shown to cause 
a robust but not maximal preference in consumption in rats (Sclafani, Bahrani et al. 
2010). Overall fluid consumption did not differ between experimental groups, 




ghrelin ligands anamorelin and HM01. Furthermore, the FUST was used to quantify 
interaction time with a rewarding olfactory stimulus, another behavioural measure of 
reward system activation (Malkesman, Scattoni et al. 2010). HM01 treated mice had 
a lower number of sniffing interactions with a female urine stimulus than control mice, 
in addition to displaying an increased latency to sniffing. These results unexpectedly 
indicate that HM01-treated mice, but not anamorelin treated, show aversive-like 
behaviour towards a rewarding stimulus. Therefore, while food intake is robustly 
increased by both treatments, an unexpected paradoxical reduction in reward-related 
behaviour was observed.  Seemingly, reward paradigms such as SPT and FUST which 
do not offer caloric benefit in hunger elicit a paradoxical negative response in reward-
directed behaviours. This may be indicative of a potential reduction in the palatability 
of a substance which offers no caloric benefit in times of food seeking, a phenomenon 
which has been reported (Kawahara, Kawahara et al. 2009). The underlying 
mechanisms explaining this unexpected behavioural phenomenon require further 
investigation.  
In summary, this paper provides valuable insight into biased signalling and 
biodistribution of ligands for the GHSR-1a. Accumulating evidence points to the 
significance of biased signalling in the future development of successful ghrelin-based 
therapies for appetite modulation (Ramirez, Oeffelen et al. , Mende, Hundahl et al. 
2018). Preferentially activating a desired pathway may help to specifically augment 
desired functional outcomes while limiting side-effects (Bologna, Teoh et al. 2017). 
Anamorelin and HM01 are potent activators of the Gq pathway and produce a robust 
effect on food intake in vivo via this signalling pathway. HM01 exerts a far greater 
effect on food intake than anamorelin despite providing no greater hypothalamic 
activation. We postulated that this may be due to increased brain penetrance of HM01 
to the mesolimbic circuitry and the subsequent recruitment of non-homeostatic 
mechanisms of appetite stimulation. c-Fos immunostaining supports this, with greater 
activity reported in key input centres of the mesolimbic pathway, such as the LH, VTA 
and NAccSh after HM01 treatment. However, the behavioural correlates of reward 
system activation undoubtedly paint a paradoxical picture which needs to be 





This paper highlights the potential importance of signalling bias in relation to 
future ghrelin therapies. HM01 and anamorelin exert potent effects on calcium 
mobilization, however anamorelin is potentially more susceptible to treatment-
induced tolerance than HM01 due to recruitment of β-arrestin and GHSR-1a 
internalization. Central access of ghrelin ligands, particularly to reward areas of the 
brain, may be important in eliciting more potent appetite-stimulating effects. c-Fos 
immunohistochemistry showed greater activation of LH and VTA neurons compared 
to control for HM01 treated animals only. The greater maximal orexigenic effect of 
HM01 over anamorelin is potentially due to access of HM01 into the brain penetrance. 
However, a paradoxical reduction in reward-related behaviour was observed for 
HM01 in both the SPT and FUST paradigms, while this effect was only evident in the 
former for anamorelin. This paper provides valuable insight into in vitro and in vivo 
aspects of GHSR-1a signalling, however further mechanistic work is needed to 
conclusively demonstrate the benefit of central penetrance and elucidate paradoxical 
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The endogenous hormone ghrelin is one of the key components in the 
neuroendocrine system controlling appetite. Receptors for ghrelin (GHSR-1a) are 
located in the primary site of energy homeostasis, the arcuate nucleus of the 
hypothalamus, but also in key nodes of the mesolimbic dopaminergic system. Hence, 
not only does ghrelin act as a barometer for energy balance, but it also functions as a 
mediator of food reward and the incentive salience applied to food. Manipulation of 
the ghrelin system can therefore play a pivotal role in altering the top-down regulation 
of food intake by altering the perception of food palatability. The synthetic ghrelin 
ligands anamorelin and HM01 have shown promising orexigenic effects in preclinical 
and clinical studies, however their effect on the reward system has not yet been 
reported. The aim of the current study was to investigate changes in extracellular DA 
content in the nucleus accumbens shell (NAccSh) of conscious, freely-feeding 
Sprague-Dawley rats using a microdialysis paradigm.  
Differences in extracellular DA in the NAccSh after treatment with ghrelin, 
HM01 and anamorelin are reported. Increased NAccSh DA was observed for HM01 
compared to control. Therefore, HM01 elicited greater effects on the reward circuitry 
than anamorelin as measured by DA output in freely-feeding rats. This in vivo proof 
of concept thus highlights the importance of targeting the mesolimbic reward circuitry 
for enhancing the efficacy of ghrelinergic therapy. The use of brain penetrant ghrelin 






Ghrelin is a peripherally-produced endogenous hormone with potent 
orexigenic and anabolic properties (Kojima, Hosoda et al. 1999, Tschop, Smiley et al. 
2000, Inui 2001, Nakazato, Murakami et al. 2001, Müller, Nogueiras et al. 2015, 
Howick, Griffin et al. 2017). In periods of calorie deprivation, X/A like cells in the 
stomach release ghrelin into the bloodstream which communicate via neuroendocrine 
methods with appetite centres in the brain (Kojima, Hosoda et al. 1999). The target 
receptor for effecting changes in appetite is the growth hormone-secretagogue receptor 
(GHSR-1a), heavily expressed in the arcuate nucleus of the hypothalamus, the primary 
fulcrum of energy homeostasis (Inui 2001, Nakazato, Murakami et al. 2001). The 
mechanism of ghrelin’s orexigenic action and it’s potential as a target for appetite 
modulating therapies has been widely described in the literature (Wren, Small et al. 
2000, Nakazato, Murakami et al. 2001, Horvath, Castaneda et al. 2003, Naleid, Grace 
et al. 2005, Müller, Nogueiras et al. 2015, Howick, Griffin et al. 2017). 
The decision to eat is largely a conscious process, based on the perception of 
hunger, the availability of food and the perceived palatability of same (Howick, Griffin 
et al. 2017). Ghrelin is thought to have a large role in the mesolimbic reward circuitry, 
thereby modulating the incentive salience of food (Naleid, Grace et al. 2005, Abizaid, 
Liu et al. 2006). In line with this, the GHSR-1a is expressed in key nodes of the reward 
system, such as the lateral hypothalamus (LH), ventral tegmental area (VTA) and 
nucleus accumbens (NAcc) (Zigman, Jones et al. 2006). Abizaid and colleagues 
demonstrated that ghrelin binds to VTA neurons, triggering dopaminergic neuronal 
activity, synaptic plasticity and increase turnover of dopamine (Abizaid, Liu et al. 
2006). Treatment with ghrelin has been shown to increase the motivation to work for 
a food reward in rodents (Skibicka, Hansson et al. 2011), as well as shifting the 
preference from standard chow towards palatable, calorie-dense foods (Egecioglu, 
Jerlhag et al. 2010). Hence, GHSR-1a signalling in the mesolimbic reward circuitry is 
considered a major driver in altering perceived palatability of food, and the motivation 




Microdialysis studies have been used previously to investigate ghrelin’s role 
in the reward system by monitoring extracellular dopamine (DA) levels. Dickson’s 
group were the first to show that ghrelin, administered centrally, induced an increase 
in extracellular DA content in the nucleus accumbens (Jerlhag, Egecioglu et al. 2006). 
A number of subsequent studies from this group, have also been reported confirming 
an important role for ghrelin in the reward circuitry (Jerlhag, Egecioglu et al. 2007, 
Jerlhag 2008, Egecioglu, Jerlhag et al. 2010, Dickson, Egecioglu et al. 2011). 
However, to the best of our knowledge, no study has been reported investigating the 
extracellular DA content after treatment with synthetic ghrelin ligands. This is despite 
the numerous potent synthetic ligands under development as therapeutic agents that 
have shown promising effects over native ghrelin on food intake and other anabolic 
parameters (Vodnik, Štrukelj et al. 2016). Despite greater stability and more 
favourable pharmacokinetics in vivo, their reward-related properties have not been 
investigated in microdialysis studies, however recent work has reported on 
behavioural changes and central c-Fos immunostaining (Chapter 4).  
There has been much debate over the ability of ghrelin to successfully 
manipulate the reward circuitry despite its lack of BBB penetrability (Cabral, De 
Francesco et al. 2015, Edwards and Abizaid 2017). Further to this, our group has 
previously shown a divergent activation of the reward system with ghrelin ligands 
anamorelin (non-brain penetrant) and HM01 (brain penetrant) (Chapter 4). We 
hypothesized that this divergent neuronal activation was due to the latter’s ability to 
traverse the BBB and activate GHSR-1a which is present in key nodes of the reward 
system such as the VTA. Hence, the aim of this study is to establish a microdialysis 
platform to measure extracellular DA levels in the nucleus accumbens shell, and 
investigate whether treatment with ghrelin ligands would alter this. The significance 
of this was intended to give an insight into whether a brain-penetrant synthetic ghrelin 
agonist would have a greater impact on the “liking” or hedonic aspect of food intake 





Materials and Methods 
5.1 Materials: 
High performance liquid chromatography (HPLC) grade acetonitrile, 
methanol, potassium dihydrogen phosphate and orthophosphoric acid (OPA) were 
obtained from Fisher Scientific Ireland, Blanchardstown, Dublin, Ireland. Ghrelin (rat) 
was obtained from Tocris Bioscience, Avonmouth, Bristol, UK (Cat. No. 1465). 
Anamorelin and HM01 were kindly gifted by Helsinn Therapeutics (Helsinn, Lugano, 
Switzerland). Guide cannulae and microdialysis probes were purchased from Charles 
River Den Bosch BV (De Mudden 16, 9747 AW Groningen, Netherlands). 
5.2 Methods: 
5.2.1 HPLC Optimization and Validation 
The HPLC system consisted of a Shimadzu LC-20AD XR Prominence Pump, 
CBM-20 communication bus module, SIL-20AC XR Prominence Autosampler, CTO-
20A Prominence Column oven (Mason Technology, Cork, Ireland). Shimadzu LC 
solutions software was coupled to this equipment. The HPLC system was coupled to 
an electrochemical detector (ED). The detector used was an ESA Coulochem III with 
a 5041 Amperometric Cell (ESA Analytical, Ltd., Brook Farm, Dorton, Aylesbury, 
Buckinghamshire, HP18 9NH England). Dialysis samples were injected onto a 
reversed phase Luna 2.6 µm C18(2) 100 x 5 mm column (Phenomenex), which was 
protected by Krudkatcher Ultra in-line 0.5µm depth filters (Phenomenex). 
5.2.2 Analyte identification and quantification  
Standard solutions of DA in aCSF were injected onto the HPLC system at 
different voltages to determine the optimal voltage for detection. Peak height was used 
as a measure of response and plotted against voltage applied in order to identify the 
optimal voltage for analyte detection. Calibration curves were constructed to confirm 
a linear relationship between DA content and peak height in the relevant concentration 




determined by standard injections which were run at regular intervals during sample 
analysis. No extraction procedure was necessary for microdialysis samples, so analyte 
peak height ratios were compared directly with standard injections and expressed as 
baseline of the individual animal and being expressed as a percentage thereof. 
The HPLC-ECD method was adapted from previously described methods 
(Sato et al., 1994; Frahnert et al., 2003). Before going on the system, the mobile phase 
was filtered through Millipore 0.22 µm Durapore filters (Millipore, Ireland) and 
vacuum degassed prior to use. Compounds were eluted isocratically over a 20 min 
runtime at a flow rate of 0.4 ml.min-1 after a 20 µl injection. The column was 
maintained at a temperature of 26oC and samples/standards were housed at 8oC in the 
autoinjector prior to analysis. The glassy carbon working electrode combined with a 
platinum reference electrode (ESA) was operated at a potential of 200mV and a range 
of 10nA.  
5.2.3 Stereotaxic guide cannula implantation 
Animals were anaesthetized prior to surgery with a ketamine/medetomidine 
admixture 7.5/5 mg/100g i.p.), with maintenance of anaesthesia achieved by repeating 
20-25% of the induction dose at 30-40 minute intervals, as required. Before the surgery 
took place, depth of breathing as well as the absence of pedal reflex and eye twitch 
was checked to confirm adequate depth of anaesthesia. Analgesia was provided by 
peri-operative administration of carprofen (5 mg.kg-1 s.c.). Throughout surgical 
procedures, the body temperature of each rat was maintained using a heating pad. The 
rats were placed in a stereotaxic frame (Model 900 Small Animal Stereotaxic 
Instrument, David Kopf Instruments, Bilaney Consultants, St Julians, Sevenoaks, UK) 
such that the head was flat and centrally aligned. An incision was made from eyes to 
ears and the skull exposed. Bregma was located and the coordinates for the guide 
cannula to be implanted were located 1.8mm anterior and 0.8mm lateral to this. A burr 
hole was made at this location and at another location lateral to this to facilitate the 
introduction of an anchoring screw. The guide cannule was slowly lowered 5.7 mm 
from dura into the nucleus accumbens shell (Paxinos and Watson, 1998) and secured 




reversal agent (Atipamezole, 25mg/100g) was administered. Rats were allowed to 
recover overnight and pain score sheets were maintained as necessary until the 
microdialysis procedures took place. All experiments were in full accordance with the 
European Community Council directive (86/609/EEC) and approved by the Animal 
Experimentation Ethics Committee of University College Cork (AE19130/P062). 
5.2.4 Microdialysis procedure 
On the morning of the microdialysis experiment, the rats were placed in 
cylindrical plexiglass containers (Instech Laboratories, Plymouth Meeting, PA) filled 
with bedding. The stylet was gently removed from the guide cannula and the dialysis 
probe was clicked into place. The inlet tube of the probe was then connected to a fluid  
swivel (Instech Laboratories, Plymouth Meeting, PA) and artificial cerebrospinal fluid 
(aCSF: 147 mM NaCl, 1.7 mM CaCl2, 0.9 mM MgCl2, and 4mM KCl) was 
continuously perfused through each microdialysis probe at a rate of 1.0 μl.min-1 by a 
microlitre ‘Pico Plus’ syringe pump (Harvard Apparatus, Fircroft Way, Edenbridge, 
Kent, UK). Microdialysis samples were taken for a baseline period of 2 hours before 
administration of a ghrelin ligand or control. Thereafter, samples were collected at 30 
minute intervals for 360 minutes. DA concentrations in the microdialysis samples 
were determined by HPLC analysis without any extraction procedure, as described 
above. 
5.2.5 Probe placement verification 
After the microdialysis sampling session was complete, animals were euthanized 
and brains removed from probe placement verification. Whole brains were gently 
removed and post-fixed in chilled 4% PFA for 7 days before being transferred to a 
30% sucrose solution for 48 hours. After this, brains were immersed in isopentane and 
snap frozen in liquid nitrogen for storage at -80C until further analysis. Frozen brains 
were cryo-sectioned on a Leica Cryostat (CM1900) and thaw-mounted on 
SuperFrost™ microscopic glass slides. Microscope images were taken to confirm that 
probe placement was correct using the stereotaxic rat atlas for reference (Paxinos, 




5.2.6 Data Analysis 
Data were analysed and graphs generated using GraphPad Prism software, 
Microsoft Excel software and IBM SPSS Statistics (v22) software. All means for the 
standard curve were calculated from the results of at least three independent 
experiments carried out in triplicate. For the in vivo dialysis experiments, data is 
calculated as a % of baseline readout for each individual subject. Baseline reading was 
taken as the absolute concentration of the final baseline sample collected immediately 
prior to the intervention with the ghrelin ligand or control. A repeated-measures 
ANOVA with Tukey’s post hoc test for multiple comparisons was used to determine 






5.3 Effect of ghrelin and ghrelin ligands on dopamine output 
Ghrelin has been shown to augment extracellular DA levels in the nucleus 
accumbens of rodents (Kawahara, Kawahara et al. 2009, Quarta, Di Francesco et al. 
2009). Here, the effects of the synthetic ligands anamorelin and HM01 on DA output 
from the NAccSh of conscious, freely-fed rats were compared to endogenous ghrelin 
and a saline control.  
5.4 HPLC Chromatogram  
A HPLC based method to quantify DA in aCSF samples was established and 
validated (Figure 5.1A). A representative chromatogram obtained from the 





























Figure 5.1. Standard curve of electrochemical detection of dopamine and a 
representative chromatogram from HPLC analysis: A standard curve of DA 
concentration, depicted as the magnitude of electrochemical response vs. 
concentration (Figure 5.1A). A representative chromatogram from an in vitro 
standard (100pg/20µl) shows a distinct DA peak at 2.5 minutes (Figure 5.1B). Also 
shown on the chromatogram are the metabolite 3,4 dihydroxyphenylacetic acid 
(DOPAC) and the precursor levodopa (L-DOPA) in the same concentrations.  
 
5.5 Baseline levels of dopamine 
 Next, basal levels of DA after treatment with saline vehicle were quantified. 
As expected, no large peaks or troughs are present although some inherent variability 
is apparent. Animals were injected after a 2 hour equilibration period and samples 
were collected every 30 minutes. The absolute baseline concentration was calculated 
to be 7.08 ± 2.58 pg/20µL per dialysis sample and subsequent readouts are expressed 






















Figure 5.2. Baseline levels of dopamine after administration of saline ip injection: 
Change in dopamine levels as a percentage (%) of baseline dopamine content over a 
300 minute period of microdialysis. The absolute baseline concentration was 
calculated to be 7.08 ± 2.58 pg/20µL dialysis sample. Pump flow rate was set at 
1.0µl/min. Samples were collected at 30 minute intervals and dopamine 




5.6 Comparing extracellular dopamine levels between treatments 
The extent of change in baseline levels of DA was compared between 
treatments with saline vehicle, ghrelin (0.3mg/kg), HM01 (3mg/kg) or anamorelin 
(3mg/kg) were quantified. A repeated measures ANOVA revealed an overall 
significant effect of treatment (p=0.0115, df=3, F=4.453). Tukey’s post-hoc test for 
multiple comparisons showed an overall increase in DA output for HM01 treated 
animals compared to both saline and anamorelin-treated animals over the 300minute 
sampling period post-injection. The absolute baseline concentrations of DA are 


























Figure 5.3. Comparison of change in baseline dopamine levels over a 300 minute 
period after dosing with saline, ghrelin or ghrelin ligand: Change in dopamine levels 
as a percentage (%) of baseline dopamine content over a 300 minute period of 
microdialysis after dosing with either saline, ghrelin, anamorelin or HM01. Flow rate 
was set at 1.0µl/min. Samples were collected at 30 minute intervals and dopamine 
concentrations in the microdialysis samples were determined by HPLC analysis. 
Table 5.1. Average absolute baseline concentration of dopamine (pg/20µL) 
Treatment Conc Std Dev 
Saline 7.08 2.58 
Ghrelin* 6.89 2.63 
HM01 9.08 4.53 






5.7 Probe placement verification 
 
 Microscope images were taken to confirm that probe placement was correct 
using the stereotaxic rat atlas for reference (Paxinos, Watson et al. 1980). Success 
rate for correct probe placement was 85%. Probe active membrane is depicted within 
the dotted line in Figure 5.5. 
 
Figure 5.4. Representative image of probe placement verification Correct probe 
placement within the NAccSh was confirmed by microscopical analysis using the 
stereotaxic rat atlas for reference (Paxinos, Watson et al. 1980) (NAccSh = Nucleus 







Ghrelin remains the only known peripheral hormone with the ability to modulate 
signalling in the brain in areas associated with food and reward-seeking (Nakazato, 
Murakami et al. 2001, Andrews 2011, Andrews 2011). Its mechanisms of stimulating 
homeostatic food intake have been widely reviewed. It has also long been known that 
“hunger is the best sauce”; a hungry state imparts an increased desire to obtain food 
(Perello and Dickson 2015). Elevated peripheral ghrelin levels during hunger are 
experimentally confirmed to increase the perceived palatability and motivation to 
work for food (Disse, Bussier et al. 2010, Egecioglu, Jerlhag et al. 2010). As such, 
ghrelin’s role in activating the mesolimbic reward circuitry and altering the incentive 
salience of food has been at the forefront of appetite-modulation research in recent 
years (Naleid, Grace et al. 2005, Depoortere 2009, Schellekens, Dinan et al. 2013, 
Perello and Dickson 2015). The mesocorticolimbic DA system is responsible for 
mediating the rewarding properties of food intake elicited by ghrelin (Naleid, Grace et 
al. 2005), and a series of publications investigating these effects using microdialysis 
have been reported (Jerlhag, Egecioglu et al. 2006, Jerlhag, Egecioglu et al. 2007, 
Egecioglu, Jerlhag et al. 2010, Skibicka, Hansson et al. 2011). Central administration 
of ghrelin was first shown to modulate in vivo DA levels in the NAc (Jerlhag, 
Egecioglu et al. 2006, Jerlhag, Egecioglu et al. 2007), which was later shown to be  
dependent on the GHSR-1a in the VTA (Jerlhag, Egecioglu et al. 2009). In addition, 
a GHSR-1a knockout model showed that DA output in the NAcc, elicited by rewarding 
food, is GHSR-1a dependent (Egecioglu, Jerlhag et al. 2010). 
Numerous synthetic ghrelin ligands have been developed and their ability to 
increase food intake and GH output has been investigated (Vodnik, Štrukelj et al. 
2016). Surprisingly, the effect of these ligands on the reward system has not yet been 
investigated. Our group previously investigated the impact of ghrelin and synthetic 
ligands, anamorelin and HM01, on the reward system using behavioural paradigms 
and c-Fos immunohistochemistry (see Chapter 4). Here, we demonstrated a divergent 
circuitry at play, which may be dependent on the biodistribution of the ligands. There 
was a greater ability of HM01 to activate areas of the brain such as the VTA, NAccSh 




investigation of extracellular DA levels in the NAccSh of conscious, freely-feeding 
rats. In the current microdialysis study, measurements were taken over a total of 6 
hours post treatment after a 2 hour baseline equilibration period. HM01 treatment 
showed an overall significant increase in DA output in the NAccSh compared to both 
Anamorelin and saline control(Figure 5.3). This is interesting given the hypothesis that 
a centrally penetrant ghrelin ligand may elicit a greater effect on the reward circuitry 
than a non-penetrant ghrelin ligand. However, while native ghrelin itself may show a 
trend towards an effect in the first 120mins of treatment, particularly at the 30minute 
timepoint, overall there was no effect of ghrelin compared to control. This is despite 
numerous studies reporting significant effects of ghrelin on DA output from NAcc 
using microdialysis paradigms, and this warrants further discussion to contextualise 
our results. 
  
While a significant treatment effect was evident for HM01, there are a number 
of confounding factors for the current study that merit further discussion. Firstly, in 
our microdialysis studies, we do not see robust changes in baseline DA levels after 
ghrelin administration of the magnitude reported in the literature (Jerlhag, Egecioglu 
et al. 2006, Jerlhag, Egecioglu et al. 2007, Egecioglu, Jerlhag et al. 2010, Skibicka, 
Hansson et al. 2011). However, the majority of these studies, which have found robust 
increases after ghrelin treatment are in mice and, notwithstanding the potential species 
difference, often do not draw a distinction between the core (NAccC) and the shell 
(NAccSh) of the nucleus accumbens, presumably due to size constraints. Both of these 
areas are known to serve distinct functions, with the NAccC being responsible for 
execution of motor function surrounding reward motivation, while the NAccSh 
dictates the perceived palatability or ‘liking’ of a reward (Bassareo and Di Chiara 
1999, Di Chiara 2002). Therefore, motor components of dopaminergic signalling from 
the NAccC may underlie the greater increase in DA outflow seen in previous such 
studies in mice. Indeed, the same studies also report robust increases in locomotor 
activity (Jerlhag, Egecioglu et al. 2006, Jerlhag, Egecioglu et al. 2007). Conversely, 
Quarta et. al used a microdialysis paradigm in rats to investigate the differences 




systemic ghrelin administration while the core had no change in output (Quarta, Di 
Francesco et al. 2009). Given the species differences and the uncertainty of core 
contribution, we chose to solely look at the NAccSh in rats due to the widespread 
reports that ghrelin alters the perceived palatability of food (Egecioglu, Jerlhag et al. 
2010, Perello, Sakata et al. 2010, Skibicka, Hansson et al. 2012, Perello and Dickson 
2015). 
Another potential limitation of the current study may be the procedure taken in 
establishing baseline conditions. Previous microdialysis setups report an overnight 
habituation period, however we based our decision to allow a 2-hour equilibration 
period as per Dickson et. al. (Dickson, Egecioglu et al. 2011) as overnight habituation 
gave rise to the possibly of probes becoming dislodged from position or becoming 
blocked. The absolute DA content in the saline-treated group decreased in the 90 
minutes post-injection, where no change should have taken place – this indicates an 
artificially high baseline figure which may be masking subtle changes in DA levels. 
Furthermore, Kawahara and colleagues used microdialysis to show a bimodal effect 
of ghrelin on NAccSh depending on whether or not food was present after treatment – 
food removal after ghrelin was administered induced a decrease in DA output, 
consistent with an aversive reaction (Kawahara, Kawahara et al. 2009). Conversely, 
feeding in the post-ghrelin administration induced a robust increase in DA output. 
Therefore, the variable feeding patterns in the current ad libitum feeding experiment 
may in itself contribute variability to DA response.  
Despite the above discussed limitations, the increase in DA output elicited by 
HM01 is an interesting finding. The fact that HM01 has a greater effect on DA output 
from the NAccSh compared to anamorelin, ghrelin and saline is consistent with the 
hypothesis that penetration into the central nervous system allows it to activate GHSR-
1a at the level of the reward circuitry, such as in the VTA. This has important 
consequences for future research in relation to targeting the reward pathway for 
appetite modulation. Although a trend towards a significant effect of ghrelin in the 
early stages is evident, overall there is no effect of ghrelin in this paradigm which 




Overall, the microdialysis results reported here are the first such results for 
synthetic ghrelin ligands in a conscious, freely-feeding rodent model. Importantly, the 
aim to establish whether there was a difference in dopaminergic output in this 
paradigm due to different ghrelin ligand treatment was achieved in the form of greater 
efficacy of centrally penetrant HM01 vs control. Subsequent studies should leave a 
longer equilibration period in order to establish a more consistent baseline. The % 
increases from baseline in this study are likely diluted by the fact that an artificially 
high baseline is being used, meaning that greater differences are likely to exist than 
those reported here. Further to this, an examination of higher doses of ligands, in 
addition to the potential divergent effects of shell vs. core, fasted vs free-access to 





The current study describes a successful microdialysis platform to detect 
extracellular DA content in the NAccSh of conscious, freely-feeding rats. We report 
that HM01 stimulates NAccSh DA outflow acutely after administration, while ghrelin 
and anamorelin fail to elicit such an increase. The fact that the centrally penetrant 
HM01 elicits a greater DA response over peripherally active anamorelin has important 
consequences for targeting the reward system for future appetite modulation 
approaches. However, optimization of the paradigm for establishment of a less 
variable baseline will help to elucidate these differences in subsequent studies. 
Furthermore, the standardization of access to food and investigation of rewarding food 
should be undertaken in the future. Overall, this is an important study which reports 
novel findings using the technique of microdialyis. These findings can be built upon 
to further investigate divergent mesolimbic signalling with brain penetrant and non-











6.1 Nutraceutical opportunities for early intervention:  
Dairy proteins are one of the most abundant sources of bioactive fragments, 
and there is growing research to indicate that some of these bioactives can have 
positive effects on appetite and metabolism (Phelan and Kerins 2011, Schellekens, 
Nongonierma et al. 2014, Torres-Fuentes, Schellekens et al. 2015, Nilaweera, 
Cabrera-Rubio et al. 2017). However, more translational studies are required to 
provide insights into the merits and mechanisms of milk-derived bioactives to treat 
appetite-related disorders. In Chapter 2, we describe for the first time a dairy-derived 
hydrolysate with inherent capacity to stimulate the GHSR-1a. The casein-derived 
1kDa permeate, designated MF1145 (CasHyd for publication) dose-dependently and 
specifically increased intracellular Ca2+ in HEK293A cells heterologously expressing 
the GHSR-1a (Howick, Wallace-Fitzsimons et al. 2018). Furthermore, we report 
ghrelin agonistic effects of a whey-based protein derivative, UL 2-141 (FHI-2571 for 
publication) in Chapter 3 (Howick, Alam et al. 2018). MF1145 displays superior 
potency (0.27 mg/ml) compared to UL 2-141, however both are considerably less than 
the endogenous GHSR-1a ligand (0.25 µg/ml), ghrelin (Figure 2.1, Figure 3.1A). This 
is likely reflective of the fact that the hydrolysates are a mixture of peptides, only 
some, or one, of which may be active on GHSR-1a.  
Furthermore, this in vitro activity has been demonstrated to translate to an 
increase in food intake in vivo in a rodent model. Evidence of MF1145 enhancing food 
intake in healthy male and female SD rats was reported in Chapter 2. Rats orally 
gavaged with a solution of MF1145 showed significant elevations in food 
consumption (Figure 2.8). Interestingly, oral delivery had a more robust effect than IP 
administered MF1145, which failed to show any increase in food intake (Figure 2.7). 
This may be reflective of the distribution of the GHSR-1a in vivo, which is proximal 
to the intestinal lumen and involved in neuronal signalling to appetite centres in the 
brain (Howick, Alam et al. 2018). The body of work described in Chapter 2 was the 
first time a dairy-derived peptide hydrolysate mixture was shown to increase GHSR-




after oral delivery. This is a significant finding given that the field in relation to 
bioactives and nutraceuticals often relies on in vitro bioinformatics, and often a 
scientific connection is not made between this and clinical use (Howick, Wallace-
Fitzsimons et al. 2018).  
In reality however, many bioactives are degraded during gastrointestinal transit 
(de Vos, Faas et al. 2010). Attempts to consolidate the orexigenic effects of MF1145 
in Chapter 2 by encapsulation into a gastro-protected delivery vehicle were initially 
unsuccessful (Figure 2.12). However, the coating platform utilised in this proof-of-
concept study was suboptimal, and may have provided a potential barrier to efficacy, 
as discussed in Chapter 3. As a result, Chapter 3 aimed to provide a robust, sustained-
release delivery platform to enable high payload of a bioactive peptide (Howick, Alam 
et al. 2018). This allowed for further investigation of the orexigenic effects of MF1145, 
as well as those of whey hydrolysate UL-2-141, in a rodent model. Crucially, the 
success and scalability of the platform also allowed for the ultimate progression to 
human studies as part of the Food for Health Ireland work package (Sullivan, Cushen 
et. al, unpublished). 
The above described work is a testament to the potential of exploiting drug 
delivery technology that is more commonly applied in the pharmaceutical industry, to 
enhance delivery and bioactivity of nutraceuticals. Conventional drug delivery 
approaches offer the ability to provide sustained release and gastro-protection of a 
bioactive peptide which would otherwise be susceptible to acid degradation in vivo in 
the stomach. Although Chapter 3 failed to show increased food intake in rats using the 
optimised coating strategy (Appendix A), considering the initial promise of Chapter 2 
and the inherent limitations of the food intake model discussed (see Limitations section 
below), the decision was made by Food for Health Ireland to progress this more robust 
sustained release formulation to human proof-of-concept studies (Sullivan, Cushen et. 
al, unpublished). Therefore, while work still remains to be revealed in order to 
elucidate if the orexigenic effect is reproducible and if it is indeed modulated through 
GHSR-1a signalling, the within described formulation work adds valuable new 




6.2 Pharmaceutical opportunities for optimization 
While there is considerable potential of GHSR-1a modulation, there are still 
major gaps in our understanding of the mechanisms of action and therapeutic potential 
of synthetic ghrelin ligands in the clinical treatment of CACS and other disorders of 
appetite (Howick, Griffin et al. 2017). Though many studies involving treatment with 
native ghrelin itself have shown promising results (Akamizu, Takaya et al. 2004, 
Neary, Small et al. 2004, Druce, Wren et al. 2005), synthetic ligands hold the distinct 
advantage of having longer half-lives and no deactivation through des-acylation (De 
Ng, Bruera et al. 2016). The pleiotropic pharmacodynamics of the GHSR-1a, as well 
as heterodimerization and downregulation/internalization of the receptor can 
ultimately impact on the observed pharmacodynamic effect (M'Kadmi, Leyris et al. 
2015, Mende, Hundahl et al. 2018, Ramirez, van Oeffelen et al. 2018). Downstream 
effects of the GHSR-1a via coupling to different G-proteins have been summarized in 
Chapter 1 and reviewed in detail elsewhere (Schellekens, Dinan et al. 2013). 
Notwithstanding this is the widespread tissue distribution of GHSR-1a which lends 
significance to the biodistribution of ligands in vivo.  
6.2.1 Biased signalling of GHSR-1a 
Largely ignored until recently, differences in the functional selectivity of 
ghrelin ligands can have an impact on the ultimate effect observed in vivo (M'Kadmi, 
Leyris et al. 2015). Selectively activating GHSR-1a signalling with pathway-specific 
ligands may lead to the development of more successful candidates to treat appetite 
disorders, while minimising off-target effects. Thus, there is a growing impetus for 
characterisation of the signalling pathway(s) activated by individual ligands, and their 
subsequent contribution to the observed behavioural effect. The results of Chapter 4 
provide in vitro and in vivo characterization of two novel, synthetic GHSR-1a agonists. 
Anamorelin (non-BBB penetrant) and HM01 (BBB penetrant) are potent and selective 
novel ghrelin receptor agonists with oral bioavailability and longer half-lives than 
ghrelin (approximately 7 and 4.5 hours respectively).  While both compounds have 
already been reported to have orexigenic and anabolic effects, evidence of their 




signalling pathways of anamorelin and HM01 were hence characterized and compared 
to native ghrelin on the GHSR-1a in vitro, while effects on appetite and reward-
motivated behaviour were also assessed.  
 Agonist activity of HM01 and anamorelin on the GHSR-1a was shown using 
both intracellular Ca2+ mobilization and IP-one accumulation (Schellekens, van 
Oeffelen et al. 2013), in HEK293A cells (human embryonic kidney cells) stably 
expressing the ghrelin receptor tagged with an enhanced green fluorescent protein 
(GHSR-1a-EGFP). As expected both ligands produced a strong agonist response on 
both assays. As well as heterogenous signalling and neuroendocrine cross-talk, the 
expression of the GHSR-1a on the cell membrane is critical to it being a successful 
therapeutic target (Ramirez, van Oeffelen et al. 2018). However, GPCRs are known to 
downregulate via receptor internalization or endocytosis causing a subsequent 
attenuation of effect (Tsao and von Zastrow 2000). Unsurprisingly, the GHSR-1a 
receptor has been shown to downregulate in response to various stimuli, including 
ghrelin- and ghrelin-ligand mediated activation (Kaji, Kishimoto et al. 2001, Orkin, 
New et al. 2003, Camina, Carreira et al. 2004). The effects of anamorelin and HM01 
on GHSR-1a internalization into endosomal vehicles were evaluated. Interestingly the 
Emax reached by anamorelin (126%) is much higher than that of ghrelin (74%) and 
HM01 (69%) as a percentage of control (3.3% FBS). This potentially indicates a 
tendency towards GHSR-1a desensitization in vivo after treatment with anamorelin, 
but not HM01. These findings are supported by the β-arrestin recruitment assay. 
6.2.2 Biodistribution and in vivo effects of ghrelin ligands 
Further to the heterogenous signalling discussed above, the widespread 
distribution of the GHSR-1a in the various tissues throughout the body is also an 
important consideration (Figure 1.4). GHSR-1a is present in a multitude of peripheral 
and central sites; the nature of this widespread distribution being responsible for the 
plethora of functional outputs (see Figure 1.3). As a result, the administration of 
ghrelin or a ghrelin ligand will lead to a number of downstream effects spanning the 
periphery and the central compartment. For appetite modulation therapy, this is a 




specificity and increasing off-target side-effects (Horvath, Castaneda et al. 2003, 
Müller, Nogueiras et al. 2015). The non-target tissue effects (e.g. glucose and insulin) 
(Chabot, Caron et al. 2014) are likely to complicate a delicate homeostatic balance. 
The fact that both insulin and glucose can have a significant effect on hunger (Woods, 
Lutz et al. 2006) means that non-specific stimulation of the GHSR-1a in the pancreas 
likely decreases efficacy of appetite modulation therapy (Lavin, Wittert et al. 1996, 
Flint, Gregersen et al. 2007). In light of this, it is unsurprising that the biodistribution 
of ghrelin ligands also would have a significant role to play in determining in vivo 
effects (Howick, Griffin et al. 2017).  
In Chapter 4 we investigate the impact of traditional brain penetrability of 
ghrelin ligands on areas pertaining to appetite and incentive salience. Traditional BBB 
penetration does not seem to be a key factor for effecting changes to appetite 
stimulation or growth hormone output due to the endogenous neural machinery to 
convey elevated peripheral ghrelin levels to higher brain centres from the 
hypothalamus (Banks 2002, Cabral, Valdivia et al. 2014, Cabral, De Francesco et al. 
2015). Indeed, despite being limited to the periphery, anamorelin is under regulatory 
consideration for the treatment of cancer-anorexia-cachexia syndrome due to its 
somatotrophic and orexigenic capacity (Garcia 2017). This has also been seen for other 
non-centrally penetrant compounds (Torsello, Luoni et al. 1998, Laferrere, Abraham 
et al. 2005). The ability to achieve this functionality despite a lack of central 
penetrance is the subject of much debate (Cabral, De Francesco et al. 2015, Edwards 
and Abizaid 2017).  
In Chapter 4, robust increases in food intake are reported in rats treated with 
ghrelin, anamorelin and HM01. HM01 produces a far greater increase in food intake 
than anamorelin. Interestingly, upon trebling the dose of anamorelin and HM01 in a 
subsequent food intake study, no greater orexigenic effect is found for either, hence 
indicating a maximal pharmacodynamic response. GH output, measured as a surrogate 
for GHSR-1a activation in vivo, was found to be equivalent for anamorelin and HM01 
groups. Furthermore, c-Fos immunostaining showed no greater activation in the Arc 
after treatment with HM01 than anamorelin or ghrelin. Therefore, the fact that HM01 




seen in vivo. This may be due to the differing biodistribution observed between both 
compounds. Nevertheless, the acute effects (<24 hours) of both anamorelin and HM01 
have not been investigated head to head before, or in comparison with ghrelin. Hence 
the finding that HM01 exerts a greater effect on food intake than anamorelin is a novel 
contribution to the field.  
It was hypothesised that this may be due to the ability of HM01 to penetrate 
into the brain and activate the mesolimbic reward pathway. Though the hypothalamus 
is the traditional site of action for food intake and body weight regulation, the GHSR-
1a is also expressed in key nodes of the reward system and contributes to so-called 
“pleasurable” eating beyond metabolic demand (Abizaid, Liu et al. 2006, Zigman, 
Jones et al. 2006). Ghrelin’s ability to effect this despite a lack of apparent ability to 
gain access to the brain is an ongoing discussion in the field (Edwards and Abizaid 
2017). The biodistribution of the GHSR-1a in areas not immediately accessible to the 
peripheral circulation has given rise to the theory that central penetrance of ghrelin 
ligands would be advantageous, by increasing the access of ghrelin ligands to the 
mesolimbic reward circuitry (Howick, Griffin et al. 2017). No studies have 
investigated the differential effects of a non-brain-penetrant and a brain-penetrant 
ghrelin ligand on reward system signalling in this respect. As a result, ex vivo 
immunohistochemistry of reward-related areas was carried out while reward-
motivated behavioural assessment and in vivo microdialysis were also undertaken. 
Immunohistochemistry revealed divergent activation in the reward circuitry 
for anamorelin and HM01 as measured by c-Fos activation. Significantly elevated c-
Fos activation was expectedly noted in the Arc for ghrelin, Anamorelin and HM01, 
while the NAccSh showed elevated activity for HM01 only, and not ghrelin or 
anamorelin. Interestingly, only HM01 showed significant elevation in the LH and the 
VTA, both of which are key areas in the reward pathway which are not peripherally 
accessible. This c-Fos activation profile indicates a divergent activation of reward-
related areas with a brain penetrant ghrelin agonist. This may bolster the theory that 
central penetrance could lead to greater efficacy of ghrelin therapeutics, through 




Reward-motivated effects were investigated using the Female Urine Sniffing 
Test (FUST) and Saccharin Preference Test (SPT) paradigms. In the latter the 
preference for saccharin was significantly reduced in rats treated with ghrelin ligands 
anamorelin and HM01. Furthermore, the FUST was used to quantify interaction time 
with a rewarding olfactory stimulus (Malkesman, Scattoni et al. 2010). HM01 treated 
mice had a lower number of sniffing interactions with a female urine stimulus than 
control mice, in addition to displaying an increased latency to sniffing. These results 
indicate that HM01-treated mice, but not anamorelin treated, show aversive-like 
behaviour towards a rewarding stimulus. Ghrelin treatment has been previously shown 
in the literature to increase the preference for sweet-taste (Disse, Bussier et al. 2010). 
Therefore, an unexpected paradoxical reduction in reward-related behaviour was 
observed. Seemingly, reward paradigms which do not offer caloric benefit in hunger 
elicit a negative response where a positive one was expected. This may be indicative 
of a potential reduction in the palatability of a substance which offers no caloric benefit 
in times of food seeking, a phenomenon which has already been reported albeit in a 
microdialysis paradigm (Kawahara, Kawahara et al. 2009).  
In vivo microdialysis investigations were undertaken in Chapter 5 in order to 
delineate changes in extracellular DA levels after dosing with anamorelin and HM01. 
The microdialysis results reported here are the first such results for synthetic ghrelin 
ligands in a conscious, freely-feeding rodent model. The fact that centrally penetrant 
HM01 has a greater effect on DA output from the NAccSh than anamorelin and ghrelin  
is consistent with the hypothesis that brain penetrability allows it to activate GHSR-
1a at the level of the reward circuitry, such as in the VTA. This work hence highlights 
important considerations for future research investigating the mesolimbic reward 
pathway in food intake. The reasons for this may be related to biased agonism, 
biodistribution or pharmacokinetics and should be considered in future studies. 
In summary, ligand-dependant signalling pathways are increasingly 
recognised for their behavioural significance in vivo. In Chapter 4, the in vitro 
signalling pathways activated by both ligands are contrasted and found that anamorelin 
is potentially more susceptible to treatment-induced tolerance. Furthermore, this is 




have different abilities to traverse the BBB. The notion that central penetrance may be 
an important consideration in the biodistribution of ghrelin ligands has gained traction 
in recent times in the context of reward system activation. Hence, given the divergent 
activation seen on c-Fos immunoactivation in Chapter 4, it was decided to utilise a 
microdialysis paradigm in Chapter 5 to further elucidate this hypothesis in a conscious, 
freely-feeding rodent model. Results prove the theory that central penetrance is an 
important consideration however further work must be done in order to elucidate the 
reasons behind this. 
6.3 Limitations and future perspectives: 
6.3.1 Nutraceutical approach 
Though the results of Chapter 2 and Chapter 3 are both interesting and novel, 
variability and reproducibility of the studies are particular caveats warranting 
discussion. These are discussed in further detail in the relevant chapters and are 
summarized here. In general, food intake studies in rodents are inherently variable and 
subject to many confounding factors, both internal (baseline satiety levels, stress 
levels, sleep status) and external (operator skill, local injury from gavage, bulk effect 
of pellets). Indeed, it is known from in-house experience that the ability of a known 
orexigen, ghrelin, to stimulate food intake in rodents during the light phase is more 
consistent the closer to the onset of the light phase, presumably due to the effect of 
diurnal oscillations (Schellekens et.al, unpublished). All experiments were also carried 
out in the light phase, when rodents normally would be asleep – circadian fluctuations 
may serve here as a confounder to assessing true appetite. Oral gavage of a solution of 
MF1145 demonstrated an increase in food intake over a 7-hour period in healthy male 
and female SD rats, however this is tempered by a relatively low quantity of food 
consumed overall compared to other such studies. Inter-experimental variability was 
evident based on the differences in baseline food consumption between experiments, 
while attempts to reproduce those seen in rodents proved difficult. The dosing 
procedure exerted a degree of restraint stress upon the animals, while there is a risk of 
minor local injury to the oesophagus in gavaged rats which is also likely to impact on 




The bioactive hydrolysate itself is also likely to be highly fragile in vivo, due 
to low gastric pH (discussed in Chapter 2 & 3), as well as intestinal peptidases. 
Variability in results may well be a consequence of breakdown in vivo. Furthermore, 
the delivery system design incorporated the peptide into a gastro-protected pellet 
which exerted a degree of processing stress on the peptide, resulting in a loss of ~40% 
bioactivity. The bulk effect of solid pellets also seems to have imparted a default 
increase in food intake in both males and females compared to oral solution. While 
this formulation was useful as proof of concept, process optimisation is required to 
minimise activity losses, reduce bulk volume and tailor the release profile further in 
vivo.  
Bioactives for appetite modulation is a growing field with a high degree of 
commercial and clinical potential. In particular, there is growing evidence of the role 
of dairy-derived peptides in this field. Despite the acknowledged limitations in this 
thesis, hitherto, much of the evidence corroborating the health claims of bioactives and 
nutraceuticals comes from in vitro bioinformatics. Many bioactives are lacking 
substantial in vivo evidence of effect (Li-Chan 2015, Nongonierma and FitzGerald 
2015). Placed in this context, this thesis is the first piece of work to report dairy 
peptide-hydrolysate fractions, MF 1145 and UL-2-141 with intrinsic GHSR-1a agonist 
activity. Furthermore, it is the first to show promising results of one of the fractions, 
MF1145, in translating a specific in vitro bioactivity with high potency, to a promising 
biofunctional effect on food intake in vivo, suggesting the overall success of this proof 
of concept work. Future studies should consider the use of automated cages for 
measuring food consumption as well as the pattern of food intake, locomotor 
behaviour, urine and faecal pellet output. This would give a broader context to the 
findings, as well as avoiding experimenter manipulation of cages and allowing for 
measurement during the dark phase. Furthermore, the use of healthy, normophagic rats 
should be replaced with elderly rats, or those with mild forms of malnutrition/cachexia 
in order to mimic the potential clinical scenario. 
The formulation paradigm developed in this thesis can also be generalised to 
other peptides and bioactives in the appetite modulation field, and beyond. This work 




amenable to delivery via oral gavage to rodents. The bioactive material can be 
encapsulated into a gastro-protected, sustained release vehicle at a high load. A high 
degree of bioactivity remains after the encapsulation process. Future studies should 
look at tailoring the release of bioactive to various intestinal areas, and maybe even 
including permeation enhancers. 
6.3.2 Pharmaceutical approach 
Despite the wealth of evidence discussed above for ghrelin in appetite 
modulation, the hormone remains as one cog in a complicated appetitive machinery; 
many complementary and compensatory neuroendocrine responses to changes in 
GHSR-1a signalling remain as barriers to the overall efficacy of ghrelinergic therapies. 
After all, despite an abundance of synthetic ghrelin ligands which have been developed 
over the years, we are faced with a lack of therapeutic success in appetite modulation 
which is as abundantly clear. Only one such ligand, anamorelin, is close to achieving 
regulatory approval for treatment of CACS (Garcia 2017). The work of this thesis 
comes at a time when the field of ghrelin research has realised the significance of 
GHSR-1a ubiquity and promiscuity, which has only recently come to the fore as 
barriers to therapeutic success (Chapter 1).  
 In relation to cumulative food intake studies in Chapter 4, though the same 
inherent variability applies as described above for Chapter 2 and 3, the robustness of 
the food intake response elicited by anamorelin and HM01 was such that these 
limitations are not relevant to our conclusions. Therefore, this section focuses on the 
caveats associated with investigation of the reward system effects of the ligands. c-
Fos immunohistochemistry was carried out and found greater activity of HM01 in key 
input centres of the mesolimbic pathway, such as the LH and VTA. This indicated a 
divergent neuronal activation at play between the centrally penetrant HM01 and the 
non-penetrant anamorelin. However, it must be said that c-Fos is a general marker of 
neuronal activation and these findings may indicate activation of inhibitory 
interneurons instead of excitatory neurons. The findings would be better supported by 
more specific double-staining which would identify the specific sub-type of the 




paradoxical findings in the reward-related behaviours. While food intake is robustly 
increased by both anamorelin and HM01 treatments, an unexpected paradoxical 
reduction in reward-related behaviour was observed in the FUST and the SPT. This 
may results from the fact that no calories were present in either of the reward 
paradigms in question, hence creating an aversive response to the perceived hunger 
conferred by the agonist treatment similar to a previous microdialysis study 
(Kawahara, Kawahara et al. 2009). The underlying mechanisms explaining this 
unexpected behavioural phenomenon require hence require further investigation.  
Finally, in Chapter 5 we used microdialysis as a technique to measure 
extracellular levels of dopamine in the NAccSh. Though this technique found a 
significant increase in baseline DA elicited by the centrally penetrant HM01, it failed 
to detect changes in baseline DA levels of the same magnitude reported in the literature 
(Jerlhag, Egecioglu et al. 2006, Jerlhag, Egecioglu et al. 2007, Egecioglu, Jerlhag et 
al. 2010, Skibicka, Hansson et al. 2011). The potential reasons for this are discussed 
in detail in Chapter 5. The current paradigm may need to be optimized slightly to 
provide for a more consistent baseline before treatment. Furthermore, though 
microdialysis has been successfully used as a tool in relation to ghrelin in many 
studies, many of those studies often did not delineate the motor contribution of the 
NAccC DA. Indeed, though Quarta et. al successfully used a microdialysis paradigm 
in rats to investigate the differences between the NAccC and NAccSh (Quarta, Di 
Francesco et al. 2009), 
The microdialysis technique quantifies tonic levels of DA over the course of 
minutes, as opposed to other techniques which monitor phasic changes of DA over the 
course of seconds. As such, the temporal resolution of DA change may be diluted over 
the 30 minute sample collection period. Therefore, it could be that a more temporally 
sensitive fast-scan cyclic voltammetry (FSCV) setup may be more appropriate to 
quantify DA in this setup. Previous studies have also considered the local tissue 
damage, potentially disrupting the BBB which may be relevant for central access (de 
Lange, de Boer et al. 2000). To limit this, we used a guide cannula through which the 
probe was inserted on the experimental day, however local injury and disruption to the 




is that absolute levels of DA were not quantified in the extracellular fluid, but rather 
relative changes in DA compared to baseline were assessed. This became problematic 
due to our problems in establishing an appropriately stable baseline. Lastly, the 
decision to eat in humans is largely a top-down decision based on many factors such 
as social acceptability and emotion among many other factors Therefore, the relevance 
of extrapolating changes in dialysate DA, as well as behavioural paradigms of reward 
to humans may be questioned. 
The body of work described here adds to the growing field investigating the 
biased-signalling of the GHSR-1a and its potential impact on 
pharmacodynamic/behavioural outcomes. Accumulating evidence points to the 
significance of biased signalling in the future development of successful ghrelin-based 
therapies for appetite modulation (Ramirez, Oeffelen et al. , Mende, Hundahl et al. 
2018). Preferentially activating a desired pathway may help to augment orexigenic 
capacity while limiting side-effects. Furthermore, given the widespread tissue 
distribution of GHSR-1a, the biodistribution of ghrelin ligands is another important 
consideration (Howick, Griffin et al. 2017). Therefore, this work provides a 
pharmacokinetic slant which is missing from most studies until now. Given the 
ubiquitous expression of GHSR-1a in the body, the heterogenous downstream 
signalling, and ability to heterodimerize with other GPCRs, a more holistic approach 
to targeting the GHSR-1a needs to be adapted. Detailed pharmacokinetic studies for 
individual ligands would provide a critical tool in order to reconcile with the observed 
pharmacodynamic effect. Due consideration of the location of activation of GHSR-1a 
in the body by a ligand, in addition to the downstream pathway activated by that 
particular ligand should be taken. Relevant parameters which can confound functional 
output should also be further investigated, such as other appetite-related biomarkers, 
acyl vs. des-acyl ghrelin levels etc. Lastly, when investigating reward system-specific 
effects, more of an effort should be made to eliminate the confound of calories that is 
found in most studies with ghrelin – in hunger, the intake of calories will by default 
generate a pleasurable neuronal response. In order to get a true estimate of ghrelinergic 
manipulation on reward system activation further detailed immunohistochemical 




6.4 Summary and Future perspectives 
A PubMed search of the term “ghrelin” reveals close to 10,000 publications. 
Seemingly, the more research that has taken place, the more questions that have been 
posed. As such, despite almost two decades and a myriad of research, no GHSR-1a 
targeting moiety is on the market for a clinical indication. This does not imply a lack 
of therapeutic potential, but rather serves as a testament to the complexity and 
heterogeneity of GHSR-1a signalling. The novelty of this thesis is two-fold; firstly, it 
investigates early intervention for a weakening ghrelin axis using a dietary-derived 
bioactive. Secondly, it adds to the growing body of evidence which calls for greater 
understanding of the significance of biased signalling and biodistribution. A new 
perspective is provided on manipulating top-down control of food intake via centrally 
penetrant ligands. There is an impetus to build on the work of this thesis and provide 
more effective appetite modulation therapies in the future. 
This thesis has shown for the first time dairy-derived hydrolysate activation on 
the GHSR-1a and evidence for this effect to translate in vivo. Furthermore, the work 
has added valuable knowledge on drug delivery strategies which could be harnessed 
for the future investigation of nutraceutical therapies through developing a simple, 
sustained release coating approach to enable zero-order release of bioactive in vivo. 
Overall this body of work has a high degree of importance to facilitate the development 
of potential bioactive candidates in the growing field of nutraceutical science. It 
highlights the importance of active collaboration between food science and 
pharmaceutical delivery science. Given the demographics of ageing populations and 
the concomitant rise in comorbid conditions, the attractiveness of a pre-emptive 
dietary based intervention for early stage cachexia is evident from both a cost and 
regulatory standpoint. 
The thesis also investigates synthetic ghrelin ligands with an emphasis on 
biodistribution and biased signalling. Biased signalling can have a profound effect on 
ultimate effect observed in vivo, while biodistribution of ligands is coming to the fore 
in relation to the ubiquity of GHSR-1a tissue distribution. Centrally penetrant ghrelin 




their ability to attain greater levels in the brain and activate the mesolimbic reward 
circuitry. In line with this, we report divergent neuronal activation of reward areas 
after treatment with anamorelin (non-penetrant) and HM01 (penetrant). Furthermore, 
more robust maximal food intake is reported for HM01 compared to anamorelin. 
Paradoxical effects on reward system signalling and limitations to our microdialysis 
platform call for further investigation into the clinical validity of this divergent 
signalling. Nevertheless, this work provides a valuable contribution to the appetite 
modulation field and lays a solid foundation for further investigations in the field, 
particularly in relation of immunohistochemistry and microdialysis. 
The work of this thesis advances knowledge in two areas of intervention for 
disorders of appetite; Chapter 2 and 3 investigate the potential of dairy-derived 
bioactives for early treatment of cachexia while providing a generalisable platform for 
bioactive encapsulation in future proof-of-concept studies. Chapters 4 and 5 spotlight 
biased signalling and biodistribution as important determinants of in vivo efficacy. 
Combined, the work of the thesis provides valuable mechanistic and technical insight 
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Supplementary Material to Chapter 3 
Pellet preparation: 
This method has been described in detail in Section 3.4 above. 
 
Pellet coating: 
This method has been described in detail in Section 3.5 above. 
Cumulative Food intake: 
Male Sprague-Dawley (SD) rats were purchased from Envigo, UK. Rats were 
7 to 8 weeks-old when received at the facility. Animals were group-housed (4 rats per 
cage) in standard holding cages with controlled light-dark cycle (12-h light; lights on 
at 7:00 a.m.) and in a temperature- (21 ± 1°C) and humidity-controlled (55 ± 10 %) 
environment. Water and standard lab chow (2018S Teklad Global 18 % Protein 
Rodent Diet, Envigo, UK) were available ad libitum. All experiments were in full 
accordance with the European Community Council directive (86/609/EEC) and 
approved by the Animal Experimentation Ethics Committee of University College 
Cork (B100/3774). Animals were habituated to experimental conditions for a week 
prior to experiments taking place. On experimental day, animals were administered 
their respective treatment at the onset of the light phase and then placed in individual 
cages for duration of food intake monitoring. Food intake was then recorded by 
weighing the chow at defined intervals. For the gastro-protected pellets, animals were 
food restricted for a period of 4 hrs before a pre-weighed quantity of chow was added 
to the cages. The dosing system for pellets consisted of a flexible PVC gavage tube 
which was filled with a pre-weighed quantity of blank or active pellets. After insertion 
of the dosing tube a guidewire was used to administer the dose of pellets directly into 





Cumulative Food intake studies: 
The potential for a casein-derived hydrolysate, MF1145, to elicit an orexigenic 
effect was discussed above in Chapter 2. Furthermore, an optimized formulation 
strategy which was called for in Chapter 2 was developed in Chapter 3 using UL-2-
141 as a model peptide. An aqueous-based bi-layer approach, and also an organic 
based monolayer approach was developed. Therefore, the orexigenic capabilities of 
two novel hydrolyates, MF1145 and UL-2-141 were investigated using this optimized 
formulation. Firstly, the whey-derived hydrolysate was tested in cumulative food 
intake (CFI) studies. However, no overall differences in food intake were observed. 
Furthermore, CFI was examined after dosing with encapsulated MF1145, however no 
differences were noted in total quantity of food consumed here either.  
 
















Figure 1. Cumulative food intake following oral administration of encapsulated 
dairy derived peptide hydrolysate, UL-2-141. Cumulative food intake (CFI) (regular 
chow) intake in male sprague-dawley rats was determined following oral 
administration with 35mg kg-1 body weight of encapsulated UL-2-141, over 8 hours. 






















Figure 2. Cumulative food intake following oral administration of encapsulated 
dairy derived peptide hydrolysate, MF1145. Cumulative food intake (CFI) (regular 
chow) intake in male sprague-dawley rats was determined following oral 
administration with 35mg kg-1 body weight of encapsulated MF1145, over 8 hours. 





The work from Chapter 2 concluded that there was a potential for appetite 
modulation, however more reliable sustained release was called for. The area of 
bioactives for appetite modulation is of growing commercial interest and the potential 
to address an unmet clinical niche (pre-cachectic states of undernutrition) needs to be 
backed up with solid scientific evidence. MF1145 (CasHyd, Chapter 2) and UL-2-141 
(FHI-2571, Chapter 3) are hydrolysates of casein and whey protein respectively. As 
discussed in Chapter 2, MF1145 is the 1kDa permeate from a highly reproducible 
enzymatic hydrolysation process which yields a peptide mixture substantially different 
from the parent casein. Similarly, UL-2-141 is a peptide hydrolysate which underwent 
a similar hydrolysation process however the size fraction of the same is larger. 
MF1145 is more potent than UL-2-141 in vitro, likely reflective of the fact that the 
1kDa permeate has smaller peptide fractions which correlate with activity on the 
GHSR-1a. 
The ability of bioactive peptides to elicit a beneficial effect in vivo is likely to 
be highly dependent on the use of a gastro-protective delivery system In vivo 
preclinical studies with this bioactive peptide show its potential to act as an appetite 
stimulant after oral administration. CFI was increased three-fold after 6 hours in male 
and female SD rats after a single oral dose. In the current study, food intake 
assessments were repeated using the optimized coating strategy described in Chapter 
3. There were no differences noted for UL-2-141 or MF1145 with a sustained-release 
coating. Importantly, it was shown in Chapter 2 that while activity of MF1145 was 
eliminated following exposure to gastric pH, administration of MF1145 in a gastro-
protected pellet formulation only showed a trend towards increased food intake in both 
males and females. Therefore, the previous caveats of the paradigm mentioned in 
Chapter 2 are still due some consideration. Specifically, the potential lack of suitability 
of the model to assess subtle appetitive changes in a normophagic rat cohort was 
discussed.  Furthermore, the optimized release mechanism of bioactive may be too 
gradual, and it could be that a burst release similar to endogenous ghrelin is required 
in order to stimulate a clinically significant orexigenic response. Overall, the potential 




promising. Future work should examine the orexigenic effect in models of 
ageing/malnutrition, while also developing release mechanism for burst release in 











Supplementary material to Chapter 4 
Materials and Methods 
Ca2+ mobilization assay  
This method has been described in detail in Section 2.3 above. 
Internalization assay  
This method has been described in detail in Section 4.2.3 above. 
 
Beta-arrestin recruitment assay 
This method has been described in detail in Section 4.2.4 above. 
Animals  
Male Sprague-Dawley rats (8 weeks) and C57Bl/6 mice (8 weeks) were 
purchased from Envigo, United Kingdom for use in in vivo behavioural experiments. 
All animals were housed in group cages at 21 ± 1°C, humidity (55± 15 %), outside air 
ventilation (15±5 cycles/h) with a 12-h light/dark cycle. Animals were acclimatized 
for at least 1 week before use in experiments. Animals were provided standard chow 
(Teklad Global 18 % Protein Rodent Diet, Envigo, UK) and tap water ad libitum. All 
experiments were performed in accordance with European guidelines following 






Female Urine Sniffing Test  
The protocol for assessing female urine sniffing behaviour in male C57Bl/6 
mice was carried out as per Malkesman et. al (Malkesman, Scattoni et al. 2010). Mice 
were randomly allocated to one of three treatment groups (Saline, Anamorelin 3mg/kg 
or HM01 3mg/kg). One week before the test, mice were placed into individual cages 
in order to remove the effect of single housing on the day of the experiment. On the 
experimental day, rodents were transferred to a dark room illuminated with a red-light. 
One hour before the test, mice were habituated to the presence of a cotton-tipped 
applicator extending into the home cage. 30 mins before the test mice were given an 
intraperitoneal (IP) injection with the appropriate treatment or saline control. The 
following protocol took place for each mouse; a three-min exposure to a cotton tip 
dipped in 60µL sterile water, during which the experimenter left the room and video 
was recorded for later analysis of duration of interaction, total number of interactions 
and latency to interact. This was followed by an inter-trial interval of 45 minutes 
during which no cotton tip was in the cage. Depending on the experimental group, 
food may or may not have been available ad libitum during the intertrial interval. 
Lastly, a three-minute exposure to a cotton tip dipped in 60µL of urine, freshly 






Open Field test 
The protocol for the open field test was adapted from a previously described 
paradigm (Carlini, Monzon et al. 2002). Male SD rats were placed in the centre of a 
circular arena (90cm diameter) Sixty cm high walls bordered the field. The animals 
were injected IP 10 mins prior to the behavioural test, after which they were placed 
into the arena and behaviour continuously monitored for 10 min by a video recorder. 
The following behavioural components were later measured: locomotion (the total 
distance travelled), mean velocity, time spent rearing (standing upright on the hind 
legs), time spent grooming (includes face cleaning, licking, and scratching), and 
latency to enter the centre zone. 
ELISAs for appetite-related biomarkers 
Next, 2 hours post-dosing with either saline, ghrelin, anamorelin or HM01, rats 
were euthanized and trunk blood collected. The blood was treated with Pefabloc® 
1mg/ml solution in a 1:100 ratio in order to inactivate serum proteases, then the sample 
was centrifuged at 5000-6000rpm and the plasma removed for snap freezing and 
storage at -80C. Plasma samples were analysed for Growth Hormone (GH) (Cat. No: 
EZRMGH-45K) and total Glucagon-Like Peptide (GLP-1) (Cat. No: K150JVC-2), 
which were purchased from Merck Millipore, Millipore Ireland B.V, Tullagreen, 
Carrigtwohill, Co. Cork, Ireland and Meso Scale Discovery, 1601 Research Blvd, 







In vitro assays with HM04 and H1498 
HM04 and H1498 are novel synthetic ligands for the GHSR-1a, the former 
being a classical competitive antagonist and the latter being an inverse agonist. We 
tested the ability of both compounds to reduce agonist-mediated calcium mobilization 
in the same assay. The antagonist behaviour of HM04 on GHSR-1a was shown using 
intracellular Ca2+ mobilization as a measure of downstream GHSR-1a signalling in 
HEK-293A cells (Schellekens, van Oeffelen et al. 2013), stably expressing the ghrelin 
receptor tagged with an enhanced green fluorescent protein (GHSR-1a-EGFP). There 
is a concentration-dependent reduction in the activity response curve for ghrelin (IC50 
= 2.7 x 10-7 M), anamorelin (IC50 = 8.8  x 10
-7 M),  and HM01 (IC50 =  7.8 x 10
-7 M) 
when exposed to HEK-293A cells pre-incubated with increasing concentrations of the 
antagonist HM04 (Figure 1). Furthermore, no Ca2+ influx was observed in wild-type 
HEK293A cells (HEK293A-WT) cells pre-incubated with HM04 alone.  Conversely, 
there is a concentration dependent increase on the activity response curve for ghrelin, 
anamorelin and HM01 when exposed to HEK-293A cells pre-incubated with 
increasing concentrations of the inverse agonist H1498. Therefore, at lower 
concentrations H1498 antagonizes GHSR-1a activity, however at higher 
concentrations it has the ability to potentiate the actions of ghrelin, anamorelin and 
HM01 on the GHSR-1a. This is confirmed by a DRC for ghrelin (Figure 3) whereby 
the maximal effect of ghrelin is increased two-fold when HEK-293A cells are pre-
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Figure 1. Concentration-dependent inhibition of GHSR-1a agonist signalling by 
GHSR-1a antagonist, HM04. Concentration response curves for the endogenous 
GHSR-1a ligand, ghrelin, and the synthetic GHSR-1a ligands, HM01 and Anamorelin, 
measured in ghrelin receptor over-expressing HEK293A cells -incubated with 
increasing concentrations of novel ghrelin receptor antagonist HM04. Intracellular 
Ca2+ increase was depicted as a percentage of maximal Ca2+influx in relative 
fluorescence unit (RFU) as elicited by control (3.3% FBS). Graph represents mean ± 
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Figure 2. Concentration-dependent inhibition of GHSR-1a agonist signalling by 
GHSR-1a inverse agonist, HM1498. Concentration response curves for the 
endogenous GHSR-1a ligand, ghrelin, and the synthetic GHSR-1a ligands, MK0677, 
HM01 and Anamorelin, measured in ghrelin receptor over-expressing HEK293A cells 
-incubated with increasing concentrations of novel ghrelin receptor inverse agonist 
H1498. Intracellular Ca2+ increase was depicted as a percentage of maximal 
Ca2+influx in relative fluorescence unit (RFU) as elicited by control (3.3% FBS). 
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Figure 3. Concentration-dependent potentiation of ghrelin’s action on GHSR-1a 
mediated calcium mobilization. Concentration response curves for the endogenous 
GHSR-1a ligand, ghrelinmeasured in ghrelin receptor over-expressing HEK293A 
cells -incubated with increasing concentrations of novel ghrelin receptor inverse 
agonist H1498. Intracellular Ca2+ increase was depicted as a percentage of maximal 
Ca2+influx in relative fluorescence unit (RFU) as elicited by control (3.3% FBS). 







HM04 was compared with a classical antagonist (JMV 2959) and an inverse agonist 
(SP) on a receptor internalization assay. Ghrelin (100nM), anamorelin (100nM) and 
HM01 (10nM) show clear GHSR-1a internalization into endosomal vehicles based on 
EGFP intensity in the cytoplasm. While JMV (1uM) decreased the receptor 
internalization slightly, HM04 (1uM) behaved like an inverse agonist and showed 















































































































































Figure 4. GHSR-1a internalization assay with JMV-2959, SP and HM04: 
Internalization of GHSR-1a was quantified after treatment with high dose ghrelin, 
anamorelin and HM01. The ability of JMV-2959, SP and HM04 to reduce the amount 
of receptor internalization was quantified. The classical antagonist HM04 was found 
to act in a similar manner to the inverse agonist, SP, at the concentration tested. There 
is a shift in the EGFP cytoplasm intensity which is evidence of GHSR-1a recycling to 
the cell membrane. Intracellular EGFP increase was depicted as a percentage of 
maximal EGFP intensity as elicited by control (100nM Ghrelin). Graph represents 





HM04 was compared with JMV in a β-arrestin recruitment assay. Ghrelin 
(100nM), anamorelin (100nM) and HM01 (10nM) show clear recruitment of the β-
arrestin subunit. While no inverse agonist activity is seen for HM04 in this assay, 
HM04 (1uM) was more potent at halting GHSR-1a mediated β-arrestin recruitment 































































































































































Figure 5. β-arrestin recruitment assay with JMV-2959, SP and HM04: GHSR-1a 
mediated β-arrestin recruitment was quantified after treatment with high dose ghrelin, 
anamorelin and HM01. The ability of JMV-2959 and HM04 to reduce the amount of 
receptor internalization was quantified based on β-arrestin recruitment. The classical 
antagonist HM04 was found to act more potently than JMV at reducing β-arrestin 
recruitment instigated by each agonist. β-arrestin recruitment was depicted as a 
percentage of maximal EGFP intensity as elicited by control (100nM Ghrelin). Graph 






Additional behavioural measures 
Female Urine Sniffing test 
Previously we showed a decrease in the number of interactions and the latency 
to interact with a female urine olfactory stimulus. Given the action of HM01 on food 
intake, it was postulated that the effect observed may be food-dependent. We hence 
adapted the FUST paradigm to allow for food to be consumed in the inter-trial interval 
(food intake data not shown). We report no changes in the behaviour elicited towards 
the stimulus for control or anamorelin treated animals. However, for HM01 we find a 
food-dependent effect on the reward-motivated behaviour towards a female urine 
stimulus. The number of interactions with the stimulus is restored to normal in rats 
who were allowed eat chow ad libitum before the session with the urine stimulus. A 
trend towards a food-dependent effect is also evident for the latency to interact with 












































































Figure 6. Effect of ad libitum on effect of HM01-mediated reduction in female urine 
sniffing behaviour. Interaction of male C57/Bl6 mice with a rewarding odour (female 
urine) was determined following intraperitoneal (IP) injection with saline or 3mg/kg 
of anamorelin or HM01 and the presentation of food or not in the inter-trial interval. 
An overall significant decrease in the total time interacting with female urine reward, 
as well as decreasing the total time interacting with the stimulus was observed for 
HM01 when food was not present, vs. when animals were able to feed before the urine 

































































Figure 7. Effect of ad libitum on effect of HM01-mediated latency to interact with a 
female urine stimulus Latency of male C57/Bl6 mice to interact with a rewarding 
odour (female urine) was determined following intraperitoneal (IP) injection with 
saline or 3mg/kg of anamorelin or HM01 and the presentation of food or not in the 
inter-trial interval. An overall significant increase in the latency of interaction with a 
female urine reward was observed for HM01 when food was not present, vs. when 
animals were able to feed before the urine interaction session. A food-dependent effect 
of HM01 on reward-related behaviour is proposed. 
The total time spent sniffing (no food present) was also recorded for HM04. 
This was intended as a control experiment to see if the opposite effect would be seen. 
There is a trend towards an overall decrease in the interaction time with the urine 









































































Figure 8. Total time spent interacting with a female urine stimulus. Interaction of 
male C57/Bl6 mice with a rewarding odour (female urine) was determined following 
intraperitoneal (IP) injection with saline or 3mg/kg of anamorelin, HM01 or HM04. 
A trend towards a decrease in the total time interacting with female urine reward was 






Open Field test 
The open field test is a fast and simple test that provides a guide on various 
behaviours ranging from general locomotor activity to emotional state, such as anxiety 
of the animal. While it is generally accepted that ghrelin increases locomotor activity 
and foraging-type behaviour (Jerlhag, Egecioglu et al. 2006, Lockie, McAuley et al. 
2017), the question of whether it is anxiolytic or anxiogenic remains under debate 
(Bali and Jaggi 2016), with both phenomena being reported (Carvajal, Carlini et al. 
2009, Jensen, Ratner et al. 2016). As a result, we chose the open-field test paradigm 
as a quick test to determine if there were any overt differences in locomotor activity, 


































































Figure 9. Total distance moved in open field test. The total distance moved was 
recorded automatically using Ethovision software. Anamorelin and HM01 treatment 
show a significant reduction in total distance moved compared to control. A one-way 
ANOVA with Tukey’s post-hoc test for multiple comparisons was carried out in order 































































Figure 10. Mean velocity in open field test. The mean velocity of movement was 
recorded automatically using Ethovision software. Anamorelin and HM01 treatment 
show a significant reduction in mean velocity compared to control. A one-way ANOVA 
with Tukey’s post-hoc test for multiple comparisons was carried out in order to assess 





















































Figure 11. Time spent rearing. The total amount of time spent in a rearing position 
was assessed and found to be significantly higher for control treated animals 
compared with anamorelin and HM01. A one-way ANOVA with Tukey’s post-hoc test 
for multiple comparisons was carried out in order to assess statistical significance; 






















































Figure 12. Time spent grooming. There were no significant differences between 
treatments for the total time spent grooming. A one-way ANOVA with Tukey’s post-







































































Figure 13. Latency to enter the centre zone. The amount of time it took for animals 
to enter the centre 25% zone of the arena was measured, however no significant 
differences were noted between treatments. A one-way ANOVA with Tukey’s post-hoc 





Open Field test 
 
Figure 14. Effect of ghrelin, HM01 and Anamorelin on growth hormone and total 
GLP-1 plasma levels. Growth Hormone (GH) and total Glucagon-like Peptide (GLP-
1) levels were assessed following intraperitoneal (IP) injection with 0.3mg/kg body 
weight of ghrelin, or 3mg/kg of anamorelin or HM01. An overall significant increase 
in GH was observed for anamorelin and HM01 while no increases were observed from 
ghrelin and saline treatment. Total GLP-1 levels remained unchanged from control. 
A one-way ANOVA using Tukey’s post-hoc test was used to determine overall 







Both the novel antagonist HM04 and the novel inverse agonist H1498 
effectively reduce the activity of ghrelin, anamorelin and HM01 on GHSR-1a 
mediated Ca2+ signalling (IC50 range 2.7 – 8.8 x10
-7 M). Furthermore, the inverse 
agonist H1498 acts like an antagonist at lower concentrations yet it can potentiate the 
actions of an agonist at higher concentrations. The maximal effect of ghrelin is 
increased two-fold (Emax = 200.7%) when HEK-293A cells are pre-incubated with a 
100nM concentration of H1498 (Figure 3). Interestingly, there is also evidence that 
HM04 can reverse the internalization of GHSR-1a into endosomal vehicles. An 
internalization assay showed a reversal of EGFP cytoplasmic intensity, similar to that 
elicited by the inverse agonist SP, after HEK293A cells were pre-incubated with 
HM04. The antagonist JMV 2959 did not elicit such an effect (Figure 4). The fact that 
no inverse agonist activity is seen for HM04 in β-arrestin recruitment may be a 
limitation of the assay, since it is also not apparent for SP. However, HM04 was 
effective than JMV (1uM) at reducing GHSR-1a mediated recruitment of the subunit. 
In vivo 
The FUST was used to quantify interaction time with a rewarding olfactory 
stimulus, another behavioural measure of reward system activation (Malkesman, 
Scattoni et al. 2010). Before, we showed that HM01 treated mice had a lower number 
of sniffing interactions with a female urine stimulus than control mice, in addition to 
displaying an increased latency to sniffing. These results indicate that HM01-treated 
mice, but not anamorelin treated, show aversive-like behaviour towards a rewarding 
stimulus. Since HM01 elicited a large orexigenic effect it was postulated that this 
behaviour may be food-dependent, and that reward paradigms which do not offer the 
opportunity for caloric intake in hunger elicit a negative response on the reward system 
(Kawahara, Kawahara et al. 2009). Indeed, this paradoxical effect on reward was 
highlighted when the antagonist HM04 exerted a similar effect to the agonist HM01 




which were allowed ad libitum food intake in the home cage during the inter-trial 
interval. Interestingly, the fed group normalized their behaviour towards the rewarding 
stimulus (Figure 6 & 7). This indicates a food-dependent effect on reward system 
activation which should be considered in the context of future work on ghrelin and the 
reward circuitry. 
The open field test was also utilized as a general tool to assess for overt 
locomotor differences induced by anamorelin or HM01 which may impact on food 
intake. Although ghrelin would be expected to increase locomotion and food-seeking, 
this was not seen here (Figure 9 & 10). Although a significant reduction in total 
distance moved and mean velocity was observed for anamorelin and HM01, this was 
not deemed to be clinically significant and later food intake studies showed a robust 
effect on food intake corroborated this. Although the open field test can also be used 
as a barometer for anxiety-like behaviour (Hall 1934), there has been conflicting 
reports of anxiogenic (Carlini, Monzon et al. 2002, Carvajal, Carlini et al. 2009) and 
anxiolytic effects (Jensen, Ratner et al. 2016) of ghrelin in this paradigm. We observed 
no differences in latency to enter the centre zone of the maze indicating no differences 









Additional information on techniques 
Pellet preparation 
• •Requisite quantities of materials were weighed out using scales and weigh boat. 
Initial process optimization studies trialled a range of different ratios of hydrolysate 
to microcrystalline cellulose (MCC). 
• •Materials were placed in a large zip-loc bag and manually blended for 1 minute. 
• •Powder was then added to Kenwood planetary mixing bowl and mixed at minimum 
setting for a further 5 minutes. 
• The resulting blend was granulated by gradual addition of deionized water under 
constant agitation by planetary mixer at minimum setting. Initial process optimization 
studies trialled a range of moisture content. 
• Deionized water was added via a spray bottle to atomize the water for homogenous 
dispersion of moisture & to avoid clumping of protein. Water was added every 15 
seconds, mixing was stopped periodically every 2-3 minutes to scrape material off the 
side of the bowl. Weight of water added was monitored. 
• End point of granulation was determined visually or when the required percentage 
water content had been attained. 
• Granulate was weighed after water addition was completed and was manually added 
to the Caleva Extruder 20 (RPM set at 16). Depending on how easy/difficult the 
mixture is to extrude, addition may be faster/slower. This is always determined 
visually. Any jams in the extruder were recorded and manually removed. 
• Extrudate was funnelled into spheronizer @ 1200-1750 rpm for 1-2 minutes. (rpm and 
time varied during process optimization). 
• Product was allowed to dry @40C/room temp for 24 hours OR in the fluidized bed 
coater @ room temperature for 15 minutes with maximum airflow.  
• Spray coating is the process by which a protective coating is sprayed onto a bed of 
fluidized pellets. The high airflow and temperature evaporates the solvent to leave a 
uniform coating on the pellets 
Pellet coating 




• Spray coating was carried out in bottom spray (Wurster) mode, according to the below 
parameters. 
Parameter Setting 
Nozzle Air 16.6 psi 
Airflow 290-300 L/min 
Preheating time 10 minutes 
Feed rate 0.25 g/min (variable depending on drying) 
Inlet temperature 65-80C 
Outlet temperature 50 – 55C 
Spray pattern Dependent on coating & drying 
 
• Duration of spray coating process was determined by the theoretical % of coating 
required, and the weight of pellets added to the coater. Container of coating solution 
was under constant agitation @900 – 1000 RPM on magnetic stirrer at room 
temperature. Container was weighed before and after coating process to determine 
weight of solution sprayed on the pellets. 
 
* During the coating process coater was observed for correct flow of pellets, and to make sure 
there were no jams in the atomizer.  After pellets were removed, solution was sprayed through 
the coater to make sure atomizer was still patent (i.e. unblocked) and the system was left flush 






In vivo cumulative food intake experiments 
• Randomization into relevant groups was carried out. 
• Rats were weighed day prior to (and on the day of) experiment. Dose of active to be 
received was calculated (35 – 50 mg/kg). Weight of pellets needed to be gavaged was 
then calculated based on weight. 
• Tubes (13ga X 90mm, Instech Laboratories) were pre-filled with pellets and 
refrigerated the day before the experiment. Each tube was labelled by rat number. 
Briefly, balance was tared with a plastic gavage tube sealed at one end with parafilm. 
Pellets were manually loaded to required weight. Other end of the tube was then sealed 
with parafilm/tin foil. Care was taken when loading tubes to omit pellets which were 
irregular or likely in any way to obstruct the flow of pellets out of the tube. A number 
of spare tubes for each group were prepared in case of blockage/ animal biting tube. 
• Animals were gavaged with pellets on the morning of experiment and placed in 
individual cages for duration of food intake monitoring. Cages were randomized 
appropriately on rack. 
• All parafilm was removed from gavage tube and a small amount of Vaseline was 
added to the end of the tube to prevent pellets from falling out and to ease insertion of 
tube. A 1ml syringe barrel (without plunger) was attached to tube and cut to length 
such that the metal guidewire terminates at the end of the dosing tube when inserted 
(Important to not cause injury to the animal).  
• Each animal was restrained, and dosing tube inserted. The guidewire was then fed 
down through the syringe barrel and dosing tube to push pellets out of tube into the 
stomach. 
• Animals were food restricted for a period of up to 4 hrs before a pre-weighed quantity 
of chow was added to the cages. The food pellets were placed at the back-left corner 
of the cage for each animal.  
• Food intake was then recorded by weighing the chow at defined intervals. 
• New food was weighed and given if levels were running low, or if pellets became wet 
due to urination. 






• Anaesthetize rat using ketamine/medetomidine admixture and set up on stereotaxic 
frame.  
• Make one incision from eyes to ears using scalpel.   
• Use 4 clips to pull back skin from four corners.  
• Use cotton buds to move away layer above skull.  
• Dip cotton buds in adrenaline/hydrogen peroxide and dab over skull to constrict 
vessels and stop bleeding. This should allow time for bregma to appear.  
• Mark bregma with marker under magnifying glass.   
• Take AP (anterior posterior) and ML (medial-lateral) co-ordinates for bregma. 
• Take AP (anterior posterior) and ML (medial-lateral) co-ordinates for lambda. 
• Check that DV co-ordinates for bregma and lambda are +/- 0.3mm.  
• Readjust nose bar to level the skull if there is a discrepancy greater than this. 
• Calculate required co-ordinates (Nucleus accumbens shell) based on co-ordinates in 
rat brain atlas (AP +1.7, ML +/- 0.8, DV 7.2 + probe glue spot length (from dura).  
• Move needle on stereotaxic frame to that point.  
• Mark skull with needle.  
• Use marker to mark spot also if required.   
• Mark one other spot to the back of the area for screws which lend support .  
• Drill all three holes (drill speed 4, only until drill pops back up). Make sure the 
microdialysis probe hole for entry is completely free of membrane by putting a needle 
in past skull to pop any remaining membrane.  
• Place screws in spare hole, holding with forceps and screwing with screwdriver (may 
require downward pressure).  
• Replace needle with guide cannula. Ensure it is pointed straight down, with adequate 
clearance from the positioning block to allow space for gluing. 
• Insert guide cannula, making sure it enters center of the hole and is pointed straight 
downward.  
• As it is being lowered in, stop just when it is in past the level of the skull, and take 
DV (dorsal ventral) co-ordinates. Calculate how far into the brain the cannula should 
be placed and gradually lower it in.  
• Mix some cement and solvent in a petri dish and start to cement the cannula in place, 
using the screws for support. This will require many layers of glue. 




• Give appropriate dose of reversal agent (atipamezole) and subcutaneous carprofen for 
post-operative analgesia. 
 
Surgery tools:  Sampling: 
Stereotaxic frame, arm and ear bars Microdialysis cage apparatus 
Anaesthetics + doses Allen keys 
Scalpel Bedding, Chow, Water bottle 
Bulldog Clips Tape 
Cotton buds HPLC glass vial inserts 
Blue needle aCSF (0.2uM filtered) 
Probe Spring for over probes 
Cannula Glue mix 
Screws Tubing (PE50/PE25, PE10) 
Forceps  Harvard Syringe micropump 
Screwdriver Blu-Tack 
Drill Balance for food 
Marker Drug aliquots 
Dental cement Ethanol (Probe activation) 
Petri dish  
Spatula Additional: 
Shaver Experimental sheet & card 
Suture kit (including spring scissors) Pain sheets/Surgical sheets 
Optic cable light Ketamine/ Atipamezole/Medetomidine 
Heating pad Carprofen 
Orange Needle for  IP anaesthesia and SC 
analgesia 
Saline 0.9%/EtOh 
 Adrenaline 0.1%/ Hydrogen Peroxide 
  
  
